



US012390508B2

(12) **United States Patent**
Brockschnieder et al.

(10) **Patent No.:** US 12,390,508 B2
(b4) **Date of Patent:** Aug. 19, 2025

(54) **BRAIN NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES**(71) Applicant: **Boehringer Ingelheim International GmbH**, Ingelheim am Rhein (DE)(72) Inventors: **Damian Brockschnieder**, Haan (DE); **Jan Tebbe**, Cologne (DE); **Andreas Wilmen**, Cologne (DE); **Frank Wunder**, Wuppertal (DE)(73) Assignee: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1192 days.

(21) Appl. No.: **17/046,648**(22) PCT Filed: **Apr. 10, 2019**(86) PCT No.: **PCT/EP2019/059101**§ 371 (c)(1),
(2) Date: **Oct. 9, 2020**(87) PCT Pub. No.: **WO2019/197475**PCT Pub. Date: **Oct. 17, 2019**(65) **Prior Publication Data**

US 2021/0147504 A1 May 20, 2021

(30) **Foreign Application Priority Data**

Apr. 12, 2018 (EP) 18167106

(51) **Int. Cl.**

A61K 38/00	(2006.01)
A61K 39/00	(2006.01)
A61P 9/12	(2006.01)
C07K 14/58	(2006.01)
C07K 16/00	(2006.01)
A61P 9/04	(2006.01)

(52) **U.S. Cl.**

CPC	A61K 38/00 (2013.01); A61P 9/12 (2018.01); C07K 14/58 (2013.01); C07K 16/00 (2013.01); A61K 2039/505 (2013.01); A61P 9/04 (2018.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01); C07K 2318/10 (2013.01); C07K 2319/31 (2013.01)
-----------	--

(58) **Field of Classification Search**

CPC	C07K 16/00; C07K 2317/21; C07K 2317/24; C07K 2317/565; C07K 2318/10; C07K 2319/31; C07K 14/58; C07K 2317/567; C07K 2317/94; C07K 2317/52; C07K 2319/00; A61K 38/00; A61K 2039/505; A61P 9/12; A61P 9/04
-----------	---

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,399,216 A	8/1983	Axel
4,510,245 A	4/1985	Cousens
4,634,665 A	1/1987	Axel
4,816,397 A	3/1989	Boss
4,968,615 A	11/1990	Koszinowski
5,168,062 A	12/1992	Stinski
5,179,017 A	1/1993	Axel
5,288,931 A	2/1994	Chang
7,112,660 B1	9/2006	Domingues
7,521,424 B2	4/2009	Rosen
7,705,043 B2	4/2010	Alonso-alija et al.
7,781,470 B2	8/2010	Alonso-alija et al.
8,796,324 B2	8/2014	Bruggemeier et al.
9,193,777 B2	11/2015	Burnett, Jr.
9,687,476 B2	6/2017	Fürstner et al.
9,993,476 B2	6/2018	Follmann et al.
2003/0045474 A1	3/2003	Sailer
2004/0253242 A1	12/2004	Bowdish

(Continued)

FOREIGN PATENT DOCUMENTS

CN	103087191 A	5/2013
CN	103649116 A	3/2014

(Continued)

OTHER PUBLICATIONS

Mezo, A.R., et al. (2012). "Atrial Natriuretic Peptide-Fc, ANP-Fc, Fusion Proteins: Semisynthesis, In Vitro Activity and Pharmacokinetics in Rats," American Chemical Society, 23: 518-526.

(Continued)

Primary Examiner — Olga N Chernyshev

(74) Attorney, Agent, or Firm — MORRISON & FOERSTER LLP

(57) **ABSTRACT**

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (NtIs), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (CtIs). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

17 Claims, 13 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**U.S. PATENT DOCUMENTS**

- 2007/0292411 A1 12/2007 Salcedo
 2010/0310561 A1 12/2010 Canada
 2012/0114659 A1 5/2012 Waterman
 2014/0148390 A1 5/2014 Haups
 2014/0154743 A1 6/2014 Levy
 2021/0079056 A1 3/2021 Brockschnieder
 2021/0139555 A1 5/2021 Mayer-Bartschmid et al.

FOREIGN PATENT DOCUMENTS

- EP 2432489 B1 10/2016
 WO 0006568 A1 2/2000
 WO 0006569 A1 2/2000
 WO 0119355 A2 3/2001
 WO 0119776 A2 3/2001
 WO 0119778 A1 3/2001
 WO 0119780 A2 3/2001
 WO 0119780 A3 9/2001
 WO 0119776 A3 11/2001
 WO 0242301 A1 5/2002
 WO 02070462 A1 9/2002
 WO 02070510 A2 9/2002
 WO 02078612 A2 10/2002
 WO 02070510 A3 1/2003
 WO 03095451 A1 11/2003
 WO 2005060642 A2 7/2005
 WO 2005082004 A2 9/2005
 WO 2005060642 A3 10/2005
 WO 2006107124 A1 10/2006
 WO 2008079995 A2 7/2008
 WO 2008079995 A3 8/2008
 WO 2005082004 A3 10/2008
 WO 2008136611 A1 11/2008
 WO 2008154226 A1 12/2008
 WO 2009033094 A2 3/2009
 WO 2010054007 A1 5/2010
 WO 2010105770 A1 9/2010
 WO 2010117760 A2 10/2010
 WO 2010117760 A3 11/2010
 WO 2010135541 A2 11/2010
 WO 2011104322 A1 9/2011
 WO 2011147809 A1 12/2011
 WO 2012004258 A1 1/2012
 WO 2012028647 A1 3/2012
 WO 2012059549 A1 5/2012
 WO 2015006337 A2 1/2015
 WO 2016071212 A1 5/2016

OTHER PUBLICATIONS

- Peng, J., et al. (Apr. 25, 2018). "Preparation of anti hCG single domain antibodies using antigen binding peptide engrafted antibody technology," Chinese Journal of Biotechnology, 34(4): 569-577. English translation of abstract only.
- Anand-Srivastava, M.B. (Jun. 2005). "Natriuretic peptide receptor-C signaling and regulation," Peptides 26(6): 1044-1059.
- Anker, S.D. et al. (Mar. 21, 2015). "Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies," Eur Heart J. 36 (12): 715-723.
- Baliga, R.S. et al. (Jul. 2014). "Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis," British Journal of Pharmacology 171(14): 3463-3475.
- Buglioni, A. et al. (2016). "New Pharmacological Strategies to Increase cGMP," Annu Rev Med. 67: 229-243.
- Dahrouj, M. et al. (Jan. 2013). "C-Type Natriuretic Peptide Protects the Retinal Pigment Epithelium against Advanced Glycation End Product-Induced Barrier Dysfunction." J Pharmacol Exp Ther. 344 (1): 96-102.
- Edelson, J.D. et al. (Apr. 2013). "In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide Hept-cyclo(Cys-His-Phe-D-Ala-Gly-Arg-D-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Argminic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator," Pulmonary Pharmacology & Therapeutics 26: 229-238.
- Hunt, P.J. et al. (1994). "Bioactivity and Metabolism of C-Type Natriuretic Peptide in Normal Man**" Journal of Clinical Endocrinology and Metabolism, 78(6):1428-1435.
- International Search Report mailed Oct. 17, 2019 for PCT International Application No. PCT/EP2019/059101, filed Apr. 10, 2019, 4 pages.
- Kimura, K. et al. (2007). "ANP is cleared much faster than BNP in patients with congestive heart failure," Eur J Clin Pharmacol, 63:699-702.
- Kimura, T. et al. (2016). "C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice," Respiratory Research, 17(19):1-17.
- Knowles, J.W. et al. (2001). "Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice," J.Clin. Invest. 107(8): 975-984.
- Lee, C. et al. (2007). "Pharmacokinetic and pharmacodynamic study of a novel chimeric natriuretic peptide, CD-NP, in the normal dog," BMC Pharmacology 7 (Suppl 1): P38.
- Lumsden, N.G. et al. (2010). "C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target," Current Pharmaceutical Design, 16:4080-4088.
- McKie, P. et al. (2010) "CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease," Curr Heart Fail Rep, 7:93-99.
- McKie, P.M. et al. (Dec. 2010). "A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension," Hypertension 56 (6): 1152-1159.
- Mitaka, C. et al. (2014) "Effects of atrial natriuretic peptide on inter-organ crosstalk among the kidney, lung, and heart in a rat model of renal ischemia-reperfusion injury," Intensive Care Medicine Experimental, 2(28):1-17.
- Moyses, A.J. et al. (2014), "Endothelial C-type natriuretic peptide maintains vascular homeostasis," The Journal of Clinical Investigation, 124(9):4039-4051.
- Pan, S. et al. (Jul. 7, 2009). "Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide," PNAS 106 (27): 11282-11287.
- Potter, L. et al. (2009) "Natriuretic Peptides: Their Structures, Receptors, Physiologic Functions and Therapeutic Applications," Handb Exp Pharmacol., 191:341-66.
- Wang, W. et al. (Nov. 2004). "AlbuBNP, a Recombinant B-TypeNatriuretic Peptide and Human Serum Albumin Fusion Hormone, as Long-Term Therapy of Congestive Heart Failure," Pharmaceutical Research, Springer 21(11):2105-2110.
- Wendt, D. J. et al. (Apr. 2015). "Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3-Related Dwarfism," J. Pharmacol Exp Ther. 353: 132-149.
- Werner, F. et al. (2016) "Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice," Basic Res Cardiol 111(22):1-16.
- Woods, R. (2004) "Cardioprotective Functions of Atrial Natriuretic Peptide and B-Type Natriuretic Peptide: A Brief Review," Clinical and Experimental Pharmacology and Physiology, 31:791-794.
- Yasoda, A. et al. (2009). "Effects of natriuretic peptides on endochondral bone growth," Clinical Calcium, 17(7):103-108. English Abstract.
- Fillippovic O. B. et al. Biochemical basis for human life activity. Textbook for for college-level.—M.: Vlados, 2005.—407 p. il; see p. 49-50 and 70. (Partial English Translation only.).
- Roitt A. et al. (2000), Immunology. Translation from English—M.: Mir, 2000.—592 p. ill.; p. 150. (Partial English Translation only.).
- Šarošina I. A. et al. (2003). "The role of natriuretic peptides for the diagnosis of heart failure," Russian Journal of Cardiology, N 2(40): 81-86.
- Alaoui-Ismaili, M.H. et al. (2009). "Design of Second Generation Therapeutic Recombinant Bone Morphogenetic Proteins," Cytokine Growth Factor Rev. 20:501-507.

(56)

References Cited**OTHER PUBLICATIONS**

- Bernier, V. et al. (2004, e-pub. Aug. 23, 2004). "Pharmacological Chaperone Action on G-protein-coupled Receptors." *Curr. Opin. Pharmacol.* 4:528-533.
- Bhattacharya, R. et al. (Mar. 15, 2017). "Impact of Genetic Variations on Three Dimensional Structure and Function of Proteins," *PLoS ONE* 12(3):e0171355, 22 pages.
- Fenton, A. W. et al. (2020, e-pub. Jun. 7, 2020). "Rheostat Positions: A New Classification of Protein Positions Relevant to Pharmacogenomics," *Medicinal Chemistry Research* 29:1133-1146.
- Guo, H. H. et al. (Jun. 22, 2004). "Protein Tolerance to Random Amino Acid Change," *PNAS* 101(25):9205-9210.
- International Search Report and Written Opinion, mailed May 17, 2019, for PCT Application No. PCT/EP2019/059101, filed Apr. 10, 2019, 10 pages.
- International Search Report and Written Opinion, mailed May 20, 2019, for PCT Application No. PCT/EP2019/059103, filed Apr. 10, 2019, 11 pages.
- Teng, S. et al. (2010, e-pub. Feb. 4, 2011). "Structural Assessment of the Effects of Amino Acid Substitutions on Protein Stability and Protein-Protein Interaction," *Int J Comput Biol Drug Des.* 3(4):334-349.
- Tobi, D. et al. (Dec. 14, 2005). "Structural Changes Involved in Protein Binding Correlate with Intrinsic Motions of Proteins in the Unbound State," *PNAS* 102(52):18908-18913.
- Tokuriki, N. et al. (2009, e-pub. Sep. 16, 2009). "Stability Effects of Mutations and Protein Evolvability," *Curr. Opin. Struc. Biol.* 19:596-604.
- Ulloa-Aguirre, A. et al. (2004). "Pharmacologic Rescue of Conformationally-Defective Proteins: Implications for the Treatment of Human Disease," *Traffic* 5:821-837.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13





Fig. 14




Fig. 15




Fig. 16






Fig. 17



1**BRAIN NATRIURETIC PEPTIDE
ENGRAFTED ANTIBODIES****CROSS REFERENCE TO RELATED
APPLICATIONS**

This application is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/EP2019/059101, filed internationally on Apr. 10, 2019, which claims the benefit of priority to European Application No. 18167106.6, filed Apr. 12, 2018.

**SUBMISSION OF SEQUENCE LISTING ON
ASCII TEXT FILE**

The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 777052044500SUBSEQLIST.TXT, date recorded: May 26, 2022, size: 215,279 bytes).

FIELD OF THE INVENTION

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (NtIs), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (CtIs). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. At least 12 amino acid residues are present between amino acid residue HC (heavy chain) res25 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRH1; amino acid residue HC res51 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRH2; amino acid residue HC res92 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRH3; amino acid residue LC (light chain) res26 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRL1; amino acid residue LC res49 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or amino acid residue LC res88 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRL3. Additionally, at least 9 amino acid residues are present between the last amino acid residue of the BNP and amino acid residue HC res35a according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH1; amino acid residue HC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH2; amino acid residue HC res106 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH3; amino acid residue LC res32 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL1; amino acid residue LC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or amino acid residue LC res98 according to Kabat in case of an incorporation of said heterologous

2

amino acid sequence within CDRL3. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

BACKGROUND OF THE INVENTION

Natriuretic peptides are a family of three structurally related peptides with neurohumoral actions. Atrial Natriuretic Peptide (ANP) is a peptide of 28 amino acids comprising a central ring structure formed by a disulfide bridge between cysteine residues 7 and 23. Human ANP is expressed as a 153 amino acid long pre-pro-hormone in atrial myocyte cells. Signal peptide cleavage yields the prohormone form, which is subsequently further cleaved into the mature ANP and the N-terminal remnant, known as NT-proANP. Similar to ANP, also Brain Natriuretic Peptide (BNP) and C-Type Natriuretic Peptide (CNP) are produced from precursor proteins and comprise a central ring structure. ANP is mainly produced and released by cardiomyocytes of the left and right heart atria, whereas BNP is mainly produced by cardiomyocytes of the ventricles. CNP is synthesized by endothelial cells of blood vessels. Apart from these locations natriuretic peptides are also produced in smaller amounts in other parts of the body, e.g., in brain, kidney and adrenal gland. Natriuretic peptides are encoded by three separate genes, NPPA, NPPB, and NPPC. The amino acid sequences of the three peptides are highly conserved in mammals (Potter et al., Handb Exp Pharmacol. 2009; (191):341-66). Yet, significant sequence modifications of natriuretic peptides such as truncations, amino acid exchanges as well chimeric fusions (e.g. CD-NP (McKie et al., Curr Heart Fail Rep. 2010 September; 7 (3): 93-9)) have been described to result in potent natriuretic peptides that activate or bind to cellular receptors and can elicit relevant physiological effects.

Natriuretic peptides bind to three different, membrane-bound receptor types—NPR-A, NPR-B, and NPR-C—thereby mediating their biological effects. ANP and BNP bind with greatest affinity to NPR-A; in contrast, CNP has the highest affinity for the NPR-B receptor. NPR-A and NPR-B comprise a (particulate) guanylate cyclase domain (pGC) whose enzymatic activity causes an increase in (intracellular) cyclic guanosine monophosphate (cGMP). As a second messenger, cGMP regulates diverse cellular processes. The NPR-C receptor exhibits no guanylate cyclase activity and is also termed “clearance” receptor, as it can bind natriuretic peptides, which leads to their degradation by endocytosis. An additional signaling function of the NPR-C receptor via modulation of cAMP has been described (Anand-Srivastava, Peptides. 2005 June; 26 (6): 1044-59).

The cardiac hormones ANP and BNP are excreted upon stretching of the ventricles and atria, e.g. due to excessive plasma volume. They exert vasodilating effects via relaxation of vascular smooth muscle and lead to a reduction in blood pressure. In the kidney ANP causes i.a. an increase in urinary excretion (diuresis), as well as an increase in the concentration of sodium ions in the urine (natriuresis). ANP is considered to constitute a compensatory antagonist of the renin-angiotensin-aldosterone system (RAAS), which is over-activated in a number of cardiovascular diseases. In addition, ANP exerts other neuro-humoral effects, including an inhibitory effect on the sympathetic nervous system, as

well as a complex regulatory effect on the baroreflex (Woods et al., Clin Exp Pharmacol Physiol. 2004 November; 31 (11): 791-4). For ANP, as well as BNP and CNP, anti-inflammatory, anti-hypertrophic and anti-fibrotic effects have been demonstrated in animal models for different diseases (e.g. Knowles et al., 2001, J. Clin. Invest. 107: 975-984; Dahrouj et al., J Pharmacol Exp Ther. 2013 January; 344 (1): 96-102; Baliga et al., Br J Pharmacol. 2014 July; 171 (14): 3463-75; Mitaka et al. Intensive Care Med Exp. 2014 December; 2 (1): 28; Werner et al., Basic Res Cardiol. 2016 March; 111 (2): 22; Kimura et al., Respir Res. 2016 Feb. 19; 17: 19). Activation of NPR-B by CNP is plays a significant role in bone growth (Yasoda et al., Clin. Calcium. 2009 July; 19 (7): 1003-8) and vascular endothelium integrity (Moyes et al., J Clin Invest. 2014 September; 124 (9): 4039-51).

The broad spectrum of physiological effects of natriuretic peptides and their receptors make them attractive targets in drug discovery (Lumsden et al., Curr Pharm Des. 2010; 16 (37): 4080-8; Buglioni et al., Annu Rev Med. 2016; 67: 229-43). For example, the natriuretic cGMP system may be suppressed under various pathophysiological conditions, which may result in hypertension, increased cell proliferation, fibrosis, inflammation, endothelial dysfunction, diabetes, metabolic syndrome, atherosclerosis, cardiac insufficiency, myocardial infarction, pulmonary hypertension, ocular and renal diseases, bone disorders, stroke and/or sexual dysfunction.

A major hurdle for the therapeutic use of natriuretic peptides is their very short plasma half-life of only a few minutes in the organism (Hunt et al., J Clin Endocrinol Metab. 1994 June; 78 (6): 1428-35; Kimura et al., Eur J Clin Pharmacol. 2007 July; 63 (7): 699-702). In addition to endocytosis by the NPR-C receptor, the natriuretic peptides are efficiently proteolytically degraded by the enzymes neprilysin (NEP) and insulin degrading enzyme (IDE). The associated short-term biological effects of administered natriuretic peptides have restricted their therapeutic use primarily to acute indications. For example, infusions of recombinant carperitide (ANP) and nesiritide (BNP) are approved for the treatment of acute decompensated heart failure in different countries.

The treatment of chronic diseases would be greatly facilitated by the provision of NPR-A and NPR-B agonists with increased plasma half-lives, higher proteolytic stability and prolonged duration of action.

In recent years, several natriuretic peptide derivatives and variants have been described, e.g., CD-NP (McKie et al., Curr Heart Fail Rep. 2010 September; 7 (3): 93-9), ZD100/ MANP (McKie et al., Hypertension. 2010 December; 56 (6): 1152-9), PL-3994 (Edelson et al., Pulm Pharmacol Ther. 2013 April; 26 (2): 229-38), Ularitide (Anker et al., Eur Heart J. 2015 Mar. 21; 36 (12): 715-2), ANX-042 (Pan et al., Proc Natl Acad Sci USA. 2009 Jul. 7; 106 (27): 11282-7) and BMN-111 (Wendt et al., J. Pharmacol Exp Ther. 2015 April; 353 (1): 132-49). The half-life of CD-NP is about 18.5 min (Lee et al., BMC Pharmacology 2007, 7 (Suppl I): P38). Further ANP and CNP derivatives are disclosed in U.S. Pat. No. 9,193,777 and EP 2 432 489 A, respectively.

In addition, natriuretic peptide fusions including Fc fusions, albumin fusion and PEGylated natriuretic peptides have been described. Natriuretic peptide-Fc fusions are for example disclosed in US 2010/0310561, WO 2008/154226, WO 2010/117760, WO 2006/107124, WO 2008/136611 and WO 2008/079995. Natriuretic peptide-albumin fusions are

disclosed in U.S. Pat. No. 7,521,424 and US 2014/0148390 and PEGylated natriuretic peptides are disclosed in US 2014/0148390.

WO 2005/060642 describes the generation of ANP and BNP peptide engrafted antibody libraries obtained by inserting ANP or BNP with two randomized flanking amino acids on both ends into the CDRH3 region of a human tetanus toxoid specific antibody. Similarly, WO 2005/082004 discloses the generation of an ANP mimetic engrafted antibody library obtained by replacing the entire original CDRH3 region of a 2G12 antibody with an ANP mimetic peptide flanked by two random amino acid residues on either side. Neither one of WO 2005/060642 and WO 2005/082004 discloses any specific natriuretic peptide engrafted antibodies, let alone functionally characterizes such antibodies.

OBJECTS OF THE INVENTION

In view of the prior art it is an object of the present invention to provide novel natriuretic peptide receptor agonists with increased stability in serum as compared to naturally occurring wild type natriuretic peptides.

SUMMARY OF THE INVENTION

The above stated object is achieved by the teaching of the subject independent claims. The present inventors have surprisingly found that biologically active natriuretic peptide variants with significantly increased stability in serum as compared to naturally occurring wild type natriuretic peptides can be obtained by incorporating a natriuretic peptide amino acid sequence into one of the CDR regions of an immunoglobulin molecule or a fragment thereof, despite the short length and high sequence conservation of immunoglobulin CDR regions, which impose considerable conformational restraints to the incorporation of biologically active peptides. However, the activity of natriuretic peptides incorporated within an immunoglobulin CDR region was shown to vary considerably. The present inventors have found that the decisive factor for a successful incorporation yielding a biologically active natriuretic peptide variant is the number of amino acid residues between the incorporated natriuretic peptide and the nearest neighboring CDR-framework junctions N-terminal and C-terminal from the incorporated natriuretic peptide. Below a certain number of N-terminal and C-terminal flanking amino acid residues between natriuretic peptide and neighboring CDR-framework junctions only natriuretic peptide immunoglobulin fusion constructs with no or drastically reduced biological activity were obtained. Specific linker sequences flanking the incorporated natriuretic peptide were found to be especially advantageous for achieving high peptide activity, good expression levels and/or low protein fragmentation levels.

Thus, in a first aspect, the present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a natriuretic peptide and a C-terminal linker sequence (Ctls), wherein optionally at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein, and wherein

a) at least 12 amino acid residues are present between
i) amino acid residue HC res25 according to Kabat (in the heavy chain having the amino acid sequence of

- SEQ ID NO 65 this corresponds to res S25) and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRH1;
- ii) amino acid residue HC res51 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res 151) and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRH2;
 - iii) amino acid residue HC res92 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res C96) and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRH3;
 - iv) amino acid residue LC res26 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res S25) and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRL1;
 - v) amino acid residue LC res49 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res Y51) and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or
 - vi) amino acid residue LC res88 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res C90) and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRL3; and wherein
- b) at least 9 amino acid residues are present between the last amino acid residue of the natriuretic peptide and
- i) amino acid residue HC res35a according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res M34) in case of an incorporation of said heterologous amino acid sequence within CDRH1;
 - ii) amino acid residue HC res57 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res T58) in case of an incorporation of said heterologous amino acid sequence within CDRH2;
 - iii) amino acid residue HC res106 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res G111) in case of an incorporation of said heterologous amino acid sequence within CDRH3;
 - iv) amino acid residue LC res 32 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res D34) in case of an incorporation of said heterologous amino acid sequence within CDRL1;
 - v) amino acid residue LC res57 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res G59) in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or
 - vi) amino acid residue LC res98 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res F102) in case of an incorporation of said heterologous amino acid sequence within CDRL3.

In further aspects, the present invention relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the following detailed description of the invention and the examples included therein.

In a first aspect, the present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a natriuretic peptide and a C-terminal linker sequence (Ctls), wherein optionally at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein.

The present inventors have found that biologically active natriuretic peptide variants with significantly increased stability in serum as compared to naturally occurring wild type natriuretic peptides can be obtained by incorporating a natriuretic peptide amino acid sequence into one of the CDR regions of an immunoglobulin molecule or a fragment thereof. This finding was entirely unexpected. As is well known in the art, the short length and high sequence conservation of immunoglobulin CDR regions, which are especially pronounced in CDRL1, CDRL2, CDRL3, CDRH1 and CDRH2, impose considerable conformational restraints to the incorporation of biologically active peptides, and the surrounding immunoglobulin sequences may negatively affect expression, folding and/or biological activity of the incorporated peptide. Indeed, the present inventors have found that the activity of natriuretic peptides incorporated within an immunoglobulin CDR region varied considerably depending on the exact way the natriuretic peptide grafted antibody was constructed. The decisive factor for a successful incorporation yielding a functional, i.e. biologically active natriuretic peptide variant was shown to be the number of amino acid residues between the incorporated natriuretic peptide and the nearest neighboring CDR-framework junctions N-terminal and C-terminal from the incorporated natriuretic peptide. Below a certain number of N-terminal and C-terminal flanking amino acid residues between natriuretic peptide and the neighboring CDR-framework junctions no biologically active natriuretic peptide immunoglobulin fusion constructs were obtained.

The terms "incorporated", "inserted", "integrated", "engrafted" and "embedded" as well as "incorporation", "insertion", "integration", "engrafting" and "embedding" are used interchangeably herein. Within the context of the present invention, these terms refer to the generation of hybrid polynucleic acids or hybrid polypeptides by the introduction of a heterologous sequence into the original sequence of an antibody or an antibody fragment. Such an incorporation may be done by any means. Typically, the antibody or fragment thereof comprising a natriuretic peptide flanked by an N-terminal and a C-terminal linker sequence is generated by recombinant DNA technology and expression as described herein.

Incorporation of the natriuretic peptide flanked by an N-terminal and a C-terminal linker sequence into a CDR region of the original antibody or antibody fragment sequence may result in the deletion of at least a portion of said CDR region. For instance, cloning of a nucleic acid sequence encoding said heterologous amino acid sequence comprising an N-terminal linker sequence, a natriuretic peptide and a C-terminal linker sequence may be performed such that part of the CDR encoding sequence is replaced by the incorporated heterologous nucleic acid sequence. In particular other embodiments, the incorporation of the heterologous amino acid sequence comprising the natriuretic peptide does not result in the deletion of amino acid residues of the CDR region into which the heterologous amino acid sequence is inserted.

Within the context of the present invention, the term "heterologous amino acid sequence" refers to an amino acid sequence that does not originate from the initial "empty" antibody or fragment thereof, into which it is incorporated. Engrafting of the heterologous amino acid sequence into an antibody or fragment thereof thus yields an engineered, recombinant antibody molecule composed of amino acid sequences of different origin.

The term "natriuretic peptide" refers to peptides that can induce natriuresis, the excretion of sodium by the kidneys. Natriuretic peptides include Atrial Natriuretic Peptide (ANP), Brain Natriuretic Peptide (BNP), C-Type Natriuretic Peptide (CNP), Dendroaspis natriuretic peptide (DNP) and Urodilatin. Natriuretic peptides within the meaning of the present invention may be of any origin. Natriuretic peptides include natural natriuretic peptides such as wild type natriuretic peptides and mutant versions thereof as well as homolog natriuretic peptides of a different species. The term however also encompasses engineered natriuretic peptides such as engineered chimeric variants of distinct natriuretic peptides. It is known that the usage of codons is different between species. Thus, when expressing a heterologous protein in a target cell, it may be necessary, or at least helpful, to adapt the nucleic acid sequence to the codon usage of the target cell. Methods for designing and constructing derivatives of a given protein are well known to anyone of ordinary skill in the art.

In particular embodiments, the natriuretic peptide is selected from a wild type natriuretic peptide of any species and a functional variant of any such wild type natriuretic peptide. Within the context of the present invention, the term "functional variant of a natriuretic peptide" or "functional natriuretic peptide variant" refers to a natriuretic peptide of any origin, including natural and engineered peptides, that differs in the amino acid sequence and/or the nucleic acid sequence encoding the amino acid sequence of a given natriuretic peptide, such as a wild type natriuretic peptide of a given species, but is still functionally active. Within the context of the present invention, the term "functionally active" refers to the ability of a natriuretic peptide variant to perform the biological functions of a naturally occurring natriuretic peptide, in particular a wild type natriuretic peptide. In particular, "functionally active" means that the natriuretic peptide variant is able to bind to its respective receptor. In case of NPR-A and NPR-B ligands, "functionally active" particularly means the ability to mediate an increase in (intracellular) cyclic guanosine monophosphate (cGMP) by binding to one or both of these receptors.

In particular embodiments, the functional natriuretic peptide variant is able to perform one or more biological functions of a given natriuretic peptide, such as a wild type natriuretic peptide of any given species to at least about

50%, particularly to at least about 60%, to at least about 70%, to at least about 80%, and most particularly to at least about 90%, wherein the one or more biological functions include, but are not limited to, binding of the natriuretic peptide to its respective receptor and/or induction of an increase in intracellular cGMP.

The functional activity of natriuretic peptides can be measured by any methods including in vitro methods that make it possible either to measure the increase of (intracellular) cyclic guanosine monophosphate (cGMP), or to measure changes in cellular processes regulated by cGMP, including the methods described in Examples 3 and 5. In particular embodiments, a (non-engrafted) natriuretic peptide variant is considered functionally active, if its EC₅₀ value as determined by the fluorescence assay described in Example 3 is below 500 nM, more particularly below 250 nM, more particularly below 150 nM, more particularly below 100 nM, more particularly below 50 nM, most particularly below 25 nM.

Incorporation of such a functional natriuretic peptide variant into one of the CDR regions of an immunoglobulin molecule or a fragment thereof as described herein yields a natriuretic peptide engrafted immunoglobulin with natriuretic peptide functional activity and significantly increased stability in serum as compared to the non-engrafted functional natriuretic peptide variant as shown in the Examples. An natriuretic peptide engrafted immunoglobulin is considered biologically active (i.e. functional), if it gives a significant positive signal in any method that measures the increase of (intracellular) cyclic guanosine monophosphate (cGMP) either directly or indirectly by assessing changes in cellular processes regulated by cGMP. In particular, the functional activity of a natriuretic peptide engrafted immunoglobulin may be assessed by the methods described in Examples 3 and 5. In case of natriuretic peptide engrafted immunoglobulins, significance is typically assessed based on i) comparison to a negative sample such as an empty immunoglobulin scaffold, e.g. construct #209, an antibody comprising SEQ ID NO 65 and SEQ ID NO 66, TPP-5657, ii) comparison to a positive sample, e.g. construct #117, an antibody comprising SEQ ID NO 67 and SEQ ID NO 66, TPP-5661, and iii) dose dependency.

Even though the functional natriuretic peptide variant according to the present invention may contain any number of mutations comprising additions, deletions and/or substitutions of one or more amino acids in comparison to the reference natriuretic peptide, a functional natriuretic peptide variant will typically maintain key features of the corresponding natriuretic peptide, such as key residues within the central ring domain. Conserved residues of natriuretic peptides are for instance described in Lincoln R. Potter et al. (Handb Exp Pharmacol. 2009; (191): 341-366). Thus, in particular embodiments, the functional natriuretic peptide variant shares at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% sequence identity with the sequence shown below:

(SEQ ID NO: 91)

X₁CFGX₂X₃X₄DRIX₅X₆X₇SX₈LGC

wherein X₁ and X₅ are G or S;

X₃ is R or K;

X₆ is A or S; and

X₂, X₄, X₇ and X₈ may be any amino acid.

In principle, natriuretic peptides of any type may be incorporated within a CDR region of an immunoglobulin or

fragment thereof as described herein. In particular, the present inventors have found that the findings for one type of natriuretic peptide regarding both minimal requirements for satisfactory biological activity of the grafted natriuretic peptide and especially suitable N-terminal and C-terminal amino acid sequences may be conferred to other types of natriuretic peptides. Without wishing to be bound by theory it is hypothesized that these similar requirements for successful embedding of a natriuretic peptide within an immunoglobulin molecule among different natriuretic peptide types may be due to structural similarities and/or mechanisms of action within the natriuretic peptide family.

In particular embodiments, the natriuretic peptide is selected from the group consisting of human ANP having the sequence of SEQ ID NO 23, human BNP having the sequence of SEQ ID NO 24, human CNP having the sequence of SEQ ID NO 25 and a peptide having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or at least 98% sequence identity with any one of SEQ ID NOS 23 to 25. Again, the natriuretic peptide having a sequence deviating from wild type human natriuretic peptides ANP, BNP and CNP may be of any natural origin, e.g. a mutant version of a wild type human natriuretic peptide, or a homolog of a different species, or an engineered natriuretic peptide. Methods for designing and constructing peptide variants are well known to anyone of ordinary skill in the art.

In particular such embodiments, the natriuretic peptide having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or at least 98% sequence identity with any one of SEQ ID NOS 23 to 25 is a functional natriuretic peptide variant.

"Percent (%) sequence identity" with respect to a reference polynucleotide or polypeptide sequence, respectively, is defined as the percentage of nucleic acid or amino acid residues, respectively, in a candidate sequence that are identical to the nucleic acid or amino acid residues, respectively, in the reference polynucleotide or polypeptide sequence, respectively, after aligning the sequences and optionally introducing gaps, if necessary, to achieve the maximum percent sequence identity. Conservative substitutions are not considered as part of the sequence identity. In particular embodiments, any gaps introduced in the candidate sequence and/or the reference sequence may in total not amount to more than 50%, more than 40%, more than 30%, more than 25%, more than 20%, more than 15% or more than 10% of the total amount of residues of the reference sequence. In particular embodiments, the percentage sequence identity is determined without introducing any gaps into the candidate or the reference sequence (i.e. using an ungapped alignment). Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are well within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

The natriuretic peptide that shares a given percentage of sequence identity with a given reference natriuretic peptide, e.g., human BNP having the amino acid sequence of SEQ ID NO 24, may contain one or more mutations comprising an addition, a deletion and/or a substitution of one or more amino acids in comparison to the reference natriuretic peptide. According to the teaching of the present invention, said deleted, added and/or substituted amino acids may be consecutive amino acids or may be interspersed over the length of the amino acid sequence of the natriuretic peptide

that shares a given percentage of sequence identity with a reference natriuretic peptide, e.g., human BNP having the amino acid sequence of SEQ ID NO 24. On the DNA level, the nucleic acid sequences encoding the natriuretic peptide that shares a given percentage of sequence identity with a given reference natriuretic peptide may differ to a larger extent due to the degeneracy of the genetic code.

According to the teaching of the present invention, any number of amino acids may be added, deleted, and/or substituted, as long as the stipulated amino acid sequence identity with the reference natriuretic peptide is adhered to. In particular embodiments, the stipulated amino acid sequence identity is adhered to and the natriuretic peptide variant is biologically active, i.e. is a functional natriuretic peptide variant. Preferably, the biologic activity of the natriuretic peptide that shares a given percentage of sequence identity with a given reference natriuretic peptide, e.g., human BNP having the amino acid sequence as found in SEQ ID NO 24, is reduced by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 25% or less than 10% compared to said reference natriuretic peptide as measured in the above described assay.

The term "antibody", as used herein, is intended to refer to immunoglobulin molecules, particularly dimeric immunoglobulin molecules comprised of four polypeptide chains—two heavy (H) chains and two light (L) chains which are typically inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region can comprise e.g. three domains CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain (CL). The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is typically composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus e.g. in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

As used herein, the term "Complementarity Determining Regions" (CDRs; e.g., CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable domain the presence of which are necessary for antigen binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3. Each complementarity determining region may comprise amino acid residues from a "complementarity determining region" as defined by Kabat (e.g. about residues 24-34 (CDRL1), 50-56 (CDRL2) and 89-97 (CDRL3) in the light chain variable domain and 31-35 (CDRH1), 50-65 (CDRH2) and 95-102 (CDRH3) in the heavy chain variable domain; (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (e.g. about residues 26-32 (CDRL1), 50-52 (CDRL2) and 91-96 (CDRL3) in the light chain variable domain and 26-32 (CDRH1), 53-55 (CDRH2) and 96-101 (CDRH3) in the heavy chain variable domain (Chothia and Lesk; J Mol Biol 196: 901-917 (1987)). In some instances, a complementarity determining region can include amino acids from both a CDR region defined according to Kabat and a hypervariable loop.

Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be

11

assigned to different “classes”. There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these maybe further divided into “subclasses” (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. Within the context of the present invention, the term “antibody” includes immunoglobulin molecules of any primary class—including IgG, IgE, IgM, IgD, IgA and IgY—and any subclass—including, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2—isolated from nature or prepared by recombinant means and includes all conventionally known antibodies. A preferred class of immunoglobulins for use in the present invention is IgG. The term “antibody” also extends to other protein scaffolds that are able to orient antibody CDR inserts into the same active binding conformation as that found in natural antibodies such that binding of the target antigen observed with these chimeric proteins is maintained relative to the binding activity of the natural antibody from which the CDRs were derived.

Within the context of the present invention, the term “fragment” of an antibody/immunoglobulin refers to any part of an antibody/immunoglobulin that comprises at least one CDR region. Particularly, the antibody fragment according to the present invention retains the ability to increase the serum half-life of a biologically active peptide, preferably a natriuretic peptide, incorporated therein. Antibody fragments according to the present invention include Fab, Fab', Fab'-SH, F(ab')₂, and Fv fragments; diabodies; single domain antibodies (Dabs); linear antibodies; single-chain antibody molecules (scFv); and disulfide-stabilized Fv antibody fragments (dsFv); as well as multispecific antibodies formed from antibody fragments and fragments comprising a VL or VH domain, which are prepared from intact immunoglobulins or prepared by recombinant means.

The F(ab')₂ or Fab may be engineered to minimize or completely remove the intermolecular disulfide interactions that occur between the CH1 and CL domains. Antibody fragments according to the present invention may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, CH3 and CL domains. Also included are antibody fragments comprising any combination of variable region(s) with a hinge region, CH1, CH2, CH3 and CL domain.

The antibody or fragment thereof constitutes a scaffold that confers stability to the natriuretic peptide incorporated therein. For example, the serum half-life of a natriuretic peptide incorporated within the CDR region of an antibody as described herein may be increased as compared to that of a naturally occurring natriuretic peptide.

Principally, the heterologous amino acid sequence comprising the natriuretic peptide may be incorporated within any immunoglobulin molecule or fragment thereof. In particular, immunoglobulins of any species (including but not limited to human, bovine, murine, rat, pig, dog, shark, *lama* and camel) and any primary class and subclass may be used according to the present invention. For therapeutic use a human or humanized antibody may however be preferable. Within the context of the present invention, the term “human antibody” refers to antibodies having the amino acid sequence of a human immunoglobulin and includes antibodies isolated from human immunoglobulin libraries, from human B cells, or from animals transgenic for one or more human immunoglobulin as well as synthetic human antibodies. In particular embodiments the amino acid light chain and heavy chain sequences of the variable domain derive from human germline sequences LV 1-40 and HV 3-23, respectively (for more information see Example 1).

12

Within the context of the present invention, the term “humanized antibody” or “humanized antibody fragment” refers to an antibody or fragment thereof that is (i) derived from a non-human source (e.g., a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; or (ii) chimeric, wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.

The antibody or fragment thereof according to the present invention may be monospecific, bispecific, trispecific or of greater multispecificity.

In the context of the present invention, the term “comprises” or “comprising” means “including, but not limited to”. The term is intended to be open-ended, to specify the presence of any stated features, elements, integers, steps or components, but not to preclude the presence or addition of one or more other features, elements, integers, steps, components or groups thereof. The term “comprising” thus includes the more restrictive terms “consisting of” and “essentially consisting of”. In one embodiment, the term “comprising” as used throughout the application and in particular within the claims may be replaced by the term “consisting of”.

In the context of the present invention, the term “about” or “approximately” means within 80% to 120%, alternatively within 90% to 110%, including within 95% to 105% of a given value.

In the antibody or fragment thereof according to the invention, a) at least 12 amino acid residues are present between

- i) amino acid residue HC res25 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res S25) and the first amino acid residue of the natriuretic peptide in case of an incorporation of the heterologous amino acid sequence within CDRH1;
- ii) amino acid residue HC res51 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res 151) and the first amino acid residue of the natriuretic peptide in case of an incorporation of the heterologous amino acid sequence within CDRH2;
- iii) amino acid residue HC res92 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res C96) and the first amino acid residue of the natriuretic peptide in case of an incorporation of the heterologous amino acid sequence within CDRH3;
- iv) amino acid residue LC res26 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res S25) and the first amino acid residue of the natriuretic peptide in case of an incorporation of the heterologous amino acid sequence within CDRL1;
- v) amino acid residue LC res49 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res Y51) and the first amino acid residue of the natriuretic peptide in case of an incorporation of the heterologous amino acid sequence within CDRL2; and/or
- vi) amino acid residue LC res88 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res C90) and the first

13

- amino acid residue of the natriuretic peptide in case of an incorporation of the heterologous amino acid sequence within CDR3; and b) at least 9 amino acid residues are present between the last amino acid residue of the natriuretic peptide and
- i) amino acid residue HC res35a according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res M34) in case of an incorporation of the heterologous amino acid sequence within CDRH1;
 - ii) amino acid residue HC res57 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res T58) in case of an incorporation of the heterologous amino acid sequence within CDRH2;
 - iii) amino acid residue HC res106 according to Kabat (in the heavy chain having the amino acid sequence of SEQ ID NO 65 this corresponds to res G111) in case of an incorporation of the heterologous amino acid sequence within CDRH3;
 - iv) amino acid residue LC res 32 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res D34) in case of an incorporation of the heterologous amino acid sequence within CDRL1;
 - v) amino acid residue LC res57 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res G59) in case of an incorporation of the heterologous amino acid sequence within CDRL2; and/or
 - vi) amino acid residue LC res98 according to Kabat (in the light chain having the amino acid sequence of SEQ ID NO 66 this corresponds to res F102) in case of an incorporation of the heterologous amino acid sequence within CDRL3.

The denomination of the above listed amino acid residues refers to the amino acid position in the original immunoglobulin molecule before incorporation of the heterologous amino acid sequence. Within the context of the present invention, the above listed amino acid residues are referred to as "reference amino acids" or "reference aa". These reference amino acid residues lie at or near CDR framework junctions but do not necessarily correspond to standard CDR border definitions (standard CDR border definitions are amino acid residues S25 and W36 for CDRH1; S49 and R67 for CDRH2; K98 and W108 for CDRH3; C22 and W37 for CDRL1; Y51 and G59 for CDRL2; C90 and F102 for CDRL3. Jarasch and Skerra, Proteins 2017 January; 85 (1): 65-71).

The nearest neighboring reference aa N-terminal from the inserted natriuretic peptide plus the amino acid stretch present between said reference aa and the first amino acid residue of the inserted natriuretic peptide are herein referred to as "N-terminal sequence". The N-terminal sequence comprises the Ntls. In particular embodiments, the N-terminal sequence consists of the Ntls plus the neighboring N-terminal reference aa.

The amino acid stretch present between the last amino acid residue of the inserted natriuretic peptide and the nearest neighboring reference aa C-terminal from the inserted natriuretic peptide plus said reference aa are herein referred to as "C-terminal sequence". The C-terminal sequence comprises the Ctls. In particular embodiments, the C-terminal sequence consists of the Ctls plus the neighboring C-terminal reference aa.

In particular embodiments, the Ntls comprises a GS linker sequence; a PN linker sequence; an amino acid sequence

14

- which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOs 1, 2 or 4, or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOs 1, 2 or 4; the sequence of any one of SEQ ID NOs 6, 7, 9, 11, 13, 15, 16, 17, 19 or 21; or a sequence that shares at least 60%, at least 70%, at least 80%, at least 90% or at least 95% sequence identity with any one of SEQ ID NO 6, 7, 9, 11, 13, 15, 16, 17, 19 or 21. The Ntls may also comprise any combination of the above listed amino acid sequences.
- In particular such embodiments, the Ntls comprises a GS linker sequence; a PN linker sequence; an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOs 1, 2 or 4, or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOs 1, 2 or 4; the sequence of any one of SEQ ID NOs 6, 7, 9, 11, 13, 15 or 21; a sequence that shares at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO 6, 7, 9, 11, 13, 15, or 21; or any combination thereof.
 - In particular embodiments, the Ctls comprises a GS linker sequence; a PN linker sequence; an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOs 1, 3 or 5, or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOs 1, 3 or 5; the sequence of any one of SEQ ID NOs 6, 8, 10, 12, 14, 15, 17, 18, 19, 20 or 22; or a sequence that shares at least 60%, at least 70%, at least 80%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOs 6, 8, 10, 12, 14, 15, 17, 18, 19, 20 or 22. The Ctls may also comprise any combination of the above listed amino acid sequences.
 - In particular embodiments, the Ctls comprises a GS linker sequence; a PN linker sequence; an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOs 1, 3 or 5, or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOs 1, 3 or 5; the sequence of any one of SEQ ID NOs 6, 8, 10, 12, 14, 15, 20 or 22; a sequence that shares at least 60%, at least 70%, at least 80%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOs 6, 8, 10, 12, 14, 15, 20 or 22; or any combination thereof.

In particular embodiments the sequence identity between the sequence comprised in the Ntls and/or the Ctls and any one of SEQ ID NOs 1 to 22 is at least 60%, particularly at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100%.

Within the context of the present invention the term "GS linker sequence" refers to a peptide linker comprising

15

mainly glycine and serine residues. Particularly, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the amino acid residues of the GS linker sequence according to the present invention are selected from glycine and serine residues. The GS linker sequence according to the present invention may for example comprise from 1 to 30 amino acid residues in total. Particularly, the GS linker sequence according to the present invention does not comprise more than 3, 2 or 1 amino acid residue(s) other than glycine or serine.

Within the context of the present invention the term "PN linker sequence" refers to a peptide linker comprising mainly proline and asparagine residues. Particularly, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the amino acid residues of the PN linker sequence according to the present invention are selected from proline and asparagine residues. The PN linker sequence according to the present invention may for example comprise from 1 to 30 amino acid residues in total. Particularly, the PN linker sequence according to the present invention does not comprise more than 3, 2 or 1 amino acid residue(s) other than proline or asparagine. Other amino acid residues that may be present in a PN linker sequence according to the present invention are for instance lysine or glutamic acid residues.

In particular embodiments, the linker sequence comprised in the Ntls and/or the Ctls and selected from a GS linker sequence; a PN linker sequence; a human IgG antibody scaffold linker sequence; a human IgG fab domain scaffold sequence; a sequence that shares at least 80% sequence identity with the human IgG antibody scaffold linker sequence, the human IgG fab domain scaffold sequence or the sequence of any one of SEQ ID NOS 1 to 5; and a sequence that shares at least 60% sequence identity with any one of SEQ ID NOS 6 to 22, comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues. The linker sequence comprised in the Ntls and/or the Ctls may for instance comprise up to 30, 28, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10 amino acid residues.

In the case of linkers comprising a sequence of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, it may be particularly advantageous to use a sequence of a scaffold region which is adjacent to the CDR into which the heterologous amino acid sequence is incorporated. For example, the Ntls and/or the Ctls may comprise a linker comprising an amino acid sequence that is part of framework region FRH2 or FRH3 in case the heterologous amino acid sequence is incorporated within the CDRH2 domain. Similarly, the Ntls and/or the Ctls may comprise a linker comprising an amino acid sequence that is part of framework region FRL2 or FRL3 in case the heterologous amino acid sequence is incorporated within the CDRL2 region.

In particular embodiments, the Ntls consists of a GS linker sequence; a PN linker sequence; an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOS 1, 2 or 4 or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOS 1, 2 or 4; the sequence of any one of SEQ ID NOS 6, 7, 9, 11, 13, 15, 16, 17, 19 or 21; a sequence that shares at least 60%, at least 70%, at least

16

80%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOS 6, 7, 9, 11, 13, 15, 16, 17, 19 or 21; or any combination thereof.

In particular embodiments, the Ctls consists of a GS linker sequence; a PN linker sequence; an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOS 1, 3 or 5 a sequence that shares at least 80% sequence identity with any one of SEQ ID NOS 1, 3 or 5; the sequence of any one of SEQ ID NOS 6, 8, 10, 12, 14, 15, 17, 18, 19, 20 or 22; a sequence that shares at least 60%, at least 70%, at least 80%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOS 6, 8, 10, 12, 14, 15, 17, 18, 19, 20 or 22; or any combination thereof.

In particular embodiments, both the Ntls and the Ctls comprise at least one of the above listed linker sequences or any combination thereof. In principle, any of the above listed Ntls linker sequences may be combined with any of the above listed Ctls linker sequences. In particular, any linker sequence may be combined with a GS linker. As a non-limiting example, a GS Ctls linker may be combined with an Ntls linker comprising the sequence of any one of SEQ ID NOS 6, 9 or 15 or a sequence that shares at least 60% sequence identity with any one of SEQ ID NOS 6, 9 or 15. A further non-limiting example is a GS Ntls linker combined with a Ctls linker comprising the sequence of SEQ ID NO 15 or a sequence that shares at least 60% sequence identity therewith.

The above listed linker sequences have proven particularly advantageous for achieving good natriuretic peptide activities, given a sufficient total length of the N-terminal and C-terminal flanking sequences. Without wishing to be bound by theory, it is believed that the above listed linker peptide stretches result in a conformation/folding that contributes to a favorable state of the system in presentation of a biologically active natriuretic peptide to its respective receptor with minimal sterical hindrance.

In particular embodiments, i) the Ntls comprises a GS linker sequence; a PN linker sequence; the sequence of SEQ ID NOS 2, 4, 9, 11, 13 or 15; a sequence that shares at least 60% sequence identity with SEQ ID NOS 2, 4, 9, 11, 13 or 15; or any combination thereof and ii) the Ctls comprises a GS linker sequence; a PN linker sequence; the sequence of SEQ ID NOS 3, 5, 12, 14, 15 or 20; a sequence that shares at least 60% sequence identity with SEQ ID NOS 3, 5, 12, 14, 15 or 20; or any combination thereof. These linker sequences have proven particularly useful as they not only achieve high natriuretic peptide activities but also good expression levels in recombinant expression and are not prone to protein fragmentation upon expression (see Table 9).

In particular embodiments, the Ntls and the Ctls each comprise a GS linker sequence; the Ntls and the Ctls each comprise a PN linker sequence; the Ntls and the Ctls each comprise an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the Ntls comprises the sequence of any one of SEQ ID NOS 1, 2 or 4 or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOS 1, 2 or 4 and the Ctls comprises the

17

sequence of any one of SEQ ID NOs 1, 3 or 5 or a sequence that shares at least 80% sequence identity therewith; the Ntls and the Ctls each comprise the sequence of SEQ ID NO 6 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 7 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 8 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 9 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 10 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 11 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 12 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 13 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 14 or a sequence that shares at least 60% sequence identity therewith; the Ntls and the Ctls each comprise the sequence of SEQ ID NO 15 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 16 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 17 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 17 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 18 or a sequence that shares at least 60% sequence identity therewith; the Ntls and the Ctls each comprise the sequence of SEQ ID NO 19 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 9 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 20 or a sequence that shares at least 60% sequence identity therewith; or the Ntls comprises the sequence of SEQ ID NO 21 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 22 or a sequence that shares at least 60% sequence identity therewith.

In particular such embodiments, the Ntls and the Ctls each comprise a GS linker sequence; the Ntls and the Ctls each comprise a PN linker sequence; the Ntls and the Ctls each comprise an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the Ntls comprises the sequence of any one of SEQ ID NOs 1, 2 or 4 or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOs 1, 2 or 4 and the Ctls comprises the sequence of any one of SEQ ID NOs 1, 3 or 5 or a sequence that shares at least 80% sequence identity therewith; the Ntls and the Ctls each comprise the sequence of SEQ ID NO 6 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 7 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 8 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 9 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 10 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence

18

of SEQ ID NO 11 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 12 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 13 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 14 or a sequence that shares at least 60% sequence identity therewith; the Ntls and the Ctls each comprise the sequence of SEQ ID NO 15 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 9 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 20 or a sequence that shares at least 60% sequence identity therewith; or the Ntls comprises the sequence of SEQ ID NO 21 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 22 or a sequence that shares at least 60% sequence identity therewith.

In particular such embodiments, the Ntls and the Ctls each comprise a GS linker sequence; the Ntls and the Ctls each comprise a PN linker sequence; the Ntls comprises the sequence of SEQ ID NO 2 or a sequence that shares at least 80% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 3 or a sequence that shares at least 80% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 4 or a sequence that shares at least 80% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 5 or a sequence that shares at least 80% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 11 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 12 or a sequence that shares at least 60% sequence identity therewith; the Ntls comprises the sequence of SEQ ID NO 13 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 14 or a sequence that shares at least 60% sequence identity therewith; the Ntls and the Ctls each comprise the sequence of SEQ ID NO 15 or a sequence that shares at least 60% sequence identity therewith; or the Ntls comprises the sequence of SEQ ID NO 9 or a sequence that shares at least 60% sequence identity therewith and the Ctls comprises the sequence of SEQ ID NO 20 or a sequence that shares at least 60% sequence identity therewith. These linker combinations have proven particularly useful for achieving high natriuretic peptide activities, good expression levels in recombinant expression and minimal or no protein fragmentation, as shown in Table 9.

In particular embodiments, the Ntls further comprises an anchoring element A1 at its C terminal end and/or the Ctls further comprises an anchoring element A2 at its N terminal end, wherein A1 and A2 predominantly comprise glycine and serine residues. In particular embodiments, A1 and/or A2 comprise at least 1, 2, 3, 4, or 5 amino acid residues. A1 and/or A2 may comprise up to 10, 9, 8, 7, 6 or 5 amino acid residues in total. In particular embodiments, at least 60%, at least 70%, at least 80%, at least 90%, or 100% of the amino acid residues of A1 and/or A2 are selected from glycine and serine residues. Particularly A1 and/or A2 do/does not comprise more than 3, 2 or 1 amino acid residue other than glycine or serine.

In particular embodiments the Ntls consists of i) an anchoring element A1 at its C terminal end and ii) a GS linker sequence; a PN linker sequence; an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a

19

sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOs 1, 2 or 4 or a sequence that shares at least 80% sequence identity with any one of SEQ ID NOs 1, 2 or 4; the sequence of any one of SEQ ID NOs 6, 7, 9, 11, 13, 15, 16, 17, 19 or 21; a sequence that shares at least 60% sequence identity with any one of SEQ ID NO 6, 7, 9, 11, 13, 15, 16, 17, 19 or 21; or any combination thereof.

In particular embodiments, the Ctls consists of i) an anchoring element A2 at its N terminal end and ii) a GS linker sequence; a PN linker sequence; an amino acid sequence which is part of a human IgG antibody scaffold or a sequence that shares at least 80% sequence identity therewith, particularly an amino acid sequence which is part of the fab domain scaffold of a human IgG antibody or a sequence that shares at least 80% sequence identity therewith, more particularly the sequence of any one of SEQ ID NOs 1, 3 or 5 a sequence that shares at least 80% sequence identity with any one of SEQ ID NOs 1, 3 or 5; the sequence of any one of SEQ ID NOs 6, 8, 10, 12, 14, 15, 17, 18, 19, 20 or 22; a sequence that shares at least 60% sequence identity with any one of SEQ ID NOs 6, 8, 10, 12, 14, 15, 17, 18, 19, 20 or 22; or any combination thereof.

In particular embodiments, the Ntis and/or the Ctls comprise(s) at least 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues in total. The Ntis and/or the Ctls may for instance comprise up to 30, 28, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10 amino acid residues in total.

In particular embodiments, the amino acid stretch present between

- i) amino acid residue HC res25 according to Kabat and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRH1;
- ii) amino acid residue HC res51 according to Kabat and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRH2;
- iii) amino acid residue HC res92 according to Kabat and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRH3;
- iv) amino acid residue LC res26 according to Kabat and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRL1;
- v) amino acid residue LC res49 according to Kabat and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or
- vi) amino acid residue LC res88 according to Kabat and the first amino acid residue of the natriuretic peptide in case of an incorporation of said heterologous amino acid sequence within CDRL3

comprises the sequence of any one of SEQ ID NOs 26 to 38 or a sequence having at least 80%, 85%, 90%, 95% or at least 98% sequence identity with any one of SEQ ID NOs 26 to 38.

In particular embodiments, the amino acid stretch present between the last amino acid residue of the natriuretic peptide and

- i) amino acid residue HC res35a according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH1;
- ii) amino acid residue HC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH2;

20

iii) amino acid residue HC res106 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH3;

iv) amino acid residue LC res 32 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL1;

v) amino acid residue LC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or

vi) amino acid residue LC res98 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL3

comprises the sequence of any one of SEQ ID NOs 39 to 51 or a sequence having at least 80%, 85%, 90%, 95% or at least 98% sequence identity with any one of SEQ ID NOs 39 to 51.

In particular embodiments, the heterologous amino acid sequence consists of the Ntis, the natriuretic peptide and the Ctls.

In particular embodiments, the amino acid stretch present between

i) amino acid residue HC res25 according to Kabat and amino acid residue HC res35a according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH1;

ii) amino acid residue HC res51 according to Kabat and amino acid residue HC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH2;

iii) amino acid residue HC res92 according to Kabat and amino acid residue HC res106 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH3;

iv) amino acid residue LC res26 according to Kabat and amino acid residue LC res 32 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL1;

v) amino acid residue LC res49 according to Kabat and amino acid residue LC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL2; and/or

vi) amino acid residue LC res88 according to Kabat and amino acid residue LC res98 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL3 comprises the sequence of any one of SEQ ID NOs 52 to 64 or a sequence having at least 80%, 85%, 90%, 95% or at least 98% sequence identity with any one of SEQ ID NOs 52 to 64.

In particular embodiments, the antibody or fragment thereof comprises at least two natriuretic peptides. In particular embodiments, both natriuretic peptides are comprised in a heterologous amino acid sequence further comprising an Ntis and a Ctls and incorporated within a CDR region of said antibody or fragment thereof, as described herein. The at least two natriuretic peptides may be incorporated within the two corresponding CDR regions of two light chains or two heavy chains or the at least two natriuretic peptides may be incorporated within two separate CDR regions. The at least two natriuretic peptides may be the same or different. In particular such embodiments, the antibody or fragment thereof comprises at least two different natriuretic peptides that are incorporated within at least two CDR regions.

Due to the dimeric structure of antibody molecules, the insertion of one nucleic acid sequence encoding the heterologous amino acid sequence (Ntis-natriuretic peptide-Ctls) into the nucleic acid encoding either the light or the heavy chain of an immunoglobulin molecule typically yields an

antibody protein carrying two natriuretic peptides located in the corresponding CDR regions of the two identical light or the two identical heavy chains. However, it is also envisaged to insert two natriuretic peptide encoding nucleic acids into two different CDR encoding regions of the nucleic acid sequences encoding the light and/or the heavy chain, thereby yielding an antibody molecule with four natriuretic peptides located in two corresponding CDR pairs of the dimeric antibody. Also encompassed are dimeric immunoglobulin molecules whose light chains and/or heavy chains are not identical, for instance including dimeric antibodies carrying a single natriuretic peptide as well as dimeric antibodies carrying two different natriuretic peptides in two corresponding CDR regions of the two light or the two heavy chains.

In particular embodiments, natriuretic peptides are inserted in the CDRH1 and CDRH2, CDRH1 and CDRH3, CDRH2 and CDRH3, CDRH1 and CDRL1, CDRH1 and CDRL2, CDRH1 and CDRL3, CDRH2 and CDRL1, or CDRH2 and CDRL2. In particular embodiments, the antibody or fragment thereof comprises one ANP and one BNP molecule; one ANP and one CNP molecule; or one BNP and one CNP molecule.

In particular embodiments, the natriuretic peptide comprised in the at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof is an BNP and the antibody or fragment thereof comprises at least one further natriuretic peptide. In particular embodiments, the at least one further natriuretic peptide is also comprised in a heterologous amino acid sequence further comprising an NtIs and a CtIs and incorporated within a CDR region of said antibody or fragment thereof. In particular embodiments, the BNP and the at least one further natriuretic peptide are incorporated within two corresponding CDR regions of either the two light or the two heavy chains of the antibody or fragment thereof. In particular other embodiments, the BNP and the at least one further natriuretic peptide are incorporated within at least two separate CDR regions. Particularly, said at least one further natriuretic peptide is selected from ANP, BNP and CNP, more particularly from ANP and CNP.

The "empty" antibody molecule not harboring a heterologous amino acid sequence comprising a natriuretic peptide which is composed of two heavy chains having the sequence of SEQ ID NO 65 and two light chains having the sequence of SEQ ID NO 66 is termed TPP-5657. In particular embodiments, an antibody molecule composed of two heavy chains having the sequence of SEQ ID NO 65 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity therewith and two light chains having the sequence of SEQ ID NO 66 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity therewith serves as the initial or parental antibody, into which the heterologous amino acid sequence comprising the natriuretic peptide is incorporated. In particular such embodiments, the heterologous amino acid sequence comprising the natriuretic peptide is incorporated within a CDR region of one or both heavy chains of such antibody molecule.

In particular such embodiments, the heavy chain(s) comprising the at least one heterologous amino acid sequence incorporated within at least one of its CDR regions has the sequence of any one of SEQ ID NOs 67 to 79 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOs 67 to 79. In particular embodiments, the antibody according to the present invention is composed of two identical heavy chains

having the sequence of any one of SEQ ID NOs 67 to 79 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOs 67 to 79 and two identical light chains having the sequence of SEQ ID NO 66 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity therewith.

In particular other embodiments, the heterologous amino acid sequence comprising the natriuretic peptide is incorporated within a CDR region of one or both light chains of such antibody molecule. In particular such embodiments, the light chain(s) comprising the at least one heterologous amino acid sequence incorporated within at least one of its CDR regions has(have) the sequence of any one of SEQ ID NOs 80 or 81 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOs 80 or 81. In particular embodiments, the antibody according to the present invention is composed of two identical light chains having the sequence of any one of SEQ ID NOs 80 or 81 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOs 80 or 81 and two identical heavy chains having the sequence of SEQ ID NO 65 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity therewith.

The table below depicts the heavy and light chain composition of exemplary antibodies according to the present invention.

TABLE 1

	Exemplary natriuretic peptide grafted antibody constructs		
TPP-Number	Heavy Chain	Light Chain	
TPP-5661	SEQ ID NO 67	SEQ ID NO 66	
TPP-10274	SEQ ID NO 68	SEQ ID NO 66	
TPP-10282	SEQ ID NO 69	SEQ ID NO 66	
TPP-10283	SEQ ID NO 70	SEQ ID NO 66	
TPP-10290	SEQ ID NO 71	SEQ ID NO 66	
TPP-10294	SEQ ID NO 72	SEQ ID NO 66	
TPP-10765	SEQ ID NO 73	SEQ ID NO 66	
TPP-10845	SEQ ID NO 74	SEQ ID NO 66	
TPP-10847	SEQ ID NO 75	SEQ ID NO 66	
TPP-10992	SEQ ID NO 76	SEQ ID NO 66	
TPP-13054	SEQ ID NO 77	SEQ ID NO 66	
TPP-13061	SEQ ID NO 78	SEQ ID NO 66	
TPP-13230	SEQ ID NO 79	SEQ ID NO 66	
TPP-10355	SEQ ID NO 65	SEQ ID NO 80	
TPP-10361	SEQ ID NO 65	SEQ ID NO 81	
TPP-9902	SEQ ID NO 442	SEQ ID NO 66	
TPP-11156	SEQ ID NO 443	SEQ ID NO 66	
TPP-18034	SEQ ID NO 444	SEQ ID NO 66	
TPP-12897	SEQ ID NO 445	SEQ ID NO 447	
TPP-12377	SEQ ID NO 445	SEQ ID NO 66	
TPP-9465	SEQ ID NO 446	SEQ ID NO 66	

Antibodies of the present invention or fragments thereof include naturally occurring purified products, products of chemical synthetic procedures, and products produced by recombinant techniques. Depending on its origin, the antibody or fragment thereof according to the present invention may be glycosylated or non-glycosylated.

For example, standard recombinant DNA methodologies may be used to prepare and/or obtain nucleic acids encoding the heavy and light chains, incorporate these nucleic acids into expression vectors and introduce the vectors into host cells for recombinant expression (see, for example, Sambrook, Fritsch and Maniatis (eds.), Molecular Cloning; A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989); Ausubel, F. M. et al. (eds.) Current Protocols

in Molecular Biology, Greene Publishing Associates, (1989); Goeddel, Gene Expression Technology, Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990); and U.S. Pat. No. 4,816,397 by Boss et al.).

Thus, in a second aspect, the present invention relates to a nucleic acid or a mixture of nucleic acids encoding the antibody or fragment thereof according to the present invention. These nucleic acid sequences may be optimized in certain cases for mammalian expression. DNA molecules of the invention are not limited to the sequences disclosed herein, but also include variants thereof.

The present invention further provides recombinant nucleic acid constructs comprising one or more of the nucleic acid sequences according to the present invention. The recombinant nucleic acid construct according to the present invention may for instance comprise a nucleic acid vector, such as a plasmid, into which a nucleic acid molecule encoding an antibody or fragment thereof according to the present invention has been inserted. It is understood that the design of the expression vector, including the selection of regulatory sequences is affected by factors such as the choice of the host cell, the desired protein expression level and whether constitutive or inducible expression is desired.

Useful expression vectors for bacterial use may be constructed by inserting one or more nucleic acid sequences according to the present invention together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. Bacterial expression vectors typically comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and, if desirable, to provide amplification within the bacterial host. Bacterial expression vectors may comprise elements derived from commercially available plasmids such as the well-known cloning vector pBR322 (ATCC 37017). A number of bacterial expression vectors may be advantageously selected depending upon the use intended of the expressed antibody or fragment thereof. For example, if a large quantity of such antibody is desired, vectors mediating high level expression of antibody fusion proteins that are readily purified may be desirable.

Recombinant nucleic acid constructs intended for antibody expression in a eukaryotic host cell may comprise regulatory sequences that are able to control the expression of an open reading frame in a eukaryotic cell, preferably a promoter and a polyadenylation signal. Promoters and polyadenylation signals are preferably selected to be functional within the specific cell type intended for antibody expression. Examples of suitable promoters include but are not limited to promoters from Cytomegalovirus (CMV), such as the strong CMV immediate early promoter, Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV), Human Immunodeficiency Virus (HIV), such as the HIV Long Terminal Repeat (LTR) promoter, Moloney virus, Epstein Barr Virus (EBV), adenovirus (e.g., the adenovirus major late promoter (AdMLP)), polyoma and from Rous Sarcoma Virus (RSV), the synthetic CAG promoter composed of the CMV early enhancer element, the promoter, the first exon and the first intron of chicken beta-actin gene and the splice acceptor of the rabbit beta globin gene, as well as promoters from mammalian genes such as actin, myosin, hemoglobin, muscle creatine, and metallothionein. In a particular embodiment, the eukaryotic expression cassette contains the CMV promoter. In the context of the present invention, the term "CMV promoter" refers to the strong immediate-early cytomegalovirus promoter.

Examples of suitable polyadenylation signals include but are not limited to the bovine growth hormone (BGH) polyadenylation site, SV40 polyadenylation signals and LTR polyadenylation signals.

In addition, the recombinant nucleic acid sequence may comprise one or more enhancer sequences. The enhancer can be, for example, an enhancer of mammalian actin, myosin, hemoglobin, muscle creatine or a viral enhancer, e.g. an enhancer from CMV, RSV, SV40 or EBV. For further description of viral regulatory elements, and sequences thereof, see e.g., U.S. Pat. No. 5,168,062 by Stinski, U.S. Pat. No. 4,510,245 by Bell et al. and U.S. Pat. No. 4,968,615 by Schaffner et al.

Regulatory sequences and codons are generally species dependent, so in order to maximize protein production, the regulatory sequences and codons are preferably selected to be effective in the species/cell type intended for antibody expression. The person skilled in the art can produce recombinant DNA molecules that are functional in a given subject species.

The mammalian recombinant expression vectors can also include origins of replication and selectable markers (see e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017).

Suitable selectable markers include genes that confer resistance to drugs such as G418, puromycin, hygromycin, blasticidin, zeocin/bleomycin or methotrexate or selectable marker that exploit auxotrophies such as Glutamine Synthetase on a host cell into which the vector has been introduced. For example, the dihydrofolate reductase (DHFR) gene confers resistance to methotrexate, the neo gene confers resistance to G418, the bsd gene from *Aspergillus terreus* confers resistance to blasticidin, puromycin N-acetyl-transferase confers resistance to puromycin, the Sh ble gene product confers resistance to zeocin, and resistance to hygromycin is conferred by the *E. coli* hygromycin resistance gene (hyg or hph). Selectable markers like DHFR or Glutamine Synthetase are also useful for amplification techniques in conjunction with MTX and MSX.

In some embodiments, the nucleic acid sequences encoding the heavy and light chains are inserted into separate vectors. In other embodiments, the nucleic acid sequences encoding the heavy and light chains are inserted into the same vector. In addition, the nucleic acid sequences encoding variable regions of the heavy and/or light chains can be converted, for example, to nucleic acid sequences encoding full-length antibody chains, Fab fragments, or to scFv. The VL- or VH-encoding DNA fragment can be operatively linked, (such that the amino acid sequences encoded by the two DNA fragments are in-frame) to another DNA fragment encoding, for example, an antibody constant region or a flexible linker. As an example, to create a polynucleotide sequence that encodes a scFv, the VH- and VL-encoding nucleic acids can be operatively linked to another fragment encoding a flexible linker such that the VH and VL sequences can be expressed as a contiguous single-chain protein, with the VL and VH regions joined by the flexible linker (see e.g., Bird et al. (1988) Science 242:423-426; Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; McCafferty et al., Nature (1990) 348:552-554). The sequences of human heavy chain and light chain constant regions are known in the art (see e.g., Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments encompassing these regions can be obtained by standard PCR amplification.

In particular embodiments, the nucleic acid sequences encoding the heavy chain into which the heterologous amino acid sequence comprising the natriuretic peptide is incorporated comprises the sequence of any one of SEQ ID NOs 82 or 83 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity with any one of SEQ ID NOs 82 or 83. In particular such embodiments, the nucleic acid sequence encoding the light chain comprises the sequence of SEQ ID NO 84 or a sequence having at least 80%, at least 85%, at least 90% or at least 95% sequence identity therewith.

In a third aspect, the present invention relates to a host cell comprising the nucleic acid or the mixture of nucleic acids according to the present invention. Within the context of the present invention, the terms "host cell", "host cell line", and "host cell culture" are used interchangeably and refer to cells into which an exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants", "transformed cells", "transfectants", "transfected cells", and "transduced cells", which include the primary transformed/transfected/transduced cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, and the comprised exogenous nucleic acid may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

Transfection of the expression vector into a host cell can be carried out using standard techniques such as electroporation, nucleofection, calcium-phosphate precipitation, lipofection, polycation-based transfection such as polyethylenimine (PEI)-based transfection and DEAE-dextran transfection.

Suitable host cells include prokaryotic and eukaryotic cells. Examples for prokaryotic host cells are e.g. bacteria and include but are not limited to *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*.

Non limiting examples of eukaryotic hosts cells include yeasts, insects and insect cells, plants and plant cells, transgenic animals and mammalian cells. Suitable mammalian host cells for antibody expression include Chinese Hamster Ovary (CHO cells) such as CHO-K1, CHO-S, CHO-K1SV (including dhfr-CHO cells, described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220 and Urlaub et al., Cell. 1983 June; 33(2):405-12, used with a DHFR selectable marker, e.g., as described in R. J. Kaufman and P. A. Sharp (1982) Mol. Biol. 159:601-621; and other knock-out cells exemplified in Fan et al., Biotechnol Bioeng. 2012 April; 109(4):1007-15), NSO myeloma cells, COS cells, HEK293 cells, HKB11 cells, BHK21 cells, CAP cells, EB66 cells, and SP2 cells.

Expression may also be transient or semi-stable in expression systems such as HEK293, HEK293T, HEK293-EBNA, HEK293E, HEK293-6E, HEK293-Freestyle, HKB11, Expi293F, 293EBNALT75, CHO Freestyle, CHO—S, CHO-K1, CHO-K1SV, CHOEBNALT85, CHOS-XE, CHO-3E7 or CAP-T cells (for instance Durocher et al., Nucleic Acids Res. 2002 Jan. 15; 30(2):E9).

In a fourth aspect, the present invention relates to a process for producing an antibody or fragment thereof, comprising culturing the host cell according to the present invention. Particularly, the host cell according to the present invention is cultured under conditions suitable for expression of the antibody or fragment thereof.

Antibody expression may be constitutive or regulated (e.g., inducible). For inducible antibody expression the host cell according to the present invention is typically grown to an appropriate cell density followed by de-repression/induction of the selected promoter by appropriate means (e.g., temperature shift or chemical induction such as addition or removal of small molecule inducers such as tetracycline in conjunction with Tet system) and culturing of the host cell for an additional period.

10 In particular embodiments, the process for producing an antibody or fragment thereof according to the present invention further comprises the step of recovering the antibody or fragment thereof from the host cell culture. Cells may for instance be harvested by centrifugation, disrupted by physical or chemical means, and the antibody or fragment thereof may be further purified from the resulting crude extract. In some embodiments, the expression vector is designed such that the expressed antibody or fragment thereof is secreted into the culture medium in which the host cells are grown. 15 In that case, the antibody or fragment thereof can be directly recovered from the culture medium using standard protein purification methods.

In particular embodiments, the process according to the present invention further comprises the step of purifying the recovered antibody or fragment thereof. Particularly, the antibody is purified (1) to greater than 90% as determined e.g. by analytical chromatography or by SDS-Capillary Gel electrophoresis (for example on a Caliper LabChip GXII, GX 90 or Biorad Bioanalyzer device), and, more particularly, purification yields an antibody homogeneity of at least about 92.5%, 95%, 98% or 99%; alternatively, the antibody is purified (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain.

Antibodies or fragments thereof according to the present invention can be recovered and purified from recombinant cell cultures by well-known methods including, but not limited to ammonium sulfate or ethanol precipitation, acid extraction, Protein A chromatography, Protein G chromatography, size exclusion chromatography, anion or cation exchange chromatography, phospho-cellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography ("HPLC") can also be employed for purification (see, e.g., Colligan, Current Protocols in Immunology, or Current Protocols in Protein Science, John Wiley & Sons, NY, N.Y., (1997-2001), e.g., Chapters 1, 4, 6, 8, 9, 10).

In a fifth aspect, the present invention relates to a composition comprising the antibody or fragment thereof according to the present invention. Particularly, the composition according to the present invention is a pharmaceutical composition suitable for use in a method for treatment, wherein the antibody or fragment thereof according to the present invention is contained in an amount effective to achieve the intended purpose, i.e. prevention or treatment of a particular disease state.

The composition optionally further comprises at least one pharmaceutically acceptable excipient. In the context of the present invention, the term "excipient" refers to a natural or synthetic substance formulated alongside the active ingredient of a medication. Suitable excipients include antiadherents, binders, coatings, disintegrants, flavors, colors, lubricants, glidants, sorbents, preservatives and sweeteners. Specific examples of pharmaceutically acceptable excipients

include but are not limited to saline, buffered saline, dextrose, and water. In the context of the present invention, the term "pharmaceutically acceptable" refers to molecular entities and other ingredients of pharmaceutical compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human). The term "pharmaceutically acceptable" may also mean approved by a regulatory agency of a Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and, more particularly, in humans.

The composition according to the present invention may further comprise one or more further therapeutically active agents.

The pharmaceutical composition may be in the form of a solution, a suspension, an enteric coated capsule, a lyophilized powder or any other form suitable for the intended use.

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable excipients well known in the art in dosages suitable for oral administration. Such excipients enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methylcellulose, hydroxypropylmethylcellulose, or sodium carboxymethyl cellulose; and gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores can be provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e. dosage.

Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations for parenteral administration include aqueous solutions of a therapeutically active agent. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances that increase viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active agent may be prepared as

appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the therapeutically active agent to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 7.5 that is combined with buffer prior to use.

Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Ed. Maack Publishing Co, Easton, Pa.).

After preparation of a pharmaceutical composition comprising the antibody or fragment thereof according to the present invention, it may be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of the antibody or fragment according to the present invention, such labeling would include amount, frequency and method of administration.

The present invention further provides pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions according to the present invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

In a sixth aspect, the present invention relates to the antibody or fragment thereof according to the present invention or the composition according to the present invention for use in a method for treatment.

Particularly, such method for treatment involves administering to a subject in need thereof a therapeutically effective amount of the antibody or fragment thereof according to the present invention. The subject may be a human or non-human animal (e.g., rabbit, rat, mouse, dog, monkey or other lower-order primate).

Within the context of the present invention, the term "therapeutically effective amount" is defined as the amount of an antibody or fragment thereof according to the present invention that is sufficient to prevent or alleviate disease symptoms of any of the disorders and diseases mentioned herein—either as a single dose or according to a multiple dose regimen, alone or in combination with other agents. In particular embodiments, said "therapeutically effective amount" is toxicologically tolerable. The determination of an effective dose is well within the capability of those skilled in the art. The therapeutically effective amount of a therapeutic agent usually largely depends on particular patient characteristics such as age, weight, gender and disease state,

time, frequency and route of administration, drug combination(s), and the nature of the disorder being treated. Common dosage amounts for antibodies vary from 0.1 to 100,000 micrograms, up to a total dose of about 10 g, depending upon the route of administration.

General guidance for its determination can be found, for example, in the publications of the International Conference on Harmonization and in REMINGTON'S PHARMACEUTICAL SCIENCES, chapters 27 and 28, pp. 484-528 (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). More specifically, determining a therapeutically effective amount will depend on such factors as toxicity and efficacy of the medicament that may be determined using methods well known in the art and found in the foregoing references. In brief, therapeutic efficacy and toxicity of therapeutic agents may be determined in cell culture assays or in animal models, e.g., as ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population), respectively. The dose ratio between ED₅₀ and LD₅₀ is the therapeutic index.

The antibody or fragment thereof according to the present invention is suitable for treatment and/or prophylaxis of cardiovascular, renal, pulmonary, skeletal, ocular, thromboembolic and fibrotic diseases and disorders, dwarfism, achondroplasia as well as other cGMP-related and/or natriuretic peptide responsive disorders. Thus, in particular embodiments, the antibody or fragment thereof is for use in the treatment and/or prophylaxis of any one of these disorders and diseases or any combination thereof.

The antibody or fragment thereof according to the present invention can therefore be used in medicaments for treatment and/or prophylaxis of cardiovascular disorders, for example arterial and pulmonary hypertension, resistant and refractory hypertension, acute and chronic heart failure, coronary heart disease, Bronchiolitis obliterans Syndrome (BOS), tumor related and oncological diseases, graft versus host disease, sickle cell disease, stable and unstable angina pectoris, peripheral and cardiac vascular disorders, arrhythmias, atrial and ventricular arrhythmias and impaired conduction, for example atrioventricular blocks degrees I-III (AB block I-III), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, Torsade de pointes tachycardia, atrial and ventricular extrasystoles, AV-junctional extrasystoles, sick sinus syndrome, syncopes, AV-nodal re-entry tachycardia, Wolff-Parkinson-White syndrome, of acute coronary syndrome (ACS), autoimmune cardiac disorders (pericarditis, endocarditis, valvulitis, aortitis, cardiomyopathies), shock such as cardiogenic shock, septic shock and anaphylactic shock, aneurysms, boxer cardiomyopathy (premature ventricular contraction (PVC)), for treatment and/or prophylaxis of thromboembolic disorders and ischaemias such as myocardial ischaemia, myocardial infarction, stroke, cardiac hypertrophy, transient and ischaemic attacks, preeclampsia, inflammatory cardiovascular disorders, spasms of the coronary arteries and peripheral arteries, oedema formation, for example pulmonary oedema, cerebral oedema, renal oedema or oedema caused by heart failure, peripheral circulatory disturbances, reperfusion damage, arterial and venous thromboses, microalbuminuria, myocardial insufficiency, endothelial dysfunction, to prevent restenosis, for example after thrombolysis therapies, percutaneous transluminal angioplasties (PTA), transluminal coronary angioplasties (PTCA), heart transplants and bypass operations, and also micro- and macrovascular damage (vasculitis), increased levels of fibrinogen and of low-density lipoprotein (LDL) and increased concentrations of

plasminogen activator inhibitor 1 (PAI-1), and also for treatment and/or prophylaxis of erectile dysfunction and female sexual dysfunction.

In the context of the present invention, the term "heart failure" encompasses both acute and chronic forms of heart failure, and also more specific or related types of disease, such as acute decompensated heart failure, right heart failure, left heart failure, global failure, ischaemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, idiopathic cardiomyopathy, congenital heart defects, heart failure associated with heart valve defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid valve stenosis, tricuspid valve insufficiency, pulmonary valve stenosis, pulmonary valve insufficiency, combined heart valve defects, myocardial inflammation (myocarditis), chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, diastolic heart failure and systolic heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF) and acute phases of worsening of existing chronic heart failure (worsening heart failure).

In addition, the antibody or fragment thereof according to the present invention can also be used for treatment and/or prophylaxis of arteriosclerosis, peripheral artery disease (PAD), impaired lipid metabolism, hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias, abetalipoproteinaemia, sitosterolemia, xanthomatosis, Tangier disease, adiposity, obesity and of combined hyperlipidaemias and metabolic syndrome.

The antibody or fragment thereof according to the present invention can additionally be used for treatment and/or prophylaxis of primary and secondary Raynaud's phenomenon, of microcirculation impairments, claudication, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers on the extremities, gangrene, CREST syndrome, erythematosis, onychomycosis, rheumatic disorders and for promoting wound healing.

The antibody or fragment thereof according to the present invention is also suitable for treating urological disorders, for example benign prostate syndrome (BPS), benign prostate hyperplasia (BPH), benign prostate enlargement (BPE), bladder outlet obstruction (BOO), lower urinary tract syndromes (LUTS, including Feline Urological Syndrome (FUS)), disorders of the urogenital system including neurogenic overactive bladder (OAB) and (IC), incontinence (UI), for example mixed urinary incontinence, urge urinary incontinence, stress urinary incontinence or overflow urinary incontinence (MUI, UUI, SUI, OUI), pelvic pain, benign and malignant disorders of the organs of the male and female urogenital system.

The antibody or fragment thereof according to the present invention is also suitable for treatment and/or prophylaxis of kidney disorders, in particular of acute and chronic renal insufficiency and acute and chronic renal failure. In the context of the present invention, the term "renal insufficiency" encompasses both acute and chronic manifestations of renal insufficiency, and also underlying or related renal disorders such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomerulopathies, glomerulonephritis, acute glomerulonephritis, glomerulosclerosis, tubulointerstitial diseases, nephropathic disorders such as primary and congenital kidney disease, nephritis, immunological kidney disorders such as kidney transplant rejection and immunocomplex-induced kidney disorders, nephropathy induced by toxic substances, nephropathy induced by

contrast agents, diabetic and non-diabetic nephropathy, pyelonephritis, renal cysts, nephrosclerosis, hypertensive nephrosclerosis and nephrotic syndrome which can be characterized diagnostically, for example by abnormally reduced creatinine and/or water excretion, abnormally elevated blood concentrations of urea, nitrogen, potassium and/or creatinine, altered activity of renal enzymes, for example glutamyl synthetase, altered urine osmolarity or urine volume, elevated microalbuminuria, macroalbuminuria, lesions on glomerular and arterioles, tubular dilatation, hyperphosphatemia and/or need for dialysis. The present invention also encompasses the use of the antibody or fragment thereof according to the present invention for treatment and/or prophylaxis of sequelae of renal insufficiency, for example pulmonary oedema, heart failure, uraemia, anaemia, electrolyte disturbances (for example hyperkalaemia, hyponatraemia) and disturbances in bone and carbohydrate metabolism.

In addition, the antibody or fragment thereof according to the present invention are also suitable for treatment and/or prophylaxis of asthmatic disorders, pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH) including left-heart disease, HIV, sickle cell anaemia, thromboembolisms (CTEPH), sarcoidosis, COPD or pulmonary fibrosis-associated pulmonary hypertension, chronic-obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), acute lung injury (ALI), alpha-1-antitrypsin deficiency (AATD), pulmonary fibrosis, pulmonary emphysema (for example pulmonary emphysema induced by cigarette smoke). Bronchiolitis obliterans Syndrom (BOS), and cystic fibrosis (CF).

The antibody or fragment thereof according to the present invention is also suitable for control of central nervous system disorders characterized by disturbances of the NO/cGMP system. It is suitable in particular for improving perception, concentration, learning or memory after cognitive impairments like those occurring in particular in association with situations/diseases/syndromes such as mild cognitive impairment, age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic craniocerebral trauma, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotrophic lateral sclerosis (ALS), Huntington's disease, demyelination, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, schizophrenia with dementia or Korsakoff's psychosis. It is also suitable for treatment and/or prophylaxis of central nervous system disorders such as states of anxiety, tension and depression, CNS-related sexual dysfunctions and sleep disturbances, and for controlling pathological disturbances of the intake of food, stimulants and addictive substances.

The antibody or fragment thereof according to the present invention is additionally also suitable for controlling cerebral blood flow and thus represent effective agents for controlling migraine. It is also suitable for the prophylaxis and control of sequelae of cerebral infarct (Apoplexia cerebri) such as stroke, cerebral ischaemias and skull-brain trauma. It can likewise be used for controlling states of pain and tinnitus.

In addition, the antibody or fragment according to the present invention has anti-inflammatory action and can

therefore be used as anti-inflammatory agents for treatment and/or prophylaxis of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory disorders of the kidney, chronic intestinal inflammations (IBD, Crohn's disease, UC), pancreatitis, peritonitis, rheumatoid disorders, inflammatory skin diseases and inflammatory eye diseases.

Furthermore, the antibody or fragment thereof according to the present invention can also be used for treatment and/or prophylaxis of autoimmune diseases.

10 The antibody or fragment thereof is also suitable for treatment and/or prophylaxis of fibrotic disorders of the internal organs, for example the lung, the heart, the kidney, the reproductive system, the bone marrow and in particular the liver, and also dermatological fibroses and fibrotic eye disorders. In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, uterine fibroids, endometriosis, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitreoretinopathy and disorders of the connective tissue (for example sarcoidosis).

20 The antibody or fragment thereof according to the present invention is also suitable for controlling postoperative scarring, for example as a result of glaucoma operations.

25 The antibody or fragment thereof according to the present invention can likewise be used cosmetically for ageing and keratinized skin.

30 Moreover, the antibody or fragment thereof according to the present invention is suitable for treatment and/or prophylaxis of hepatitis, neoplasms, osteoporosis, glaucoma and gastroparesis.

35 The antibody or fragment thereof according to the present invention is moreover suitable for treatment and/or prophylaxis of eye disorders such as ophthalmic diseases responsive to natriuretic peptides, retina disorders, glaucoma including primary open angle glaucoma (POAG), angle closure glaucoma, and congenital/developmental glaucoma, retinopathies, ocular trauma, optic neuropathies, ocular hypertension, elevated intraocular pressure, diabetic retinopathy, macular degeneration (AMD), age-related eye diseases, macular oedema, scleritis, uveitis, dry eye, corneal epithelial abrasion, corneal ulcer.

40 Moreover, the antibody or fragment thereof according to the present invention is suitable for the treatment of bone and cartilage disorders such as bone and cartilage diseases responsive to natriuretic peptides, arthritis, degenerative diseases of cartilage tissue, osteoarthritis, cartilage degeneration, bone fractures, skeletal dysplasias, achondroplasia, osteoporosis, osteogenesis imperfecta, Paget disease of bone (PDB), metabolic bone disease, age-related bone diseases, 45 osteomyelitis, osteonecrosis, rickets, osteomalacia, growth plate injuries and diseases, joint and bone replacement associated defects, Marfan syndrome, sports injuries, muscular dystrophies, Duchenne muscular dystrophy.

45 Thus, in another aspect, the present invention relates to the use of the antibody or fragment thereof according to the present invention for treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.

50 In particular embodiments, the antibody or fragment thereof according to the present invention is for use in a method for treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency, throm-

33

boembolic disorders, fibrotic disorders, skeletal and bone disorders, ocular disorders and arteriosclerosis.

In another aspect, the present invention relates to the use of antibody or fragment thereof according to the present invention for production of a medicament for treatment and/or prophylaxis of disorders, especially of the aforementioned disorders.

In particular embodiments, the present invention relates to the use of the antibody or fragment thereof according to the present invention for production of a medicament for treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency, thromboembolic disorders, fibrotic disorders, dementia illness, arteriosclerosis, skeletal and bone disorders, ocular disorders, dwarfism, achondroplasia and erectile dysfunction.

In another aspect, the present invention relates to a method for treatment and/or prophylaxis of disorders, in particular the disorders mentioned above, using an effective amount of at least one antibody or fragment thereof according to the present invention.

In particular embodiments, the present invention relates to a method for treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency, thromboembolic disorders, fibrotic disorders, tumor and oncological diseases, skeletal and bone disorders, ocular disorders, dwarfism, achondroplasia and arteriosclerosis using an effective amount of at least one antibody or fragment thereof according to the present invention.

An antibody of the invention or fragment thereof according to the present invention may be administered as the sole pharmaceutical agent or in combination with one or more additional therapeutic agents, and in some instances the antibody might itself be modified. For example, an antibody or fragment thereof could be conjugated to a chemical entity e.g., to further increase efficacy, stability and/or half-life. Particularly, the antibody or fragment thereof according to the present invention may be PEGylated and/or HESylated.

Thus, in particular embodiments, the antibody or fragment thereof according to the present invention is used in combination with at least one additional therapeutic agent in a method of treatment, in particular for the above cited purposes.

The present invention further provides pharmaceutical combinations comprising at least one antibody or fragment thereof according to the present invention and at least one additional therapeutic agent.

Within the context of the present invention, the term "pharmaceutical combination" is used as known to persons skilled in the art, it being possible for such combination to be a fixed combination, a non-fixed combination or a kit-of-parts.

Within the context of the present invention, the term "fixed combination" is used as known to persons skilled in the art and is defined as a combination wherein, for example, a first active ingredient, such as one or more antibody or fragment thereof according to the present invention, and a further active ingredient are present together in one unit dosage or in one single entity, e.g., a single dosage formulation. One example of a "fixed combination" is a pharmaceutical composition wherein a first active ingredient and a further active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a "fixed combination" is a pharmaceutical combination wherein a first active ingredient and a further active ingredient are present in one unit without being in admix-

34

ture. The present invention thus provides such pharmaceutical compositions comprising at least one antibody or fragment thereof and at least one additional therapeutic agent, in particular for use in treatment and/or prophylaxis of the aforementioned disorders.

Within the context of the present invention, the terms "non-fixed combination" and "kit-of-parts" are used as known to persons skilled in the art and are defined as a combination wherein a first active ingredient and a further active ingredient are present in more than one unit, e.g., in separate dosage formulations. One example of a non-fixed combination or kit-of-parts is a combination wherein the first active ingredient and the further active ingredient are present separately.

It is possible for the components of the non-fixed combination or kit-of-parts to be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.

The antibody or fragment thereof according to the present invention may be administered simultaneously with, prior to or after said further therapeutically active agent. In the context of the present invention, the term "simultaneously with" means administration of the antibody or fragment thereof according to the present invention and the at least one further therapeutically active agent on the same day, more particularly within 12 hours, more particularly within 2 hours.

In particular embodiments, administration of the antibody or fragment thereof according to the present invention and the at least one further therapeutically active agent occurs within eight consecutive weeks, more particularly within one to six consecutive weeks. The antibody or fragment thereof according to the present invention and the at least one further therapeutically active agent may be administered via the same route or via different routes.

The antibody or fragment thereof according to the present invention may for instance be combined with known agents of the same indication treatment group, such as agents used for the treatment and/or prophylaxis of diseases and/or conditions associated with hypertension, heart failure, pulmonary hypertension, COPD, asthma, cystic fibrosis, achondroplasia, hyperphosphatemia, chronic kidney disease (CKD), soft tissue calcification, chronic kidney disease associated calcification, non-chronic kidney disease associated calcification, media calcifications including Moenckeberg's medial sclerosis, atherosclerosis, intima calcification, CKD associated heart hypertrophy, CKD associated renal dystrophy, osteoporosis, post-menopausal osteoporosis, diabetes mellitus II, chronic renal disease, aging, hypophosphaturia, hyperparathyroidism, Vitamin D disorders, Vitamin K deficiency, Vitamin K-antagonist coagulants, Kawasaki disease, ACDC (arterial calcification due to deficiency of CD73), GACI (generalized arterial calcification of infancy), IBGC (idiopathic basal ganglia calcification), PXE (pseudoxanthoma elasticum), rheumatoid arthritis, Singleton-Merten syndrome, P-thalassemia, calciphylaxis, heterotrophic ossification, preterm placental calcification, calcification of the uterus, calcified uterine fibroids, morbus fahr, mircocalcification and calcification of the aortic valve.

Preferred examples of suitable further therapeutic agents to be combined with the antibody or fragment thereof according to the present invention:

organic nitrates and NO donors, for example sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;

35

compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP), for example inhibitors of phosphodiesterases (PDE) 1, 2 and/or 5, especially PDE 5 inhibitors such as sildenafil, vardenafil, tadalafil, udenafil, desantafil, avanafil, mirodenafil, lodenafil or PF-00489791; antithrombotic agents, by way of example and with preference from the group of the platelet aggregation inhibitors, the anticoagulants or the profibrinolytic substances; 10 hypotensive active ingredients, by way of example and with preference from the group of the calcium antagonists, angiotensin All antagonists, ACE inhibitors, NEP-inhibitors, vasopeptidase-inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, rho-kinase-inhibitors and the diuretics; 15 antiarrhythmic agents, by way of example and with preference from the group of sodium channel blocker, beta-receptor blocker, potassium channel blocker, calcium antagonists, If-channel blocker, digitalis, parasympatholytics (vagolytics), sympathomimetics and other antiarrhythmics as adenosin, adenosine receptor agonists as well as vernakalant; 20 positive-inotropic agents, by way of example cardiac glycoside (Dodoxin), beta-adrenergic and dopaminergic agonists, such as isoprenalin, adrenalin, noradrenalin, dopamin or dobutamin; 25 vasopressin-rezeptor-antagonists, by way of example and with preference from the group of conivaptan, tolvaptan, lixivaptan, moxavaptan, satavaptan, SR-121463, RWJ 676070 or BAY 86-8050, as well as the compounds described in WO 2010/105770, WO2011/ 30 104322 and WO 2016/071212; active ingredients which alter lipid metabolism, for example and with preference from the group of the thyroid receptor agonists, PCSK9 inhibitors, cholesterol synthesis inhibitors such as, by way of example and preferably, HMG-CoA reductase inhibitors or squalene synthesis inhibitors, of ACAT inhibitors, 35 CETP inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or PPAR-delta agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbents, bile acid reabsorption inhibitors and lipoprotein(a) antagonists. 40 45 anti-inflammatory agents, for example and with preference from the group of the gluco-corticoids, such as, by way of example and preferably, prednison, prednisolon, methylprednisolon, triamcinolon, dexamethason, beclomethason, betamethason, flunisolid, budesonid or fluticasone as well as the non-steroidal anti-inflammatory agents (NSAIDs), by way of example and preferably, acetyl salicylic acid (aspirin), ibuprofen and naproxen, 5-amino salicylic acid-derivates, leukotriene-antagonists, TNF-alpha-inhibitors and chemo-kine-receptor antagonists, such as CCR1, 2 and/or 5 inhibitors; 50 55 agents that inhibit the signal transductions cascade, for example and with preference from the group of the kinase inhibitors, by way of example and preferably, from the group of the tyrosine kinase and/or serine/threonine kinase inhibitors; agents that inhibit the degradation and modification of the extracellular matrix, for example and with preference from the group of the inhibitors of the matrix-metalloproteases (MMPs), by way of example and preferably, inhibitors of chymasee, stromelysine, col-

36

lagenases, gelatinases and aggrecanases (with preference from the group of MMP-1, MMP-3, MMP-8, MMP-9, MMP-10, MMP-11 and MMP-13) as well as of the metallo-elastase (MMP-12) and neutrophil-elastase (HNE), as for example sivelestat or DX-890; agents, that block the binding of serotonin to its receptor, for example and with preference antagonists of the 5-HT2b-receptor; anti-fibrotic agents, for example and with preference, nintedanib, pirfenidone, adenosine A2b receptor antagonists, sphingosine-1-phosphate receptor 3 (S1P3) antagonists, autotaxin-inhibitors, lysophosphatidic acid receptor 1 (LPA-1) and lysophosphatidic acid receptor 2 (LPA-2) antagonists, lysyloxidase (LOX) inhibitors, lysyloxidase-like-2 inhibitors, CTGF inhibitors, IL-13 antagonists, integrin antagonists, TGF-beta antagonists, inhibitors of wnt signaling, CCR2-antagonists; 10 agents, that act as bronchodilators, for example and with preference antagonists of the 5-HT2b-receptor; β_2 ("beta two")-adrenergic agonists (short- and long-acting), anticholinergics, and theophylline; agents that are antagonists of cytokines and chemokines, for example and with preference antagonists of TGF-beta, CTGF, IL-1, IL-4, IL-5, IL-6, IL-8, IL-13, IL-25, IL-33, TSLP and integrins; 15 organic nitrates and NO-donators, for example and with preference sodium nitroprussid, nitro-glycerine, isosorbid mononitrate, isosorbid dinitrate, molsidomine or SIN-1, as well as inhaled NO; 20 NO-independent, but heme-dependent stimulators of the soluble guanylate cyclase, for example and with preference the compounds described in WO 00/06568, WO 00/06569, WO 02/42301, WO 03/095451, WO 2011/ 147809, WO 2012/004258, WO 2012/028647 and WO 2012/059549; 25 NO-independent and heme-independent activators of the soluble guanylate cyclase, for example and with preference the compounds described in WO 01/19355, WO 01/19776, WO 01/19778, WO 01/19780, WO 02/070462 and WO 02/070510; 30 agents, that stimulate the synthesis of cGMP, for example sGC modulators, for example and with preference riociguat, cinaciguat, vericiguat; prostacyclin-analogs or IP receptor agonists, for example and with preference iloprost, beraprost, treprostinal, epoprostenol or Selexipag; 35 endothelin receptor antagonists, for example and with preference Bosentan, Darusentan, Ambrisentan oder Sitaxsentan; agents, that inhibit soulble epoxidhydrolase (sEH), for example and with preference N,N'-Di-cyclohexyl urea, 12-(3-Adamantan-1-yl-ureido)-dodecanic acid or 1-Adamantan-1-yl-3-[5-[2-(2-ethoxyethoxy)ethoxy] pentyl]-urea; 40 agents that interact with glucose metabolism, for example and with preference insuline, biguanide, thiazolidinedione, sulfonyl urea, acarbose, DPP4 inhibitors, GLP-1 analogs or SGLT-1 inhibitors; 45 natriuretic peptides, for example and with preference Atrial Natriuretic Peptide (ANP, Carperitide), Brain Natriuretic Peptide (BNP, Nesiritide), C-Type Natriuretic Peptide (CNP) or urodilatin; natriuretic peptide derivatives, for example and with preference vosoritide, cenderitide, PL 3994; 50 activators of the cardiac myosin, for example and with preference omecamtiv mecarbil (CK-1827452); 55

calcium-sensitizers, for example and with preference levosimendan; agents that affect the energy metabolism of the heart, for example and with preference etomoxir, dichloroacetat, ranolazine or trimetazidine, full or partial adenosine A1 receptor agonists such as GS-9667 (formerly known as CVT-3619), capadenoson and neladenoson; agents that affect the heart rate, for example and with preference ivabradin.

Antithrombotic agents are preferably understood to mean compounds from the group of the platelet aggregation inhibitors, the anticoagulants or the profibrinolytic substances.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a platelet aggregation inhibitor, by way of example and with preference aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidin or dipyridamole.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a thrombin inhibitor, by way of example and with preference ximelagatran, dabigatran, melagatran, bivalirudin or clexane.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a GPIIb/IIIa antagonist such as, by way of example and with preference, tirofiban or abciximab.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a factor Xa inhibitor, by way of example and with preference rivaroxaban, DU-176b, apixaban, betrixaban, otamixaban, fidexaban, razaxaban, letaxaban, eribaxaban, fondaparinux, idraparinux, PMD-3112, darexaban (YM-150), KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with heparin or with a low molecular weight (LMW) heparin derivative.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a vitamin K antagonist, by way of example and with preference coumarin.

Hypotensive agents are preferably understood to mean compounds from the group of the calcium antagonists, angiotensin All antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors and the diuretics.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a calcium antagonist, by way of example and with preference nifedipine, amlodipine, verapamil or diltiazem.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an alpha-1-receptor blocker, by way of example and with preference prazosin.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a beta-receptor blocker, by way of example and with preference propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipranolol, nadolol, mepindolol, carazolol, sotalol, meto-

prolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epaproanol or bucindolol.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an angiotensin All antagonist, by way of example and with preference losartan, candesartan, valsartan, telmisartan or embusartan or a dual angiotensin All antagonist/neprilysin-inhibitor, by way of example and with preference LCZ696 (valsartan/sacubitril).

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an ACE inhibitor, by way of example and with preference enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an endothelin antagonist, by way of example and with preference bosentan, darusentan, ambrisentan or sitaxsentan.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a renin inhibitor, by way of example and with preference aliskiren, SPP-600 or SPP-800.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a mineralocorticoid receptor antagonist, by way of example and with preference finerenone, spironolactone or eplerenone.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a loop diuretic, for example furosemide, torasemide, bumetanide and piretanide, with potassium-sparing diuretics, for example amiloride and triamterene, with aldosterone antagonists, for example spironolactone, potassium canrenoate and eplerenone, and also thiazide diuretics, for example hydrochlorothiazide, chlorthalidone, xipamide and indapamide.

Lipid metabolism modifiers are preferably understood to mean compounds from the group of the CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase inhibitors or squalene synthesis inhibitors, the ACAT inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or PPAR-delta agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbents, bile acid reabsorption inhibitors, lipase inhibitors and the lipoprotein(a) antagonists.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a CETP inhibitor, by way of example and with preference dalcetrapib, anacetrapib, torcetrapib (CP-529 414), JJT-705 or CETP vaccine (Avant).

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a thyroid receptor agonist, by way of example and with preference D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214).

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an HMG-CoA reductase inhibitor from the class of statins, by way of example and with preference lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a squalene synthesis inhibitor, by way of example and with preference BMS-188494 or TAK-475.

39

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an ACAT inhibitor, by way of example and with preference avasimibe, melinamide, pactimibe, efuzimibe or SMP-797.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an MTP inhibitor, by way of example and with preference implitapide, BMS-201038, R-103757 or JTT-130.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a PPAR-gamma agonist, by way of example and with preference pioglitazone or rosiglitazone.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a PPAR-delta agonist, by way of example and with preference GW 501516 or BAY 68-5042.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a cholesterol absorption inhibitor, by way of example and with preference ezetimibe, tirosideside or pamaquaside.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a lipase inhibitor, a preferred example being orlistat.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a polymeric bile acid adsorbent, by way of example and with preference cholestyramine, colestipol, colesolvam, CholestaGel or colestimide.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a bile acid reabsorption inhibitor, by way of example and with preference ASBT (=IBAT) inhibitors, for example AZD-7806, S-8921, AK-105, BARI-1741, SC-435 or SC-635.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a lipoprotein(a) antagonist, by way of example and with preference, gemcabene calcium (CI-1027) or nicotinic acid.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a lipoprotein(a) antagonist, by way of example and with preference, gemcabene calcium (CI-1027) or nicotinic acid.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with sGC modulators, by way of example and with preference, riociguat, cinaciguat or vericiguat.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an agent affecting the glucose metabolism, by way of example and with preference, insulin, a sulfonyl urea, acarbose, DPP4 inhibitors, GLP-1 analogs or SGLT-1 inhibitors.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a TGFbeta antagonist, by way of example and with preference pirenidone, nintedanib or fresolimumab.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a CCR2 antagonist, by way of example and with preference CCX-140.

40

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a TNFalpha antagonist, by way of example and with preference adalimumab.

5 In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a galectin-3 inhibitor, by way of example and with preference GCS-100.

In particular embodiments, the antibody or fragment 10 thereof according to the present invention is administered in combination with a Nrf-2 inhibitor, by way of example and with preference bardoxolone.

In particular embodiments, the antibody or fragment 15 thereof according to the present invention is administered in combination with a BMP-7 agonist, by way of example and with preference THR-184.

In particular embodiments, the antibody or fragment 20 thereof according to the present invention is administered in combination with a NOX1/4 inhibitor, by way of example and with preference GKT-137831.

In particular embodiments, the antibody or fragment 25 thereof according to the present invention is administered in combination with a medicament which affects the vitamin D metabolism, by way of example and with preference calcitriol, alfacalcidol, doxercalciferol, maxacalcitol, paricalcitol, cholecalciferol or paracalcitol.

In particular embodiments, the antibody or fragment 30 thereof according to the present invention is administered in combination with a cytostatic agent, by way of example and with preference cyclophosphamide.

In particular embodiments, the antibody or fragment 35 thereof according to the present invention is administered in combination with an immunosuppressive agent, by way of example and with preference ciclosporin.

In particular embodiments, the antibody or fragment 40 thereof according to the present invention is administered in combination with a phosphate binder, by way of example and with preference colestilan, sevelamer hydrochloride and sevelamer carbonate, Lanthanum and lanthanum carbonate.

In particular embodiments, the antibody or fragment 45 thereof according to the present invention is administered in combination with renal proximal tubule sodium-phosphate co-transporter, by way of example and with preference, niacin or nicotinamide.

In particular embodiments, the antibody or fragment 50 thereof according to the present invention is administered in combination with a calcimimetic for therapy of hyperparathyroidism.

In particular embodiments, the antibody or fragment 55 thereof according to the present invention is administered in combination with agents for iron deficit therapy, by way of example and with preference iron products.

In particular embodiments, the antibody or fragment 60 thereof according to the present invention is administered in combination with agents for the therapy of hyperuricaemia, by way of example and with preference allopurinol or rasburicase.

In particular embodiments, the antibody or fragment 65 thereof according to the present invention is administered in combination with glycoprotein hormone for the therapy of anaemia, by way of example and with preference erythropoietin.

In particular embodiments, the antibody or fragment 70 thereof according to the present invention is administered in combination with biologics for immune therapy, by way of example and with preference abatacept, rituximab, eculizumab or belimumab.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with vasopressin antagonists (group of the vaptanes) for the treatment of heart failure, by way of example and with preference tolvaptan, conivaptan, lixivaptan, mozavaptan, satavaptan or relcovaptan.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with Jak inhibitors, by way of example and with preference ruxolitinib, tofacitinib, baricitinib, CYT387, GSK2586184, lestaurtinib, pacritinib (SB1518) or TG101348.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with prostacyclin analogs for therapy of micro-thrombi.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an alkali therapy, by way of example and with preference sodium bicarbonate.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an mTOR inhibitor, by way of example and with preference everolimus or rapamycin.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an NHE3 inhibitor, by way of example and with preference AZD1722 or tenapanor.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with an eNOS modulator, by way of example and with preference sapropterin.

In particular embodiments, the antibody or fragment thereof according to the present invention is administered in combination with a CTGF inhibitor, by way of example and with preference FG-3019.

The antibody or fragment thereof for use in a method for treatment according to the present invention may be formulated in any conventional manner using one or more physiologically acceptable carriers or excipients. The antibody or fragment thereof according to the present invention may be administered by any suitable means, which can vary, depending on the type of disorder to be treated. Possible administration routes include enteral (e.g., oral), parenteral (e.g., intravenous, intra-arterial, intraperitoneal, intramuscular, subcutaneous, intracardiac, intraventricular, intrathecal, intramedullary, intralesional), intrapulmonary and intranasal administration. In addition, an antibody or fragment thereof according to the present invention may be administered by pulse infusion, with, e.g., declining doses of the antibody or fragment thereof. Preferably, the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the condition is acute or chronic. The amount to be administered will depend on a variety of factors such as the clinical symptoms, sex, age, and/or weight of the individual, whether other drugs are administered, and others. The skilled artisan will recognize that the route of administration will vary depending on the disorder or condition to be treated.

Methods of parenteral delivery include topical, intra-arterial, intratumoral, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.

In particular embodiments, the method for treatment comprises a single or multiple administrations of the antibody or fragment thereof or the pharmaceutical composition comprising the same. The single dose of the administrations

may be the same or different. In particular, the method for treatment comprises 1, 2, 3, 4, 5 or 6 administrations of the antibody or fragment thereof according to the present invention, preferably wherein the multiple administrations occur within one to six consecutive months. The antibody or fragment thereof according to the present invention may for instance be administered every 3 to 4 days, every week, once every two weeks, or once every three weeks, depending on its half-life and clearance rate.

SHORT DESCRIPTION OF FIGURES

FIG. 1: Mean plasma concentrations of TPP-10992 and TPP-5661 after intravenous administration of 5 mg/kg in rat.

FIG. 2: Mean plasma concentrations of TPP-12897 after intraperitoneal administration of 5 mg/kg in mice.

FIG. 3: Stability of ANP (A-C), TPP-10992 (D-F) and TPP-5661 (G-I) against proteolytic degradation. ANP, TPP-10992 and TPP-5661 activity were tested on the stable rat ANP receptor cell line directly (A, D, G), or after 4 h incubation at 37° C. with 0.6 µg/ml NEP (B, E, H) or 0.6 µg/ml IDE (C, F, I).

FIG. 4: Stability of BNP (A-C) and TPP-11155 (D-F) against proteolytic degradation. BNP and TPP-11155 activity were tested on the stable rat BNP receptor cell line directly (A, D), or after 4 h incubation at 37° C. with 0.6 µg/ml NEP (B, E) or 0.6 µg/ml IDE (C, F).

FIG. 5: Stability of CNP (A-C) and TPP-12897 (D-F) against proteolytic degradation. CNP and TPP-11155 activity were tested on the stable rat CNP receptor cell line directly (A, D), or after 4 h incubation at 37° C. with 0.6 µg/ml NEP (B, E) or 0.6 µg/ml IDE (C, F).

FIG. 6: ANP Peptide and TPP-10992 induced vasodilation dose-response curves in PE-contracted aortic rings. Concentration-response curves (0.0001-10 µM; n=3 Rats) to the ANP peptide (open circles) and TPP-10992 (closed circles) in endothelium-intact rat aortic rings contracted by phenylephrine (1 µM). Experimental values were calculated relative to the maximal changes from the contraction produced by phenylephrine in each tissue, which was taken as 100%. Potency of ANP peptide and TPP-10992 were -7.4 and -6.7 respectively (log EC₅₀ values). Data represent the mean±S.E.M. of 2 experiments.

FIG. 7: ANP Peptide and TPP-5661 induced vasodilation dose-response curves in PE-contracted aortic rings. Concentration-response curves (0.0001-10 µM; n=3 Rats) to the ANP peptide (open circles) and TPP-5661 (closed circles) in endothelium-intact rat aortic rings contracted by phenylephrine (1 µM). Experimental values were calculated relative to the maximal changes from the contraction produced by phenylephrine in each tissue, which was taken as 100%. Potency of ANP peptide and TPP-5661 were -7.4 and -6.5 respectively (log EC₅₀ values). Data represent the mean±S.E.M. of 2 experiments.

FIG. 8: Hemodynamic effect of ANP in conscious rats. Rat ANP was given intraperitoneally at 0 hours. A 500 µg dose of ANP resulted in an approximately 25% drop in mean arterial blood pressure (MAP) with a duration of effect around 6-8 hours.

FIG. 9: Hemodynamic effect TPP-5661 in conscious rats. TPP-5661 was given intraperitoneally at 0 hours. A 15 mg/kg dose resulted in an approximately 20% reduction in mean arterial blood pressure (MAP) with maximum effect at 24-48 hours post application and a duration of effect greater than 6 days.

FIG. 10: Hemodynamic effect TPP-10992 in conscious rats. TPP-10992 was given intraperitoneally at 0 hours. A 30

mg/kg dose resulted in an approximately 20% reduction in mean arterial blood pressure (MAP) with maximum effect at 48 hours post application and a duration of effect greater than 6 days.

FIG. 11: Activity of BNP engrafted antibody constructs on hNPRA cells. The activity of purified compound samples on stable hNPRA-CHO k1 cells was assessed by comparison to reference sample TPP-5661 and TPP-5657. Samples were tested in dilution series in quadruplets.

FIG. 12: Different human IgG isotypes provide equally suitable antibody scaffolds. Exemplary activity determination of compounds 9, 33, 65, 91, 127 and 191 IgG1 (TPP-10294, TPP-10277, TPP-10279, TPP-10282, TPP-10269 and TPP-10355, respectively), IgG2 and IgG4 isotypes. The activity of purified compound samples on stable hNPRA-CHO k1 cells was assessed by comparison to reference samples compound 117 human IgG1 TPP-5661 and compound 209 human IgG1 TPP-5657. Samples were tested in dilution series in quadruplets.

FIG. 13: Equally suitable IgG antibody scaffolds originated from different species. Exemplary activity determination of compound 117 human IgG1 (TPP-5661) and compound 9 human IgG1 (TPP-10294) and their non-human IgG1 counterparts. The activity of purified compound samples on stable hNPRA-CHO k1 cells was assessed by comparison to reference sample compound 209 human IgG1 (TPP-5657). Samples were tested in dilution series in quadruplets.

FIG. 14: Equally suitable human IgG antibody scaffolds originated from different germline sequences. The activity of purified compound samples on stable hNPRA-CHO k1 cells was assessed by comparison to reference sample TPP-10992. Samples were tested in dilution series in quadruplets.

FIG. 15: Protective effects of TPP-12899 against LPS, IL-113 and thrombin induced endothelial barrier permeability as assessed by real-time impedance measurement.

FIG. 16: Therapeutic effects of TPP-13992 on survival (A), body weight gain (B), urinary protein/creatinine ratio (C) and left atrial weight (D); (n=8-12 (healthy control n=5), mean \pm SEM, One-Way ANOVA vs TPP-10155 (isotype specific control antibody).

FIG. 17: Hemodynamic assessment after Placebo, 0.1, 0.3 and 1.0 mg/kg of TPP-10992. TPP-10992 shows a dose-dependent and long-lasting (>5d) reduction in blood pressure. **p<0.01, ***p<0.0001 in comparison to placebo group using an One-way ANOVA test for repeated measurements followed by Tukey's multiple comparison test.

EXAMPLES

Example 1: Construction of Candidate TPP-5661

Candidate TPP-5661 was designed by fusion of a heterologous amino acid sequence comprising a Ntls, wild type rat ANP and a Ctls to the C-terminus of HV 3-23 (SEQ ID NO 85) by substituting the two C-terminal residues of HV 3-23 by the two N-terminal residues of the heterologous amino acid sequence and to the N-terminus of IGHJ1 (SEQ ID NO 86) by substituting the nine N-terminal residues of IGHJ1 by the 9 C-terminal residues of the heterologous amino acid sequence. The corresponding full length heavy chain sequence of SEQ ID NO 67 further comprises amino acid sequence Constant-H (SEQ ID NO 87).

Pairing of the full length heavy chain sequence of SEQ ID NO 67 harboring the inserted rat ANP (rANP) with the full length light chain sequence of SEQ ID NO 66 built by combining sequences LV 1-40 (SEQ ID NO 88), IGLJ2

(SEQ ID NO 89) and Constant-L (SEQ ID NO 90) yields the full IgG candidate TPP-5661 (see Table 1).

Shown below is the full length heavy chain sequence (SEQ ID NO 67); the incorporated heterologous amino acid sequence (Ntls-rANP-Ctls) is underlined; sequences derived from HV 3-23 and IGHJ1 are shown in bold:

```

EVQLLESGGLVQPGGSLRLSCAASGTFSSYAMSWVRQAPGKGLEWVS
10 AISGSGGSTYYADSVKGKFTISRDNSKNTLYLQMNSLRAEDTAVYYCT_
VHQETKTYQSSPDGGSGGSLRRSSCFGGRIDRIGAQSGLG CNSFRYGSY
SYTYNYEWHDVWQGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
15 CLVKDVFPEPVTVWNSGALTSGVHTPPAVLQSSGLYSLSSVTVPSS
LGTQTYICNVNKHPSNTKVDDKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
20 PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
25 QKSLSLSPG

```

The designed and synthesized antibody construct was cloned according to well-known methods in the art and confirmed by DNA sequencing using plasmid specific oligonucleotides.

Example 2: Insertion of NPs within Antibody-CDRs Results in an Increased Serum Half-Life

Determination of In Vivo Pharmacokinetic Parameters

Pharmacokinetic parameters of TPP-10992 (SEQ ID NO 76 and SEQ ID NO 66) and TPP-5661 (SEQ ID NO 67 and SEQ ID NO 66) were determined after intravenous administration of 5 mg/kg to male Wistar rats (n=3). TPP-10992 and TPP-5661 were given as a bolus injection via the tail vein. Blood samples were collected from the jugular vein via previously implanted catheters in time intervals up to 14 days (336 hours). Generated EDTA-plasma was stored at -20° C. until further analysis.

The quantification of TPP-10992 and TPP-5661 in plasma samples was performed employing an anti-human IgG ELISA (enzyme-linked immunosorbent assay) format. Pharmacokinetic parameters were calculated from plasma concentration time profiles using non-compartmental data analysis.

Mean plasma concentrations of TPP-10992 and TPP-5661 after intravenous administration over time are graphically depicted in FIG. 1.

Mean clearance and terminal half-life of TPP-10992 and TPP-5661 are summarized in Table 2 below.

TABLE 2

Mean clearance (CL) and terminal half-life ($t_{1/2}$) of TPP-10992 and TPP-5661 after intravenous administration of 5 mg/kg in rat.			
Analyte	TPP-5661	TPP-10992	
CL $t_{1/2}$	[mL/h/kg] [h]	0.62 297	0.27 184

Determination of In Vivo Pharmacokinetic Parameters

Pharmacokinetic parameters of TPP-12897 were determined after intraperitoneal administration to female Balb/c mice ($n=3$). Blood samples were collected from 15 minutes up to 72 hours post application. Generated EDTA-plasma was stored at -20°C . until further analysis. The quantification of TPP-12897 in plasma samples was performed by an anti-human IgG (Immunoglobulin G) ELISA format.

Pharmacokinetic parameters were calculated from plasma concentration time profiles using non-compartmental data analysis.

Mean plasma concentrations of TPP-12897 after intraperitoneal administration over time are graphically depicted in FIG. 2.

Mean area under the curve (AUC) and terminal half-life of TPP-12897 are summarized in Table 3 below.

TABLE 3

Mean area under the curve (AUC) and terminal half-life ($t_{1/2}$) of TPP-12897 after intraperitoneal administration of 5 mg/kg in mice.		
Analyte	TPP-12897	
AUC	[mg · h/L]	7705
$t_{1/2}$	[h]	194

Example 3: In Vitro, Ex Vivo and In Vivo Potency of NP Engrafted Antibodies

Activity Data of ANP Engrafted Antibodies in NPR-A Receptor Cell Line

A luminescence-based rat ANP receptor (NPR-A) cell line was generated as described previously (Wunder et al. (2013), *Eur J Pharmacol.* 698: 131). Accordingly, a fluorescence-based rat ANP receptor (NPR-A) cell line was generated by co-transfected a CHO cell line, stably expressing the fluorescent calcium sensor protein GCaMP6, with plasmid constructs encoding CNGA2 (cGMP biosensor) and rat NPR-A.

ANP receptor GCaMP6 cells were cultured for one day on black, clear-bottom 384-well microtiter plates (2500 cells/well). After removal of the cell culture medium reporter cells were loaded for 20 min with Tyrode (130 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 20 mM HEPES, 1 mM MgCl₂, 4.8 mM NaHCO₃ at pH 7.4) containing a black masking dye at 37°C . and 5% CO₂. IBMX (0.2 mM) was used to prevent cGMP degradation by endogenous phosphodiesterases.

Fluorescence measurements (3 min, kinetic mode) were directly started upon agonist addition. Receptor ligands were added in Tyrode containing a black masking dye and 0.1% BSA. Measurements were done on a FLIPR Tetra®.

ANP (Bachem, H-2100) stimulated concentration-dependent fluorescence signals on the NPR-A cell line with an EC₅₀ values of 0.22 nM. TPP-5661 and TPP-10992 stimulated the rat ANP receptor reporter cell line with EC₅₀ values of 17 nM and 180 nM, respectively. The control antibody construct TPP-5657 did not significantly stimulate the NPR-A cell line (tested up to the max. concentration of 460 nM).

To determine the sensitivity towards proteolytic degradation, the activity of receptor ligands was also characterized after 4 hours incubation with 0.6 µg/ml neutral endopeptidase (NEP, R&D Systems, 1182-ZNC) or 0.6 µg/ml insulin degrading enzyme (IDE, Merck, 407241-50UG) at 37°C .

FIG. 3 graphically depicts the stability of ANP (A-C), TPP-10992 (D-F) and TPP-5661 (G-I) against proteolytic

degradation. As shown in FIG. 3, the natriuretic peptide ANP (Bachem, H-2100) showed high sensitivity towards degradation by NEP and IDE. In contrast, TPP-5661 and TPP-10992 showed high resistance to proteolytic degradation by NEP and IDE.

Activity Data of BNP Engrafted Antibodies in NPR-A Receptor Cell Line

A luminescence-based rat BNP receptor (NPR-A) cell line was generated as described previously (Wunder et al. (2013), *Eur J Pharmacol.* 698: 131). Accordingly, a fluorescence-based rat BNP receptor (NPR-A) cell line was generated by co-transfected a CHO cell line, stably expressing the fluorescent calcium sensor protein GCaMP6, with plasmid constructs encoding CNGA2 (cGMP biosensor) and rat NPR-A.

BNP receptor GCaMP6 cells were cultured for one day on black, clear-bottom 384-well microtiter plates (2500 cells/well). After removal of the cell culture medium reporter cells were loaded for 20 min with Tyrode (130 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 20 mM HEPES, 1 mM MgCl₂, 4.8 mM NaHCO₃ at pH 7.4) containing a black masking dye at 37°C . and 5% CO₂. IBMX (0.2 mM) was used to prevent cGMP degradation by endogenous phosphodiesterases.

Fluorescence measurements (3 min, kinetic mode) were directly started upon agonist addition. Receptor ligands were added in Tyrode containing a black masking dye and 0.1% BSA. Measurements were done on a FLIPR Tetra®.

BNP (Bachem, H-5968) stimulated concentration-dependent fluorescence signals on the NPR-A cell line with an EC₅₀ value of 2.9 nM. TPP-9902, TPP-11153, TPP-1154, TPP-11155, TPP-11156 and TPP-11157 stimulated the rat BNP receptor reporter cell line with EC₅₀ values of 2.3 µM, >1.9 µM, 7 nM, 12 nM, 1.2 µM and 11 nM, respectively. The control antibody construct TPP-5657 did not significantly stimulate the NPR-A cell line (tested up to the max. concentration of 460 nM).

To determine the sensitivity towards proteolytic degradation, the activity of receptor ligands was also characterized after 4 hours incubation with 0.6 µg/ml neutral endopeptidase (NEP, R&D Systems, 1182-ZNC) or 0.6 µg/ml insulin degrading enzyme (IDE, Merck, 407241-50UG) at 37°C . The natriuretic peptide BNP (Bachem, H-5968) showed high sensitivity towards degradation by NEP and IDE. In contrast, TPP-11155 and TPP-11157 showed high resistance to proteolytic degradation by NEP and IDE.

FIG. 4 graphically depicts the stability of BNP (A-C) and TPP-11155 (D-F) against proteolytic degradation.

Activity Data of CNP Engrafted Antibodies in NPR-B Receptor Cell Line

A luminescence-based rat CNP receptor (NPR-B) reporter cell line was generated and luminescence measurements were performed as described previously (Wunder et al. (2013), *Eur J Pharmacol.* 698: 131).

CNP receptor cells (2500 cells/well) were cultured for 1 day on opaque 384-well microtiter plates. After removal of the cell culture medium, cells were loaded for 3 h with 2.5 µg/ml coelenterazine in Ca²⁺-free Tyrode (130 mM NaCl, 5 mM KCl, 20 mM HEPES, 1 mM MgCl₂, 4.8 mM NaHCO₃ at pH 7.4) at 37°C . and 5% CO₂. Receptor ligands were added for 10 min in Ca²⁺-free Tyrode containing 0.1% BSA. IBMX (0.2 mM) was used to prevent cGMP degradation by endogenous phosphodiesterases. Immediately before adding calcium ions (final concentration 3 mM), luminescence measurements were started by using a charge-coupled device (CCD) camera in a light tight box. Luminescence was monitored continuously for 50 s.

CNP (Bachem, H-1296) stimulated concentration-dependent luminescence signals on the rat NPR-B cell line with an EC₅₀ value of 0.024 nM. TPP-9465, TPP-12377, TPP-12378, TPP-12897 and TPP-12899 stimulated the rat CNP receptor reporter cell line with EC₅₀ values of 5.2 nM, 4.1 nM, 25 nM, 10 nM and 3.2 nM, respectively. TPP-12374 stimulated the rat CNP receptor reporter cell line with EC₅₀ values of 150 nM, and TPP-12375, TPP-12376 showed only weak indication of activity.

To determine the sensitivity towards proteolytic degradation, the activity of receptor ligands was also characterized after 4 hours incubation with 0.6 µg/ml neutral endopeptidase (NEP, R&D Systems, 1182-ZNC) or 0.6 µg/ml insulin degrading enzyme (IDE, Merck, 407241-50UG) at 37°C.

In contrast to the natriuretic peptide CNP (Bachem, H-1296), TPP-12377, TPP-12897 and TPP-12899 showed high resistance to proteolytic degradation by NEP and IDE.

FIG. 5 graphically depicts the stability of CNP (A-C) and TPP-12897 (D-F) against proteolytic degradation.

Activity Data of ANP Engrafted Antibodies Determined with Isolated Rat Aortic Rings

All experiments were conducted in accordance with institutional guidelines and approved by the local committee on animal experiments. Male Sprague-Dawley rats (weighing 250-300 g) were anesthetized with pentobarbital sodium (40 mg/kg i.p.), killed by decapitation, and exsanguinated. The thoracic aorta was excised and placed in ice-cold Krebs buffer of the following composition: 130 mM NaCl, 14.9 mM NaHCO₃, 5.5 mM dextrose, 4.7 mM KCl, 1.18 mM KH₂PO₄, 1.17 mM MgSO₄·7H₂O, and 1.6 mM CaCl₂·2H₂O. The vessel was pinned in a Sylgard Petri dish filled with chilled Krebs' solution, cleaned of fat and connective tissue, and cut into ring segments of approximately 3 to 4 mm in length. Aortic rings were vertically mounted in 50-ml chambers (ADInstruments) containing Krebs' solution at 37°C. continuously bubbled with a mixture of 95% O₂ and 5% CO₂. Changes in isometric force were recorded using a PowerLab data acquisition system (software Lab Chart 7.0)

After the equilibration period, aortic rings were challenged with 80 mM KCl to check tissue viability. Next, the endothelial integrity of the preparations was determined by verifying the responsiveness to acetylcholine (ACh, 1 µM) in vessels pre-contracted with Phenylephrine (PE, 1 µM). After wash-out and a period of equilibration, Phenylephrine (PE, 1 µM) was used to induce contraction, thereafter natriuretic peptides and natriuretic peptide engrafted IgGs were evaluated for vasorelaxation. Rat ANP peptide (ADH-GM-10057T, Santai Labs) was used as a reference.

As shown in FIG. 6, both ANP peptide and TPP-10992 induced dose-dependent vasodilation in PE-contracted aortic rings.

As shown in FIG. 7, both ANP peptide and TPP-5661 induced dose-dependent vasodilation in PE-contracted aortic rings.

Activity Data of ANP Engrafted Antibodies Obtained in Conscious Rats

Blood pressure and heart rate were monitored in freely moving conscious animals by radiotelemetry (Data Sciences International). Female spontaneously hypertensive rats (SHR/N Crl BR, Charles River) with a body weight of 210-300 g were used for these studies. All animals were housed in individual cages at 22-24°C ambient temperature and maintained on a 12-hour light/dark cycle with free access to standard laboratory rat chow and water ad libitum. Telemeter (HD-10, DSI) implantation was performed a minimum of 14 days before animals were used for blood pressure measurements. Surgery was performed under asep-

tic conditions. After shaving the abdominal wall, a midline abdominal incision was made, and the fluid-filled sensor catheter was inserted upstream into the exposed descending aorta between the iliac bifurcation and the renal arteries. According to the DSI guidelines the tip of the telemetric catheter was located caudal to the renal arteries and secured by tissue adhesive. The transmitter body was affixed to the inner peritoneal wall before closure of the abdomen. For postsurgical protection against infections and pain a single dosage of an antibiotic (Oxytetracyclin® 10%, 60 mg/kg s.c., 0.06 ml/100 g body weight, Beta-Pharma GmbH & Co, Germany) and analgesic were injected (Rimadyl®, 4 mg/kg s.c., Pfizer, Germany). Telemetric data acquisition was performed by DSI software was predefined to sample hemodynamic data for 10 seconds repeated every 5 minutes. Data collection was started at least 2 hours before drug administration and finished after completion of measurement cycles. Data are expressed as % of basal values±SEM of at least 4 animals per group. The basal value for each animal was calculated as the average of the values measured in two hours prior to substance application (7:00-9:00 AM). Data are then expressed as averages every half hour, starting 15 minutes post application. All animals were treated with a single intraperitoneal (ip) application of test substances dissolved in phosphate buffered saline (PBS). Drug administration took place at 9:00 AM (0 hours).

The hemodynamic effect of ANP peptide is graphically depicted in FIG. 8. The hemodynamic effect of TPP-5661 is graphically depicted in FIG. 9. The hemodynamic effect of TPP-10992 is graphically depicted in FIG. 10.

Example 4: Generation of Different NP Engrafted Antibody Constructs

For constructs with a natriuretic peptide incorporation in a CDR region other than CDRH3 a presumably functionally neutral CDRH3 was designed by fusion of the three residues stretch Leu Thr Gly (IGHD7-27*01) to the C-terminus of HV 3-23 and the N-terminus of IGHJ1 (compare Example 1). The corresponding full length heavy chain sequence of SEQ ID NO 65 further comprises amino acid sequence Constant-H (SEQ ID NO 87).

Pairing of the full length heavy chain sequence of SEQ ID NO 65 without any natriuretic peptide insertion with the full length light chain sequence of SEQ ID NO 66 described in Example 1 yields the synthetic and presumably neutral IgG negative control TPP-5657.

The designed and synthesized antibody construct was cloned according to well-known methods in the art and confirmed by DNA sequencing using plasmid specific oligonucleotides.

Starting from this antibody scaffold, the following ANP engrafted antibody constructs were generated.

TABLE 4

Design of ANP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	SEQ ID NO	SEQ ID NO	# aa	# aa
			comprised in Nts	comprised in Cts	N-term ¹	C-term ²
1	TPP-13057	CDRH1			6	2
2	TPP-13056	CDRH1			9	5

US 12,390,508 B2

49

TABLE 4-continued

Design of ANP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	SEQ ID NO comprised in Ntls	SEQ ID NO comprised in Ctls	# aa N-term ¹	# aa C-term ²
3	TPP-13055	CDRH1			12	8
4	TPP-13054	CDRH1			15	11
5	TPP-12545	CDRH1			18	10
6	TPP-10454	CDRH1			19	17
7	TPP-10453	CDRH1			19	17
8	TPP-11172	CDRH1	6		20	17
9	TPP-10294	CDRH1			23	14
10	TPP-12547	CDRH1			23	14
11	TPP-11171	CDRH1	6		24	13
12	TPP-10841	CDRH2			3	3
13	TPP-10842	CDRH2			7	7
14	TPP-11009	CDRH2			8	9
15	TPP-11008	CDRH2			10	11
16	TPP-11018	CDRH2			11	14
17	TPP-10775	CDRH2			12	8
18	TPP-10767	CDRH2			13	12
19	TPP-11012	CDRH2	9		14	9
20	TPP-10774	CDRH2	13	14	14	10
21	TPP-11007	CDRH2			14	11
22	TPP-11179	CDRH2			14	14
23	TPP-10773	CDRH2	13	14	15	10
24	TPP-10770	CDRH2	1	1	15	12
25	TPP-10766	CDRH2			15	14
26	TPP-10772	CDRH2	13	14	16	11
27	TPP-11005	CDRH2			16	11
28	TPP-11006	CDRH2			16	11
29	TPP-11017	CDRH2			16	14
30	TPP-11169	CDRH2	9	10	16	15
31	TPP-11181	CDRH2			16	15
32	TPP-11182	CDRH2			16	17
33	TPP-10277	CDRH2	9	10	17	11
34	TPP-12553	CDRH2	9	10	17	11
35	TPP-12554	CDRH2	9	10	17	11
36	TPP-12555	CDRH2	9	10	17	11
37	TPP-12542	CDRH2	9	10	17	11

50

TABLE 4-continued

Design of ANP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	SEQ ID NO comprised in Ntls	SEQ ID NO comprised in Ctls	# aa N-term ¹	# aa C-term ²
38	TPP-12543	CDRH2	9		10	17
39	TPP-12544	CDRH2	9		10	17
40	TPP-13058	CDRH2	9		10	17
41	TPP-13059	CDRH2	9		10	17
42	TPP-13060	CDRH2	9		20	17
43	TPP-13061	CDRH2	9		20	17
44	TPP-13062	CDRH2	9		10	17
45	TPP-13063	CDRH2	9		10	17
46	TPP-13064	CDRH2	9		10	17
47	TPP-13065	CDRH2	9		10	17
48	TPP-13066	CDRH2	9		10	17
49	TPP-12546	CDRH2	9		10	17
50	TPP-10452	CDRH2	13		14	17
51	TPP-10846	CDRH2	4		5	17
52	TPP-10852	CDRH2				17
53	TPP-10851	CDRH2	6			17
54	TPP-10769	CDRH2	1		1	17
55	TPP-10765	CDRH2				17
56	TPP-11180	CDRH2				17
57	TPP-11177	CDRH2				17
58	TPP-11178	CDRH2				17
59	TPP-11176	CDRH2	17		18	17
60	TPP-10278	CDRH2	9		10	18
61	TPP-10847	CDRH2	4		5	18
62	TPP-11004	CDRH2				18
63	TPP-10844	CDRH2	2		3	18
64	TPP-10853	CDRH2				18
65	TPP-10279	CDRH2	9		10	18
66	TPP-11170	CDRH2	9		10	18
67	TPP-11010	CDRH2	9			18
68	TPP-11011	CDRH2	9			18
69	TPP-10764	CDRH2				18
70	TPP-11183	CDRH2	16		17	17
71	TPP-11175	CDRH2	15			19
72	TPP-11016	CDRH2				12

US 12,390,508 B2

51

TABLE 4-continued

Design of ANP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	SEQ ID NO comprised in Ntls	SEQ ID NO comprised in Ctls	# aa N-term ¹	# aa C-term ²
73	TPP-11015	CDRH2	15		19	14
74	TPP-10451	CDRH2	13	14	19	14
75	TPP-10768	CDRH2	1	1	19	14
76	TPP-10848	CDRH2	4	5	19	14
77	TPP-11003	CDRH2			19	14
78	TPP-11002	CDRH2			19	14
79	TPP-10843	CDRH2	2	3	19	14
80	TPP-10845	CDRH2	2	3	19	14
81	TPP-10284	CDRH2			19	14
82	TPP-10446	CDRH2	11	12	19	14
83	TPP-10447	CDRH2			19	14
84	TPP-10854	CDRH2			19	14
85	TPP-11014	CDRH2	15		19	15
86	TPP-10849	CDRH2	6	6	19	15
87	TPP-10850	CDRH2	6		19	15
88	TPP-11013	CDRH2			20	14
89	TPP-10771	CDRH2	1	1	20	15
90	TPP-10287	CDRH2	1	1	20	15
91	TPP-10282	CDRH2			20	15
92	TPP-10285	CDRH2			20	15
93	TPP-10286	CDRH2			20	15
94	TPP-10283	CDRH2			20	15
95	TPP-11168	CDRH2	9	10	20	15
96	TPP-10857	CDRH2			20	15
97	TPP-10856	CDRH2			20	15
98	TPP-10855	CDRH2			20	15
99	TPP-10281	CDRH3			10	3
100	TPP-10280	CDRH3			10	8
101	TPP-10583	CDRH3			12	10
102	TPP-10582	CDRH3	7		14	12
103	TPP-10270	CDRH3	7	8	15	18
104	TPP-10264	CDRH3	7	8	16	14
105	TPP-10581	CDRH3			16	14
106	TPP-10263	CDRH3	7	8	17	15
107	TPP-10271	CDRH3	7	8	17	18
108	TPP-10262	CDRH3	7	8	18	16
5						

52

TABLE 4-continued

Design of ANP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	SEQ ID NO comprised in Ntls	SEQ ID NO comprised in Ctls	# aa N-term ¹	# aa C-term ²
109	TPP-10272	CDRH3	7		8	18
110	TPP-10261	CDRH3	7		8	19
111	TPP-10289	CDRH3				19
112	TPP-10273	CDRH3	7		8	19
113	TPP-10260	CDRH3	7		8	20
114	TPP-10275	CDRH3	9		10	20
115	TPP-10580	CDRH3				20
116	TPP-10274	CDRH3	7		8	20
117	TPP-5661	CDRH3	7		8	20
118	TPP-13226	CDRH3	7		8	18
119	TPP-13227	CDRH3	7		8	16
120	TPP-13228	CDRH3	7		22	20
121	TPP-13229	CDRH3	7		22	20
122	TPP-13230	CDRH3	21		22	20
123	TPP-13231	CDRH3	21		22	20
124	TPP-10276	CDRH3	9		10	18
125	TPP-10290	CDRH3				20
126	TPP-10445	CDRH3	11		12	20
127	TPP-10269	CDRH3	7		8	18
128	TPP-10288	CDRH3	2		3	20
129	TPP-10265	CDRH3	7		8	19
130	TPP-10268	CDRH3	7		8	19
131	TPP-10593	CDRH3	19			20
132	TPP-11174	CDRH3	6		12	20
133	TPP-10266	CDRH3	7		8	20
134	TPP-11173	CDRH3	6		12	20
135	TPP-10444	CDRH3	11		12	20
136	TPP-10267	CDRH3	7		8	22
137	TPP-10443	CDRH3	11		12	22
138	TPP-11163	CDRL1	6			14
139	TPP-10360	CDRL1				13
140	TPP-10462	CDRL1				18
141	TPP-10460	CDRL1				19
142	TPP-10461	CDRL1				19
143	TPP-11161	CDRL1	6		6	19
144	TPP-11162	CDRL1	6			19

53

TABLE 4-continued

Design of ANP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	SEQ ID NO comprised in Ntls	SEQ ID NO comprised in Ctls	# aa N-term ¹	# aa C-term ²
145	TPP-10359	CDRL1			23	14
146	TPP-10824	CDRL2			1	6
147	TPP-10825	CDRL2			5	10
148	TPP-11019	CDRL2			12	16
149	TPP-11021	CDRL2			13	17
150	TPP-11020	CDRL2			13	17
151	TPP-10789	CDRL2			14	14
152	TPP-11022	CDRL2			15	19
153	TPP-10829	CDRL2	4	5	16	15
154	TPP-10835	CDRL2			16	15
155	TPP-10788	CDRL2			16	16
156	TPP-10571	CDRL2	15	15	17	16
157	TPP-10830	CDRL2	4	5	17	16
158	TPP-10790	CDRL2			17	16
159	TPP-10573	CDRL2			19	17
160	TPP-10827	CDRL2	2	3	17	16
161	TPP-10572	CDRL2	19		17	16
162	TPP-10836	CDRL2			17	16
163	TPP-10834	CDRL2	6		17	17
164	TPP-10787	CDRL2			18	16
165	TPP-10831	CDRL2	4	5	18	17
166	TPP-10828	CDRL2	2	3	18	17
167	TPP-10826	CDRL2	2	3	18	17
168	TPP-10837	CDRL2			18	17
169	TPP-10361	CDRL2			19	17
170	TPP-11023	CDRL2	11	12	19	18
171	TPP-10838	CDRL2			19	18
172	TPP-10840	CDRL2			19	18
173	TPP-10839	CDRL2			19	18
174	TPP-10832	CDRL2	6		19	19
175	TPP-10833	CDRL2	6		19	19
176	TPP-11024	CDRL2	11	12	20	19
177	TPP-10353	CDRL3			2	2
178	TPP-10780	CDRL3			14	9
179	TPP-10786	CDRL3			16	10
180	TPP-10779	CDRL3			16	11

54

TABLE 4-continued

Design of ANP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	SEQ ID NO comprised in Ntls	SEQ ID NO comprised in Ctls	# aa N-term ¹	# aa C-term ²
181	TPP-10778	CDRL3				16
182	TPP-10783	CDRL3	11		12	11
183	TPP-10785	CDRL3				18
184	TPP-10776	CDRL3				18
185	TPP-10777	CDRL3				18
186	TPP-10784	CDRL3	11		12	13
187	TPP-10782	CDRL3	7		8	14
188	TPP-10352	CDRL3				19
189	TPP-10356	CDRL3				14
190	TPP-10354	CDRL3				19
191	TPP-10355	CDRL3				14
192	TPP-10781	CDRL3	11		12	15
193	TPP-10436	CDRL3	7		8	14
194	TPP-10440	CDRL3	11		12	14
195	TPP-10442	CDRL3				20
196	TPP-10351	CDRL3	7		8	15
197	TPP-10348	CDRL3	7		8	15
198	TPP-10358	CDRL3				15
199	TPP-10439	CDRL3	6		12	15
200	TPP-11167	CDRL3	11		12	15
201	TPP-10438	CDRL3	11		12	15
202	TPP-10441	CDRL3				15
203	TPP-10349	CDRL3	7		8	16
204	TPP-10350	CDRL3	7		8	17
205	TPP-10437	CDRL3	11		12	17
206	TPP-11166	CDRL3	6		12	18
207	TPP-10362	CDRL3	6		6	20
208	TPP-10363	CDRL3	6		6	20
209	TPP-5657	no			na	n

¹The number of amino acid residues present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide;²The number of amino acid residues present between the last amino acid of the inserted natriuretic peptide and the respective C-terminal reference amino acid residue

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
1	TPP-13057	SGFTFSS (SEQ ID NO: 92)	YAM
2	TPP-13056	SGFTFGSGSG (SEQ ID NO: 93)	GSGSGM (SEQ ID NO: 94)
3	TPP-13055	SGFTFGSGSGSGS (SEQ ID NO: 95)	SGSGSGSGM (SEQ ID NO: 96)
4	TPP-13054	SGFTFGSGSGSGGG (SEQ ID NO: 97)	GGSGGGSGSGSM (SEQ ID NO: 98)
5	TPP-12545	SGFTFGSGSGSGSGGG (SEQ ID NO: 99)	GSGSGGSGSGM (SEQ ID NO: 100)
6	TPP-10454	SPAVVYIEILDRLRHPDGGSGG (SEQ ID NO: 101)	GSGREVPISNGSGFVVAM (SEQ ID NO: 102)
7	TPP-10453	SGAVVYIEILDRLRHPDGGSGG (SEQ ID NO: 103)	GSGREVPISNGSGFVVAM (SEQ ID NO: 102)
8	TPP-11172	SSSDRSALLKSKLRLALLTAPR (SEQ ID NO: 104)	GSGREVPISNGSGFVVAM (SEQ ID NO: 102)
9	TPP-10294	SGFTFGSGSGSGSGSPDGGSGG (SEQ ID NO: 105)	GSYGSGSGSGSGM (SEQ ID NO: 106)
10	TPP-12547	SGFTFGSGSGSGSGSPDGGSGG (SEQ ID NO: 105)	GSYGSGSGSGSGM (SEQ ID NO: 106)
11	TPP-11171	SGFTFSSDRSALLKSKLRLALLTAPR (SEQ ID NO: 107)	GSGSGSGSGSGSGM (SEQ ID NO: 108)
12	TPP-10841	ISGS (SEQ ID NO: 109)	GGST (SEQ ID NO: 110)
13	TPP-10842	ISGSGSGS (SEQ ID NO: 111)	GSGSGGST (SEQ ID NO: 112)
14	TPP-11009	ISGSGSGSG (SEQ ID NO: 113)	GSSGSGSGST (SEQ ID NO: 114)
15	TPP-11008	ISGSGSGSGSG (SEQ ID NO: 115)	GSSGSGSGSGST (SEQ ID NO: 116)
16	TPP-11018	ISGSGSGSGSGG (SEQ ID NO: 117)	GEKEKEKVSTAVGST (SEQ ID NO: 118)
17	TPP-10775	ISGSAGVNVNGSGG (SEQ ID NO: 119)	GKIAIGGST (SEQ ID NO: 120)
18	TPP-10767	ISGPNPKNPNPGG (SEQ ID NO: 121)	GSNENPNPNPGST (SEQ ID NO: 122)
19	TPP-11012	ISGSVVVTSHGGSGG (SEQ ID NO: 123)	GGSGSGSGST (SEQ ID NO: 124)
20	TPP-10774	ISGSAGVNVRGSGG (SEQ ID NO: 125)	GGDKIAIGGST (SEQ ID NO: 126)
21	TPP-11007	ISGSGSGSGSGSGGG (SEQ ID NO: 127)	GSSGSGSGSGST (SEQ ID NO: 116)
22	TPP-11179	ISGLAVQIRRGSGG (SEQ ID NO: 128)	GGSGRETLTLYVGST (SEQ ID NO: 129)
23	TPP-10773	ISGSAGVNVRAAGSGG (SEQ ID NO: 130)	GGDKIAIGGST (SEQ ID NO: 126)
24	TPP-10770	ISGSYAMSWVRGGSGG (SEQ ID NO: 131)	GSYAMSWVRQGST (SEQ ID NO: 132)
25	TPP-10766	ISGPNPKNPNPGG (SEQ ID NO: 133)	GSNPNENPNPNPGST (SEQ ID NO: 134)
26	TPP-10772	ISGSAGVNVRADGGSGG (SEQ ID NO: 135)	GSGDKIAIGGST (SEQ ID NO: 136)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
27	TPP-11005	ISGSGSGSGSPDGGSGG (SEQ ID NO: 137)	GSSGSGSGSGST (SEQ ID NO: 116)
28	TPP-11006	ISGSGSGSGSGGGSGG (SEQ ID NO: 138)	GSSGSGSGSGST (SEQ ID NO: 116)
29	TPP-11017	ISGSGSGSGSGSGGSGG (SEQ ID NO: 138)	GEKEKEKVSTAVGST (SEQ ID NO: 118)
30	TPP-11169	ISGSVVVTSHQAPGSGG (SEQ ID NO: 139)	GSGEKKKLKSLAYGST (SEQ ID NO: 140)
31	TPP-11181	ISGRYNILKIQKVGSGG (SEQ ID NO: 141)	GGSGEYLITYQIMGST (SEQ ID NO: 142)
32	TPP-11182	ISGRQLLFCRVTLGSGG (SEQ ID NO: 143)	GGSGEQAYPEYLITYGST (SEQ ID NO: 144)
33	TPP-10277	ISVVVVTSHQAPGEGGSGG (SEQ ID NO: 145)	GEKKKLKSLAST (SEQ ID NO: 146)
34	TPP-12553	ISGVVVTSHQAPGEGGSGG (SEQ ID NO: 147)	GEKKKLKSLAST (SEQ ID NO: 146)
35	TPP-12554	ISVVVVTSHQAPGEGGSGG (SEQ ID NO: 145)	GEKKKLKSLGST (SEQ ID NO: 148)
36	TPP-12555	ISVVVVTSHQAPGEGGSGG (SEQ ID NO: 145)	GEKKKLKSGGST (SEQ ID NO: 149)
37	TPP-12542	ISGVVVTSHQAPGEGGSGG (SEQ ID NO: 147)	GEKKKLKSGGST (SEQ ID NO: 149)
38	TPP-12543	ISGSVTSHQAPGEGGSGG (SEQ ID NO: 150)	GEKKKLKSGGST (SEQ ID NO: 149)
39	TPP-12544	ISGSVTSHQAPGEGGSGG (SEQ ID NO: 150)	GEKKKGKSGGST (SEQ ID NO: 151)
40	TPP-13058	ISVVVVTSHQAPGSGGSGG (SEQ ID NO: 152)	GEKKKLKSLAST (SEQ ID NO: 146)
41	TPP-13059	ISVVVVTSHQAPTSGGSGG (SEQ ID NO: 153)	GEKKKLKSLAST (SEQ ID NO: 146)
42	TPP-13060	ISVVVVTSHQSPTPGGSGG (SEQ ID NO: 154)	GGSTPLKSLAST (SEQ ID NO: 155)
43	TPP-13061	ISVVVVTSHQAPGEGGSGG (SEQ ID NO: 145)	GGSTPLKSLAST (SEQ ID NO: 155)
44	TPP-13062	ISVVVVTSHQAPGEGGSGG (SEQ ID NO: 145)	GSTPKLKSLAST (SEQ ID NO: 156)
45	TPP-13063	ISVVVVTSHQSPTPGGSGG (SEQ ID NO: 154)	GEKKKLKSLAST (SEQ ID NO: 146)
46	TPP-13064	ISVVVVTSHPTPGEGGSGG (SEQ ID NO: 157)	GEKKKLKSLAST (SEQ ID NO: 146)
47	TPP-13065	ISVVVVTSHQAPSPGSTGG (SEQ ID NO: 158)	GEKKKLKSLAST (SEQ ID NO: 146)
48	TPP-13066	ISVVVVTSHQANGSGGSGG (SEQ ID NO: 159)	GEKKKLKSLAST (SEQ ID NO: 146)
49	TPP-12546	ISVVVVTSHQAPGEGGSGG (SEQ ID NO: 145)	GEKKKLKSLAST (SEQ ID NO: 146)
50	TPP-10452	ISGSAVVNVRAPDGGSGG (SEQ ID NO: 160)	GSKGDKIAIGGST (SEQ ID NO: 161)
51	TPP-10846	ISTSASLAITGPDGGSGG (SEQ ID NO: 162)	GSDRFSGSKSGST (SEQ ID NO: 163)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
52	TPP-10852	ISGFILPIEVYPDGGSGG (SEQ ID NO: 164)	GSKVRFDYDLFST (SEQ ID NO: 165)
53	TPP-10851	ISSALLKSKLALLTAPG (SEQ ID NO: 166)	GGSGSGSGSGSGST (SEQ ID NO: 167)
54	TPP-10769	ISGSYAMSWVRQAGGS GG (SEQ ID NO: 168)	GSSSYAMSWVRQGST (SEQ ID NO: 169)
55	TPP-10765	ISGPNPKNPNPNPGSGG (SEQ ID NO: 170)	GSNPNENPNPNPGST (SEQ ID NO: 134)
56	TPP-11180	IHPLQNRWALWFFKGSGG (SEQ ID NO: 171)	GGSGNLRLISKFDVT (SEQ ID NO: 172)
57	TPP-11177	ISGSVTIFSLATNEGSGG (SEQ ID NO: 173)	GGSGKTTWHRISVFGGST (SEQ ID NO: 174)
58	TPP-11178	IYLEGKIDYGEYMDGSGG (SEQ ID NO: 175)	GGSNVRRQATTIIADNIT (SEQ ID NO: 176)
59	TPP-11176	ISGSVQGIINFEQKGS GG (SEQ ID NO: 177)	GGSGPVKVWGSIKGGGST (SEQ ID NO: 178)
60	TPP-10278	ISGVVVTSHQAPGEGGSGG (SEQ ID NO: 179)	GEKKKLKSLAGST (SEQ ID NO: 180)
61	TPP-10847	ISGTTSASLAITGPDGGS GG (SEQ ID NO: 181)	GSDRFSGSKSGGST (SEQ ID NO: 182)
62	TPP-11004	ISGSGSGSGSGSPDGGSGG (SEQ ID NO: 183)	GSSGSGSGSGSGST (SEQ ID NO: 184)
63	TPP-10844	ISGYTIISNVNHKPDGGS GG (SEQ ID NO: 185)	GSNTKVDKKVEGST (SEQ ID NO: 186)
64	TPP-10853	ISGGFILPIEVYPDGGSGG (SEQ ID NO: 187)	GSKVRFDYDLFGST (SEQ ID NO: 188)
65	TPP-10279	ISGSVVVTSHQAPGGGSGG (SEQ ID NO: 189)	GEKKKLKSLAYGST (SEQ ID NO: 190)
66	TPP-11170	ISGSVVVTSHQAPGGGSGG (SEQ ID NO: 189)	GEKPKPKPLAYGST (SEQ ID NO: 191)
67	TPP-11010	ISGSVVVTSHQAPGGGSGG (SEQ ID NO: 189)	GSSGSGSGSGSGST (SEQ ID NO: 184)
68	TPP-11011	ISGSVVVTSHQAPGGGSGG (SEQ ID NO: 189)	GSGSGSGSGSGGST (SEQ ID NO: 192)
69	TPP-10764	ISGPNPKNPNPNPGGGSGG (SEQ ID NO: 193)	GSNPNENPNPNPGST (SEQ ID NO: 134)
70	TPP-11183	ISGDIYLAINITNGEGSGG (SEQ ID NO: 194)	GGSGDIYLAINITNGEST (SEQ ID NO: 195)
71	TPP-11175	ISGSATKAVSVLKGDGSGG (SEQ ID NO: 196)	GGSGVQGIINFEQKGGST (SEQ ID NO: 197)
72	TPP-11016	ISGSVPKEKEKEKVSTAVGG (SEQ ID NO: 198)	GSGSGSGSGSGST (SEQ ID NO: 199)
73	TPP-11015	ISGSVPKEKEKEKVSTAVGG (SEQ ID NO: 198)	GSGSGSGSGSGSGST (SEQ ID NO: 200)
74	TPP-10451	ISGSSGAVVNVRAPDGGS GG (SEQ ID NO: 201)	GSKGDKIAIWTTGST (SEQ ID NO: 202)
75	TPP-10768	ISGSYAMSWVRQAPDGGS GG (SEQ ID NO: 203)	GSSSYAMSWVRQGST (SEQ ID NO: 169)
76	TPP-10848	ISGTSASLAITGPDGGS GG (SEQ ID NO: 204)	GSDRFSGSKSGGGST (SEQ ID NO: 205)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
77	TPP-11003	ISGSGSGSGSGSPDGGSGG (SEQ ID NO: 206)	GSGSGSGSGSGSGST (SEQ ID NO: 200)
78	TPP-11002	ISGSGSGSGSGSPDGGSGG (SEQ ID NO: 448)	GSYSGSGSGSGSGST (SEQ ID NO: 208)
79	TPP-10843	ISTQTYISNVNKHKPDPGGSGG (SEQ ID NO: 209)	GSNTKVDKKVEPKST (SEQ ID NO: 210)
80	TPP-10845	ISGSTYISNVNKHKPDPGGSGG (SEQ ID NO: 211)	GSNTKVDKKVEGGST (SEQ ID NO: 212)
81	TPP-10284	ISGPNPNPNPNPNPDPGGSGG (SEQ ID NO: 213)	GSNPNPNPNPNPNGST (SEQ ID NO: 214)
82	TPP-10446	ISAVQVKLELGHRPDPGGSGG (SEQ ID NO: 215)	GSNHLRSEKLTFNST (SEQ ID NO: 216)
83	TPP-10447	ISGFILPIEVYFKPDGGSGG (SEQ ID NO: 217)	GSPRKVRFDYDLFNST (SEQ ID NO: 218)
84	TPP-10854	ISGSGFILPIEVYPDGGSGG (SEQ ID NO: 219)	GSKVRFDYDLFGST (SEQ ID NO: 220)
85	TPP-11014	ISGSVPKEKEKEKVSTAVGG (SEQ ID NO: 198)	GSYGSGSGSGSGSGST (SEQ ID NO: 221)
86	TPP-10849	ISDRSALLKSKLRLALLTAPR (SEQ ID NO: 222)	GSDRSALLKSKLRAST (SEQ ID NO: 223)
87	TPP-10850	ISDRSALLKSKLRLALLTAPG (SEQ ID NO: 224)	GGSGSGSGSGSGSGST (SEQ ID NO: 225)
88	TPP-11013	ISGSSDKHTHTSPPSPDGGSGG (SEQ ID NO: 226)	GSKTHTSPSPGGST (SEQ ID NO: 227)
89	TPP-10771	ISGSYAMSWVRQASPDGGSGG (SEQ ID NO: 228)	GSYSSYAMSWVRGGST (SEQ ID NO: 229)
90	TPP-10287	ISGSYAMSWVRQASPDGGSGG (SEQ ID NO: 228)	GSYSSYAMSWVRQGST (SEQ ID NO: 230)
91	TPP-10282	ISGSGSGSGSGSPDGGSGG (SEQ ID NO: 231)	GSYGSGSGSGSGSGST (SEQ ID NO: 221)
92	TPP-10285	ISGSPNPNPNPNPSPDGGSGG (SEQ ID NO: 232)	GSYPNPNPNPNPNSGST (SEQ ID NO: 233)
93	TPP-10286	ISGPNPNKPNPNPNSPDGGSGG (SEQ ID NO: 234)	GSYNPNENPNPNPGST (SEQ ID NO: 235)
94	TPP-10283	ISGPNPNPNPNPNSPDGGSGG (SEQ ID NO: 236)	GSYNPNPNPNPNPNGST (SEQ ID NO: 237)
95	TPP-11168	ISGSVVVTSHQAPGGSGGSGG (SEQ ID NO: 238)	GSGEKKKLKSLAGST (SEQ ID NO: 140)
96	TPP-10857	ISGSVYYIEILDHPDGGSGG (SEQ ID NO: 239)	GSGREVPISNGSGST (SEQ ID NO: 240)
97	TPP-10856	ISGAVVVIEILDHPDGGSGG (SEQ ID NO: 241)	GSGREVPISNGSGST (SEQ ID NO: 240)
98	TPP-10855	ISPAVYYIEILDHPDGGSGG (SEQ ID NO: 242)	GSGREVPISNGSGFST (SEQ ID NO: 243)
99	TPP-10281	CAKSPDGGSGG (SEQ ID NO: 244)	GSYG (SEQ ID NO: 245)
100	TPP-10280	CAKSPDGGSGG (SEQ ID NO: 244)	GSYQHWGQG (SEQ ID NO: 246)
101	TPP-10583	CAKVHQETGGSGG (SEQ ID NO: 247)	GSHWHVQHWGQG (SEQ ID NO: 248)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
102	TPP-10582	CAKVHQETPDGGSGG (SEQ ID NO: 249)	GSYEWHVQHWGQG (SEQ ID NO: 250)
103	TPP-10270	CTSVHQETKKYQSSGG (SEQ ID NO: 251)	GSYSYTNYEWHVDVWGQG (SEQ ID NO: 252)
104	TPP-10264	CTSVHQETSSPDGGSGG (SEQ ID NO: 253)	GSYSYEWHVDVWGQG (SEQ ID NO: 254)
105	TPP-10581	CAKTHTSPSPDGGSGG (SEQ ID NO: 255)	GSSPPSPYFQHWGQG (SEQ ID NO: 256)
106	TPP-10263	CTSVHQETKSSPDGGSGG (SEQ ID NO: 257)	GSYSNYEWHVDVWGQG (SEQ ID NO: 258)
107	TPP-10271	CTSVHQETKKYQSSPDGG (SEQ ID NO: 259)	GSYSYTNYEWHVDVWGQG (SEQ ID NO: 252)
108	TPP-10262	CTSVHQETKKSSPDGGSGG (SEQ ID NO: 260)	GSYSYNYEWHVDVWGQG (SEQ ID NO: 261)
109	TPP-10272	CTSVHQETKKYQSSGGGG (SEQ ID NO: 262)	GSYSYTNYEWHVDVWGQG (SEQ ID NO: 252)
110	TPP-10261	CTSVHQETKKQSSPDGGSGG (SEQ ID NO: 263)	GSYSYYNYEWHVDVWGQG (SEQ ID NO: 264)
111	TPP-10289	CAKVHPNPNPNPNPDPGGSGG (SEQ ID NO: 265)	GSNPNPNPNPVHDVWGQG (SEQ ID NO: 266)
112	TPP-10273	CTSVHQETKKYQSSPDGGSG (SEQ ID NO: 267)	GSYSYTNYEWHVDVWGQG (SEQ ID NO: 252)
113	TPP-10260	CTSVHQETKKYQSSPDGGSGG (SEQ ID NO: 268)	GSYSYYNYEWHVDVWGQG (SEQ ID NO: 264)
114	TPP-10275	CAKLTVVVTSHQAPGEGGSGG (SEQ ID NO: 269)	GEKKKLKSLAYFQHWGQG (SEQ ID NO: 270)
115	TPP-10580	CAKSSDKHTSPSPDGGSGG (SEQ ID NO: 271)	GSKTHTSPSPYFQHWGQG (SEQ ID NO: 272)
116	TPP-10274	CTSVHQETKKYQSSPDGGSGG (SEQ ID NO: 268)	GSYSYTNYEWHVDVWGQG (SEQ ID NO: 252)
117	TPP-5661	CTSVHQETKKYQSSPDGGSGG (SEQ ID NO: 268)	GSYSYTNYEWHVDVWGQG (SEQ ID NO: 252)
118	TPP-13226	CAKVETKKYQSSPDGGSGG (SEQ ID NO: 273)	GSYSYTNYEVQHWGQG (SEQ ID NO: 274)
119	TPP-13227	CAKVHTKKYQSSPDGGSGG (SEQ ID NO: 275)	GSYSYTNYHVQHWGQG (SEQ ID NO: 276)
120	TPP-13228	CAKLTVETKKYQSSPDGGSGG (SEQ ID NO: 277)	GSYSYTNYEWHVQHWGQG (SEQ ID NO: 278)
121	TPP-13229	CAKLTAETKKYQSSPDGGSGG (SEQ ID NO: 279)	GSYSYTNYENYFQHWGQG (SEQ ID NO: 280)
122	TPP-13230	CAKGITGTTKKYQSSPDGGSGG (SEQ ID NO: 281)	GSYSYTNYAEMYFQHWGQG (SEQ ID NO: 282)
123	TPP-13231	CAKGITGTTKKYQSSPDGGSGG (SEQ ID NO: 281)	GSDYDVWGSYAYFQHWGQG (SEQ ID NO: 283)
124	TPP-10276	CAKLTSVVVTSHQAPGGSGG (SEQ ID NO: 284)	GEKKKLKSLAYYFQHWGQG (SEQ ID NO: 285)
125	TPP-10290	CAKVHPNPNPNPSPDGGSGG (SEQ ID NO: 286)	GSYNPNPNPNPVHDVWGQG (SEQ ID NO: 287)
126	TPP-10445	CAKLTVQVKLELGHRPDGGSGG (SEQ ID NO: 288)	GSNHLRSEKLTYFQHWGQG (SEQ ID NO: 289)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
127	TPP-10269	CAKVHQETKKYQSSPDGGSGG (SEQ ID NO: 290)	GSYSYTNYEWHVQHVGQG (SEQ ID NO: 278)
128	TPP-10288	CAKTQTYISNVNHKPDGGSGG (SEQ ID NO: 291)	GSNTKVDKKAELYFQHVGQG (SEQ ID NO: 292)
129	TPP-10265	CTSVHQETKKYQSSPDGGSGG (SEQ ID NO: 268)	GSYSYTNYEWHVWDVGQG (SEQ ID NO: 293)
130	TPP-10268	CATSVHQETKKYQSSPDGGSGG (SEQ ID NO: 294)	GSYSYTNYEWHVWDVGQG (SEQ ID NO: 295)
131	TPP-10593	CAKLTAEEWKKYEKEKEKNKGS (SEQ ID NO: 296)	GGSGGGSGGGAEYFQHVGQG (SEQ ID NO: 297)
132	TPP-11174	CADSSDRSALLKSKLRLALLTAPR (SEQ ID NO: 298)	GSNHLRSEKLTTFNYFQHVGQG (SEQ ID NO: 299)
133	TPP-10266	CTSVHQETKKYQYQSSPDGGSGG (SEQ ID NO: 300)	GSYSYTYYTNYEWHVWDVGQG (SEQ ID NO: 301)
134	TPP-11173	CAKLTDRLSALLKSKLRLALLTAPR (SEQ ID NO: 302)	GSNHLRSEKLTTFNYFQHVGQG (SEQ ID NO: 299)
135	TPP-10444	CAKLTAQVKLELGHRPDGGSGG (SEQ ID NO: 303)	GSNHLRSEKLTTFNYFQHVGQG (SEQ ID NO: 299)
136	TPP-10267	CTSVHQETKKYQSSYQSSPDGGSGG (SEQ ID NO: 304)	GSPVNHLRSEKLTTFNYFQHVGQG (SEQ ID NO: 305)
137	TPP-10443	CAKLTAQVKLELGHRPAQPDGGSGG (SEQ ID NO: 306)	GSPVNHLRSEKLTTFNYFQHVGQG (SEQ ID NO: 307)
138	TPP-11163	SSSNIGSKLRALLTAPR (SEQ ID NO: 308)	GSGGGGGSGSGSYD (SEQ ID NO: 309)
139	TPP-10360	SGSGSGSGSGSPDGGS GG (SEQ ID NO: 29)	GSYGGGGSGSGSGD (SEQ ID NO: 310)
140	TPP-10462	SSLGQIQLTIRHSSPDGGSGG (SEQ ID NO: 311)	GSNKLIIVVVHASRNLLIGYD (SEQ ID NO: 312)
141	TPP-10460	SPLGQIQLTIRHSSQPDGGSGG (SEQ ID NO: 313)	GSRNKLIVVVHASRNLLIAYD (SEQ ID NO: 314)
142	TPP-10461	SSLGQIQLTIRHSSQPDGGSGG (SEQ ID NO: 315)	GSRNKLIVVVHASRNLLIGYD (SEQ ID NO: 316)
143	TPP-11161	SSSNIGSALLKSKLRLALLTAPR (SEQ ID NO: 317)	GSSDRSALLKSKLRLALLTAD (SEQ ID NO: 318)
144	TPP-11162	SSSNIGSALLKSKLRLALLTAPR (SEQ ID NO: 317)	GSGGGGGGGSGSGSGSYD (SEQ ID NO: 319)
145	TPP-10359	SSSNIGSGSGSGSGSPDGGS GG (SEQ ID NO: 320)	GSYGGGGSGSGSGD (SEQ ID NO: 321)
146	TPP-10824	YG	NSNRPSG (SEQ ID NO: 322)
147	TPP-10825	YGGSGS (SEQ ID NO: 323)	GSGSNSNRPSG (SEQ ID NO: 324)
148	TPP-11019	YGKTHTSPPSPGG (SEQ ID NO: 325)	GGKTHTSPPSPGNRPSG (SEQ ID NO: 326)
149	TPP-11021	YGSGGSGSGSGGG (SEQ ID NO: 327)	GGKTHTSPPSPGNRPSG (SEQ ID NO: 328)
150	TPP-11020	YGSKTHTSPPSPGG (SEQ ID NO: 329)	GGKTHTSPPSPGNRPSG (SEQ ID NO: 328)
151	TPP-10789	YGSGGSGSGGGGG (SEQ ID NO: 330)	GSGGGSGSGGNRPSG (SEQ ID NO: 331)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
152	TPP-11022	YGSSSDKTHTSPPSPGG (SEQ ID NO: 332)	GGSAGSGSGSGSGSGGNRPSG (SEQ ID NO: 333)
153	TPP-10829	YTSASLAITGPDGGSGG (SEQ ID NO: 334)	GSDRFSGSKSGGNRPSG (SEQ ID NO: 335)
154	TPP-10835	YGFILPIEVYPDGGSGG (SEQ ID NO: 336)	GSKVRFDYDLFNRRPSG (SEQ ID NO: 337)
155	TPP-10788	YGSAGSGSGSGSGGGSGG (SEQ ID NO: 338)	GSGSGGGSGSGSGGNRPSG (SEQ ID NO: 339)
156	TPP-10571	YGVPKKEKEKEKVSTAVGG (SEQ ID NO: 340)	GSAPLEVPKKEKEKVG (SEQ ID NO: 341)
157	TPP-10830	YGTTSASLAITGPDGGSGG (SEQ ID NO: 342)	GSDRFSGSKSGGNRPSG (SEQ ID NO: 343)
158	TPP-10790	YGGSGSGSGSGSPDGGSGG (SEQ ID NO: 344)	GSGSGGGSGSGSGGNRPSG (SEQ ID NO: 339)
159	TPP-10573	YGSAGSGSGSGSGSGGG (SEQ ID NO: 345)	GSYEKEKEKNKTLKNVVG (SEQ ID NO: 346)
160	TPP-10827	YGTYYISNVNHPDGGSGG (SEQ ID NO: 347)	GSNTKVDKKVEGNRPSG (SEQ ID NO: 348)
161	TPP-10572	YGAEIEWKKKYEKEKEKGG (SEQ ID NO: 349)	GSGSGSGSGSGSGSGSG (SEQ ID NO: 350)
162	TPP-10836	YGGFILPIEVYPDGGSGG (SEQ ID NO: 351)	GSKVRFDYDLFGNRPSG (SEQ ID NO: 352)
163	TPP-10834	YGSALLKSKLRLALLTAPG (SEQ ID NO: 353)	GSDGSAGSGSGSGSGGNRPSG (SEQ ID NO: 354)
164	TPP-10787	YGSAGSGSGSGSPDGGSGG (SEQ ID NO: 355)	GSGSGGGSGSGSGGNRPSG (SEQ ID NO: 339)
165	TPP-10831	YGGTTSASLAITGPDGGSGG (SEQ ID NO: 356)	GSDRFSGSKSGGGNRPSG (SEQ ID NO: 357)
166	TPP-10828	YGGTYISNVNHPDGGSGG (SEQ ID NO: 358)	GSNTKVDKKVEGGNRPSG (SEQ ID NO: 359)
167	TPP-10826	YTQTYISNVNHPDGGSGG (SEQ ID NO: 360)	GSNTKVDKKVEPKNRPSG (SEQ ID NO: 361)
168	TPP-10837	YGGGFILPIEVYPDGGSGG (SEQ ID NO: 362)	GSKVRFDYDLFGGNRPSG (SEQ ID NO: 363)
169	TPP-10361	YGSAGSGSGSGSPDGGSGG (SEQ ID NO: 364)	GSYGSGSGSGSGSGGNRPSG (SEQ ID NO: 365)
170	TPP-11023	YGSQVKLELGHRAPDGGSGG (SEQ ID NO: 366)	GSVNHRLSEKLTSGNRPSG (SEQ ID NO: 367)
171	TPP-10838	YPAVYVIEILDHRPDGGSGG (SEQ ID NO: 368)	GSGREVPISNGSGFNRPSG (SEQ ID NO: 369)
172	TPP-10840	YGGVVVIEILDHRPDGGSGG (SEQ ID NO: 370)	GSGREVPISNGSGGNRPSG (SEQ ID NO: 371)
173	TPP-10839	YGAVVVIEILDHRPDGGSGG (SEQ ID NO: 372)	GSGREVPISNGSGGNRPSG (SEQ ID NO: 371)
174	TPP-10832	YGSRSALLKSKLRLALLTAPR (SEQ ID NO: 373)	GSDGSAGSGSGSGSGSGGNRPSG (SEQ ID NO: 374)
175	TPP-10833	YGSRSALLKSKLRLALLTAPG (SEQ ID NO: 375)	GSDGSAGSGSGSGSGSGGNRPSG (SEQ ID NO: 374)
176	TPP-11024	YGSAVQVKLELGHRPDGGSGG (SEQ ID NO: 376)	GSVNHRLSEKLTNFSGNRPSG (SEQ ID NO: 377)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP-	N-terminal sequence ³	C-terminal sequence ⁴
177	TPP-10353	CQS	VVF
178	TPP-10780	CGSGSGSGPDGGSGG (SEQ ID NO: 378)	GSGSGSGSGF (SEQ ID NO: 379)
179	TPP-10786	CQSYDILPIEPDGGSGG (SEQ ID NO: 380)	GSRFDYDGVVF (SEQ ID NO: 381)
180	TPP-10779	CGSGSGSGSGPDGGSGG (SEQ ID NO: 382)	GSGSGSGSGSGF (SEQ ID NO: 383)
181	TPP-10778	CGSGSGSGSGSGGGSGG (SEQ ID NO: 384)	GSGSGSGSGSGSGF (SEQ ID NO: 385)
182	TPP-10783	CQSYDKLELGHPDGGSGG (SEQ ID NO: 386)	GSHLRSEKGVVF (SEQ ID NO: 387)
183	TPP-10785	CQSYDILPIEVYPDGGSGG (SEQ ID NO: 388)	GSKVRFDYDGVVF (SEQ ID NO: 389)
184	TPP-10776	CGSGSGSGSGSPDGGSGG (SEQ ID NO: 390)	GSGSGSGSGSGSGF (SEQ ID NO: 385)
185	TPP-10777	CGSGSGSGSGSGSDGGSGG (SEQ ID NO: 391)	GSGSGSGSGSGSGF (SEQ ID NO: 385)
186	TPP-10784	CQSYDGFIPIEVYGGSGG (SEQ ID NO: 392)	GSKVRFDYDLFGVVF (SEQ ID NO: 393)
187	TPP-10782	CQSYDKLELGHRAPDGGSGG (SEQ ID NO: 394)	GSVNHLRSEKGVVF (SEQ ID NO: 395)
188	TPP-10352	CQVHQETKKYQSSPDGGSGG (SEQ ID NO: 396)	GSYSYTNYEWHVVF (SEQ ID NO: 397)
189	TPP-10356	CGSGSGSGSGSPDGGSGG (SEQ ID NO: 398)	GSYGSGSGSGSGGF (SEQ ID NO: 399)
190	TPP-10354	CQSYDPNPNPNPNPDPGGSGG (SEQ ID NO: 400)	GSNPNPNPNSPGVVF (SEQ ID NO: 401)
191	TPP-10355	CAAWNPNPNPNPNPNGSGG (SEQ ID NO: 402)	GSNPNPNPNPNPNVF (SEQ ID NO: 403)
192	TPP-10781	CQSYDQVKLELGHRAAGSGGG (SEQ ID NO: 404)	GSVNHLRSEKLTGVVF (SEQ ID NO: 405)
193	TPP-10436	CQSVHQETKKYQSSPDGGSGG (SEQ ID NO: 406)	GSYSYTNYEWHVVF (SEQ ID NO: 397)
194	TPP-10440	CQSYDQVKLELGHRPDGGSGG (SEQ ID NO: 407)	GSNHLRSEKLTGVVF (SEQ ID NO: 408)
195	TPP-10442	CQSYDGFIPIEVYPDGGSGG (SEQ ID NO: 409)	GSKVRFDYDLFGVVF (SEQ ID NO: 393)
196	TPP-10351	CTSVHQETKKYQSSPDGGSGG (SEQ ID NO: 268)	GSYSYTNYEWHDVVF (SEQ ID NO: 410)
197	TPP-10348	CQSVHQETKKYQSSPDGGSGG (SEQ ID NO: 406)	GSYSYTNYEWHVVVF (SEQ ID NO: 411)
198	TPP-10358	CGGSGSGSGSGSPDGGSGG (SEQ ID NO: 412)	GSYGSGSGSGSGGF (SEQ ID NO: 413)
199	TPP-11167	CQCQSYDSSALLKSKLALLTAPR (SEQ ID NO: 414)	GSVNHLRSEKLTGVVF (SEQ ID NO: 405)
200	TPP-10438	CQSAVQVKLELGHRAPDGGSGG (SEQ ID NO: 415)	GSVNHLRSEKLTNFVF (SEQ ID NO: 416)
201	TPP-10439	CQSYDQVKLELGHRAPDGGSGG (SEQ ID NO: 417)	GSVNHLRSEKLTGVVF (SEQ ID NO: 405)

-continued

Table 4 cont.: Design of ANP engrafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
202	TPP-10441	CQSYDGFILPIEVYFPDGGSGG (SEQ ID NO: 418)	GSRKVRFDYDLFGVVF (SEQ ID NO: 419)
203	TPP-10349	CQSYVHQETKKYQSSPDGGSGG (SEQ ID NO: 420)	GSYSYTNYEWHVGVVF (SEQ ID NO: 421)
204	TPP-10350	CQSYDVHQETKKYQSSPDGGSGG (SEQ ID NO: 422)	GSYSYTNYEWHVSGVVF (SEQ ID NO: 423)
205	TPP-10437	CQSYDAVQVKLELGHRAPDGGSGG (SEQ ID NO: 424)	GSVNHLRSEKLTFNGVVF (SEQ ID NO: 425)
206	TPP-11166	CQCQSYDSSDRSALLKSKLRLALLTAPR (SEQ ID NO: 426)	GSGGSVNHLRSEKLTVGVVF (SEQ ID NO: 427)
207	TPP-10362	CQSYDSSDRSALLKSKLRLALLTAPR (SEQ ID NO: 426)	GSDRSALLKSKLRLALLTAVVF (SEQ ID NO: 428)
208	TPP-10363	CQSYDSSDRSALLKSKLRLALLTAPE (SEQ ID NO: 429)	GSDRSALLKSKLRLALLTAVVF (SEQ ID NO: 428)
209	TPP-5657		

³The N-terminal sequence corresponds to the nearest neighboring reference aa N-terminal from the inserted natriuretic peptide plus the amino acid stretch present between said reference aa and the first amino acid residue of the inserted natriuretic peptide

⁴The C-terminal sequence corresponds to the amino acid stretch present between the last amino acid residue of the inserted natriuretic peptide and the nearest neighboring reference aa C-terminal from the inserted natriuretic peptide plus said reference aa

In addition, the following BNP engrafted human IgG1 antibody constructs were generated starting from the anti-body scaffold TPP-5657.

TABLE 5

Design of BNP engrafted antibody constructs						
Cmpd	TPP	Insertion Site	# aa N-term ¹	# aa C-term ² BNP	Corresp. ANP Cpd ³	
B1	TPP-9902	CTSVHQETKKYQSSPDGGSGG (SEQ ID NO: 268)	GSYSYTNYEWHVDWGQG (SEQ ID NO: 252)	18	Hum28aa	#117
B2	TPP-11153	CTSVHQETKKYQSSPDGGSGSG (SEQ ID NO: 430)	GGSYSYTNYEWHVDWGQG (SEQ ID NO: 431)	19	Hum25aa	
B3	TPP-11154	CTSVHQETKKYQSSPDGGSGG (SEQ ID NO: 268)	GSYSYTNYEWHVDWGQG (SEQ ID NO: 252)	18	Rat28aa	#117
B4	TPP-11155	CTSVHQETKKYQSSPDGG (SEQ ID NO: 259)	SYSYTNYEWHVDWGQG (SEQ ID NO: 432)	17	Rat32aa	
B5	TPP-11156	ISGSVVVTSHQAPGGGS (SEQ ID NO: 189)	GEKKKLKSLAYGST (SEQ ID NO: 190)	13	Hum28aa	#65
B6	TPP-11157	ISGSVVVTSHQAPGGGS (SEQ ID NO: 189)	GEKKKLKSLAYGST (SEQ ID NO: 190)	13	Rat28aa	#65
B7	TPP-18029	SGFTFGSGSGSGSGSPDGGSGG (SEQ ID NO: 105)	GSYGSNSGSGSGSGM (SEQ ID NO: 106)	14	Hum28aa	#9
B8	TPP-18031	ISGS (SEQ ID NO: 109)	GGST (SEQ ID NO: 110)	3	Hum28aa	#12
B9	TPP-18032	ISGSGSGS (SEQ ID NO: 111)	GSGSGGST (SEQ ID NO: 112)	7	Hum28aa	#13
B10	TPP-18033	ISGSTYISNVNHPDGGSGG (SEQ ID NO: 211)	GSNTKVDKKVEGGST (SEQ ID NO: 212)	14	Hum28aa	#80

TABLE 5-continued

Design of BNP engrafted antibody constructs						
B11	TPP-18028	ISGPNPNPNPNPSPDGGSGG (SEQ ID NO: 236)	GSYNPNPNPNPNPNGST (SEQ ID NO: 237)	15	Hum28aa	#94
B12	TPP-18034	CAKGITGTTKYQSSPDGGSGG (SEQ ID NO: 281)	GGSYTYNYAEYFQHVGQG (SEQ ID NO: 282)	18	Hum28aa	#122
B13	TPP-18030	CAAWNPNPNPNPNPNGSGG (SEQ ID NO: 402)	GSNPNPNPNPNPNVF (SEQ ID NO: 403)	14	Hum28aa	#191
Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴			
B1	TPP-9902	CTSVHQETKKYQSSPDGGSGG	GGSYTYNYEWHVDVWGQG			
B2	TPP-11153	CTSVHQETKKYQSSPDGGSGG	GGSYTYNYEWHVDVWGQG			
B3	TPP-11154	CTSVHQETKKYQSSPDGGSGG	GGSYTYNYEWHVDVWGQG			
B4	TPP-11155	CTSVHQETKKYQSSPDGG	SYSYTYNYEWHVDVWGQG			
B5	TPP-11156	ISGSVVVTSHQAPGGSGG	GEKKKLKSLAYGST			
B6	TPP-11157	ISGSVVVTSHQAPGGSGG	GEKKKLKSLAYGST			
B7	TPP-18029	SGFTFGSGSGSGSGSPDGGSGG	GSYGSGSGSGSMSM			
B8	TPP-18031	ISGS	GGST			
B9	TPP-18032	ISGSGSGS	GSGGGST			
B10	TPP-18033	ISGTYISNVNHKPDGGSGG	GSNTKVDKVVEGGST			
B11	TPP-18028	ISGPNPNPNPSPDGGSGG	GSYNPNPNPNPNGST			
B12	TPP-18034	CAKGITGTTKYQSSPDGGSGG	GGSYTYNYAEYFQHVGQG			
B13	TPP-18030	CAAWNPNPNPNPNGSGG	GSNPNPNPNPNVF			

¹The number of amino acid residues present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide;

²The number of amino acid residues present between the last amino acid of the inserted natriuretic peptide and the respective C-terminal reference amino acid residue

³Corresponding ANP Cpd. refers to an ANP engrafted antibody construct with the same integration locus and comprising the same N-terminal and C-terminal sequence

⁴The N-terminal sequence corresponds to the nearest neighboring reference aa N-terminal from the inserted natriuretic peptide plus the amino acid stretch present between said reference aa and the first amino acid residue of the inserted natriuretic peptide

⁵The C-terminal sequence corresponds the amino acid stretch present between the last amino acid residue of the inserted natriuretic peptide and the nearest neighboring reference aa C-terminal from the inserted natriuretic peptide plus and said reference aa

In addition, the following CNP engrafted human IgG1 antibody constructs were generated.

TABLE 6

Design of CNP engrafted antibody constructs

Cmpd	TPP	Insertion Site	SEQ ID NO	SEQ ID NO	# aa	# aa	%	Corresp.	
			comprised in Ntts	comprised in Ctls	N-term ¹	C-term ²	μg/ml	purity	ANP Cpd ³
C1	TPP-9465	CDRH3	7	8	21	23	69-242	97	
C2	TPP-12374	CDRL3	11	12	20	20	212		
C3	TPP-12375	CDRH3	7	8	21	23	6		
C4	TPP-12376	CDRH3	7	8	20	22	7		
C5	TPP-12377	CDRH3	8	21	23	7			

TABLE 6-continued

Design of CNP grafted antibody constructs								
C6	TPP-12378	CDRH2	9	10	19	18	3	
C13	TPP-18036	CDRH1			23	14	259	100
C14	TPP-18038	CDRH2			3	3	0	#12
C15	TPP-18039	CDRH2			7	7	301	100
C16	TPP-18040	CDRH2	2		19	14	300	100
C17	TPP-18035	CDRH2			20	15	243	100
C18	TPP-18041	CDRH3	21		20	18	287	100
C19	TPP-18037	CDRL3			19	14	246	100
Cmpds based on TPP-12377:								
C7	TPP-12895				LC_G99E			
C8	TPP-12896				LC_G99L		101-131	
C9	TPP-12897				LC_S98D		198-304	
C10	TPP-12898				LC_S98G		147-258	
C11	TPP-12899				LC_A33Y		165-197	82
C12	TPP-12900				LC_A33E		109-195	

¹The number of amino acid residues present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide;

²The number of amino acid residues present between the last amino acid of the inserted natriuretic peptide and the respective C-terminal reference amino acid residue

³Corresponding ANP Cpd. refers to an ANP grafted antibody construct with the same integration locus and comprising the same N-terminal and C-terminal sequence

Table 6 cont.: Design of CNP grafted antibody constructs

Cmpd	TPP	N-terminal sequence ³	C-terminal sequence ⁴
C1	TPP-9465	CTSVHQETKKYQSSPDGGSGGS (SEQ ID NO: 433)	GSGGYGSYSYTNYEWHVDVWGQG (SEQ ID NO: 434)
C2	TPP-12374	CQSYDQVKLELGHAGGSGGS (SEQ ID NO: 435)	GSGGSGSVNHLRSEKLTGVVF (SEQ ID NO: 436)
C3	TPP-12375	CTSVHQETKKYQSSPDGGSGGS (SEQ ID NO: 433)	GSGGSGSYSYTNYEWHVDVWGQG (SEQ ID NO: 437)
C4	TPP-12376	CTSVHQETKKYQSSPDGGSGGG (SEQ ID NO: 268)	GSGGSGSYSYTNYEWHVDVWGQG (SEQ ID NO: 438)
C5	TPP-12377	CTSVHQETKKYQSSPYKGANKK (SEQ ID NO: 439)	GSGGSGSYSYTNYEWHVDVWGQG (SEQ ID NO: 437)
C6	TPP-12378	ISGSVVVTSHQAPGGSGGS (SEQ ID NO: 440)	GSGGSGEKKLKSLAYGST (SEQ ID NO: 441)

³The N-terminal sequence corresponds to the nearest neighboring reference aa N-terminal from the inserted natriuretic peptide plus the amino acid stretch present between said reference aa and the first amino acid residue of the inserted natriuretic peptide of the inserted natriuretic peptide and the nearest

⁴The C-terminal sequence corresponds to the amino acid stretch present between the last amino acid residue neighboring reference aa C-terminal from the inserted natriuretic peptide plus said reference aa

Example 5: In Vitro Activities of Generated Constructs

All constructs were expressed transiently in HEK293 cells according to well-known methods in the art, targeting a cell density of about 2×10^6 cells/ml, a total DNA concentration of about 1 μ g/ml for the two plasmids encoding the light and heavy chain and a 5 day incubation for the expression.

Raw compound samples (rcs) were expressed in a culture volume of 0.4 ml, and the supernatant separated by centrifugation was directly used for testing. The compound concentration was assessed by an IgG-Fc quantification ELISA according to well-known methods in the art. Briefly, 1:1500 diluted supernatant and a 2-fold dilution series of Human Reference Serum (Bethyl, RS-110-4) starting with 400 ng/ml were immobilized in black Maxisorp 384 micro titer plates (MTP) coated with anti-human Fc [Sigma 12136] in a 1:440 dilution in 1× coating buffer (Candor, 121125) for

50 1 h, 37° C. After blocking with 100% SMART Block (Candor, 113125) anti-human Fc-HRP [Sigma, A0170] was applied in a 1:10000 dilution for the detection of antibodies in rcs and reference samples. Dose curves of the reference sample were used for the quantitative assessment of compound concentrations shown in Tables 7 and 8, column 55 “ μ g/ml rcs”. All samples were applied in quadruplets.

Isolated compound samples (ics) were generated by 1-step purification via protein-A from 6 ml expression culture and according to well-known methods in the art. Acid eluates were neutralized by addition of 8% (v/v) 1M 60 Tris/HCl pH 9.0, quantified via absorption at 280 nm and normalized to a concentration of 125 nM.

Purified compound samples (pcs) were generated by 2-step purification via protein-A and subsequent SEC in PBS buffer from expression culture of at least 35 ml. Values 65 shown in Tables 7 and 8, column “ μ g/ml pcs”, refer to the compound concentration in the expression culture supernatant determined by analytical Protein A chromatography.

All activities shown in Tables 7 and 8 were measured on cells with heterologous over expression of human NPRA (hNPRA) by use of a cGMP quantification assay conducted according to manufacturer's instructions (cisbio; 62GM2PEH). In brief, the assay quantifies cGMP in buffered solution or cell-culture supernatants based on the competition between cGMP produced by the cell as result of the NPRA stimulation through the (natriuretic peptide) sample and d2 labelled cGMP for binding to a Cryptate labelled antibody. Sample cGMP and d2 labeled cGMP compete for binding to a limited number of sites on Cryptate labeled anti-cGMP antibodies, and consequently, HTRF® specific fluorescent signal (i.e. energy transfer) is inversely proportional to the concentration of cGMP in the sample.

Dose-response curve data were analyzed with GraphPad Prism (version 7.00 for Windows, GraphPad Software, La Jolla California USA) and EC50 were fitted according to $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{(\text{LogEC50} - X) * \text{Hill-Slope}})$ applying constraints for bottom, top and slope (shared value for all data sets of the respective experiment).

The raw compound sample activity on stable hNPRA-CHO k1 cells was first assessed by comparison to the negative control TPP-5657 and to a positive sample, in particular TPP-5661. Controls and rcs were tested in quadruplets in two concentrations with a relative dilution factor of 5 aiming for a fluorescent signal (s) in the dynamic range of the assay. The assay window was defined as the difference in signal of inactive (max. signal, s_max) and highly active samples (min. signal, s_min), and for both compound concentrations the activity in % was calculated as $100 * (s_{\text{max}} - s) / (s_{\text{max}} - s_{\text{min}})$. Values listed in Table 7, columns "activity rcs" and "stdev activity rcs", represent the average of the results for the two concentrations and the respective standard deviation. Rcs signals less than half of the signal of the reference compound TPP-5661 (36%) were assessed as not active (n.a.).

The activity of several raw compound samples on stable hNPRA-CHO k1 cells was reassessed by comparison to reference sample TPP-5661 in 2.5-fold dilution series (8 concentrations) starting with a 5-fold dilution. The "log EC50" fit value as activity measure of the rcs was set in relation to the corresponding value of the reference rcs TPP-5661 by calculating the delta "log EC50"_compound-"log EC50"_TPP-5661; resulting values are listed in Table 7, column "rel. activity rcs". Notably, the compound concentrations in the rcs was not considered, and consequently given values are influenced by compound activity and concentration in equal measure. All samples were applied in quadruplets.

The activity of isolated compound samples on stable hNPRA-CHO k1 cells was assessed by EC50 determination and comparison to reference sample TPP-5661. Samples

were tested in 2.5-fold dilution series from 80 nM to 0.13 nM. The log EC50 fit value as activity measure of the rcs was set in relation to the corresponding value of the reference rcs TPP-5661 (-8.8) by calculating the delta log EC50_compound-log EC50_TPP-5661; resulting values are listed in Table 7, column "rel. log EC50 rcs". All samples were applied in quadruplets.

The activity of purified compound samples on stable hNPRA-CHO k1 cells was assessed in multiple experiments 10 by EC50 determination and comparison to reference sample TPP-5661. Samples were tested in dilution series at least in quadruplets. Values listed in Table 7, columns "rel. log EC50 pcs 1, 3 and 4" result from 5-fold dilution series (>4 concentrations) starting with 20 or 25 nM. Values listed in 15 Table 7, column "rel. log EC50 pcs 2" result from 10-fold dilution series (4 concentrations) starting with 25 nM. Values listed in Table 7, columns "rel. log EC50 pcs 5, 6, 7, 8 and 9" result from 2.5-fold dilution series, with 8 or 12 concentrations starting with 40 to 200 nM, respectively. The 20 log EC50 fit value as activity measure of the pcs was set in relation to the corresponding value of the reference TPP-5661 in the respective experiment (in average -9.2, standard deviation 0.5) by calculating the delta log EC50_compound-log EC50_TPP-5661.

The activity of purified compound samples on transient hNPRA-HEK293 cells was assessed in three experiments by 25 EC50 determination and comparison to reference sample TPP-5661. Samples were tested in 5-fold dilution series from 1000 nM to 0.013 nM. The log EC50 fit value as 30 activity measure of the pcs was set in relation to the corresponding value of the reference TPP-5661 in the respective experiment (average of three experiments -9.0, standard deviation 0.4) by calculating the delta log EC50_compound-log EC50_TPP-5661; resulting values 35 are listed in Table 7, columns "rel. log EC50*pcs". All samples were applied in duplicates.

A summarized qualitative assessment of the activity of compounds is given in the column "qualit. activity", values listed in column "average rel. log EC50" were calculated as 40 average of given rel. log EC50 values. Compounds showing an EC50 values > 50-fold of the reference compound TPP-5661, meaning average rel. log EC50 > 1.7, were qualitatively assessed as not active ("."), compounds showing a relative log EC50 between 0.7 and 1.7 were assessed as 45 active ("+"), compounds showing a relative log EC50 < 0.7 were assessed as very active ("++"); highest activities were observed at relative log EC50 below -0.7 ("+++"). Compounds showing an activity in rcs without confirmation as rcs or pcs are marked with an unified "y", and compounds assessed as not active ("n.a." in column "activity rcs") probably due to their very low expression level ($\leq 1 \mu\text{g/ml}$, "n.e." in column "μg/ml rcs") are marked accordingly.

US 12,390,508 B2

79

80

TABLE 7

US 12,390,508 B2

81

82

TABLE 7-continued

US 12,390,508 B2

83

84

TABLE 7-continued

US 12,390,508 B2

85

86

TABLE 7-continued

TABLE 7-continued

Compound	# aa N- term ¹	# aa C- term ²	Expression levels and activities of atrial natriuretic peptide grafted antibody constructs																				
			#			% purity			activ- ity			rel. activ- ity			rel. log- ics			rel. log- ics			rel. log- ics		
			μg/ml res	μg/ml pes	μg/ml pes	res	res	res	res	res	res	res	res	res	res	res	res	res	res	res	res	res	res
#204	22	17	5.7	20	n.d.	45%	17%																
#205	23	17	34.0	n.d.	n.d.	84%	19%																y
#206	24	18	11.0	n.d.	n.d.	47%	33%																y
#207	24	20	12.0	115	95	59%	17%																y
#208	24	20	9.5	182	92	74%	11%																-
#209	na	na	18.3	402	100	n.a.	n.a.																++
																							0.5
																							-

Not determined (n.d.), not active (na.), not expressed (n.e.), not applicable (na)

¹The number of amino acid residues present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide;²The number of amino acid residues present between the last amino acid of the inserted natriuretic peptide and the respective C-terminal reference amino acid residue

No conclusive data for compounds #104 and #135 were obtained. 12 compounds (#54, #61, #89, #139, #162, #168, #170, #171, #172, #173, #176, #196) showed very low expression levels ($\leq 1 \mu\text{g/ml}$ in rcs) and consequently no activity; activity of #61 was shown after compound preparation (pcs). 7 compounds (#7, #24, #70, #83, #90, #154, #167) showed in most cases low activity as rcs, although their expression level was very low; the activity of #24 and #90 was confirmed by compound preparation (pcs). No activity was observed in rcs of compounds #18, #26, #29, #92, #96, #101, #104, #158, #164, #179; however, the activity of compounds #18, #92, #158, #164 was shown using higher concentrations (rel. activity rcs); the lack of activity of #26 was thereby confirmed.

TABLE 8

Compound	TPP	# aa N-term ¹	# aa C-term ²	$\mu\text{g/ml}$ pps	% purity pps	qualit. activity on hNPRA	qualit. activity of ANP cpd. ³
B1	TPP-9902	20	18	304	96	++	++
B2	TPP-11153	22	19	202	99	+	
B3	TPP-11154	20	18	205	100	-	++
B4	TPP-11155	17	17	226	97	-	
B5	TPP-11156	18	13	115	75	++	+++
B6	TPP-11157	18	13	125	93	-	+++
B7	TPP-18029	23	14	265	99	+	++
B8	TPP-18031	3	3	260	99	-	-
B9	TPP-18032	7	7	262	99	-	-
B10	TPP-18033	19	14	310	98	+	++
B11	TPP-18028	20	15	74	99	+	+++
B12	TPP-18034	20	18	315	97	++	++
B13	TPP-18030	19	14	304	100	+	++
#209	TPP-5657	na	na	402	100	-	-

¹The number of amino acid residues present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide;

²The number of amino acid residues present between the last amino acid of the inserted natriuretic peptide and the respective C-terminal reference amino acid residue

³Corresponding ANP Cpd. refers to an ANP engrafted antibody construct with the same integration locus and comprising the same N-terminal and C-terminal sequence

Purified compound samples were tested as described in Example 3 in quadruplets in dilution series on stable hNPRA-CHO k1 cells. The activities of BNP engrafted antibody constructs are graphically depicted in FIG. 11.

TPP-11156, TPP-9902 and TPP-11153 showed significant activity on hNPRA cells in contrast to TPP-1154, TPP-11155, and TPP-11157. Opposed results were observed on rNPRA with EC₅₀<20 nM for TPP-1154, TPP-11155, and TPP-11157, and EC₅₀>1 μM for TPP-9902, TPP-11153, and TPP-11156 (see Example 3). This can be explained by the

presence of a human BNP sequence in TPP-11156, TPP-9902 and TPP-11153, whereas TPP-1154, TPP-11155, and TPP-11157 comprise a rat BNP sequence (see Table 5). In contrast to all other human BNP engrafted antibody constructs, TPP-18031 and TPP-18032 with low numbers of additional amino acids N- and C-terminal to BNP showed no activity on hNPRA.

Example 6: Specific Linker Sequences are Particularly Advantageous for Achieving Good Homogeneity and Expression Levels

The purity of purified compound samples (Example 5, Table 7, column "% purity pcs") was determined by capillary Gel Electrophoresis according to manufacturer's instructions (LabChip GX, Caliper Life Sciences) under reduced conditions. The purity in % was calculated as sum of peak areas corresponding to the intact light and heavy chain relative to the sum of all peaks observed.

Ntls sequences comprising a GS linker sequence, a PN linker sequence or the sequence of SEQ ID NOs 2, 4, 9, 11, 13 or 15 and Ctls sequences comprising a GS linker sequence, a PN linker sequence or the sequence of SEQ ID NOs 3, 5, 12, 14, 15 or 20 have proven particularly useful as they not only achieve high natriuretic peptide activities (provided that at least 12 amino acid residues are present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide) but also good expression levels (in contrast to e.g., sequences used in compounds #186, #195 and #202) and (in contrast to e.g., sequences used in compounds 6 and 7) a low degree of inhomogeneity (see Table 9). With linker sequences comprising a GS linker sequence as well as linker sequences comprising a PN linker sequence very good purities of 98% in average were observed. Similarly good values were observed for compounds with linkers comprising sequences of SEQ ID NOs 2, 3, 4, 5, 9, 11, 12, 13, 14, 15 and 20. Notably, the Ntls having the sequence of SEQ ID NO 9 resulted only in combination with the Ctls having the sequence of SEQ ID NO 20 in compounds with very good purity; compounds with a combination of the Ntls having the sequence of SEQ ID NO 11 and the Ctls having the sequence of SEQ ID NO 12 showed only very good purity when SEQ ID NO 11 was flanked by Asp (D) on the N-terminal side and not by Thr (T) or Val (V) and when the SEQ ID NO 12 VNHLRSEKLT was flanked by Gly (G) on the C-terminal side but not by Tyr (Y) or Phe (F) as in compounds #126 and #135.

TABLE 9

Ntls and Ctls effects on antibody purity (excerpt of Table 7)						
Cpd	TPP	Insertion Site	SEQ ID NO comprised in Ntls	SEQ ID NO comprised in Ctls	# aa N-term ¹	# aa C-term ²
2	TPP-13056	CDRH1	GS	GS	9	5
3	TPP-13055	CDRH1	GS	GS	12	8
4	TPP-13054	CDRH1	GS	GS	15	10
5	TPP-12545	CDRH1	GS	GS	18	10
9	TPP-10294	CDRH1	GS	GS	23	14

TABLE 9-continued

Ntls and Ctls effects on antibody purity (excerpt of Table 7)						
10	TPP- 12547	CDRH1	GS	GS	23	14
91	TPP- 10282	CDRH2	GS	GS	20	15
99	TPP- 10281	CDRH3	GS	GS	10	3
100	TPP- 10280	CDRH3	GS	GS	10	8
169	TPP- 10361	CDRL2	GS	GS	19	17
184	TPP- 10776	CDRL3	GS	GS	18	13
185	TPP- 10777	CDRL3	GS	GS	18	13
189	TPP- 10356	CDRL3	GS	GS	19	14
198	TPP- 10358	CDRL3	GS	GS	20	15
18	TPP- 10767	CDRH2	PN	PN	13	12
55	TPP- 10765	CDRH2	PN	PN	17	14
93	TPP- 10286	CDRH2	PN	PN	20	15
94	TPP- 10283	CDRH2	PN	PN	20	15
111	TPP- 10289	CDRH3	PN	PN	19	17
125	TPP- 10290	CDRH3	PN	PN	20	18
191	TPP- 10355	CDRL3	PN	PN	19	14
63	TPP- 10844	CDRH2	2	3	18	13
80	TPP- 10845	CDRH2	2	3	19	14
128	TPP- 10288	CDRH3	2	3	20	18
61	TPP- 10847	CDRH2	4	5	18	13
76	TPP- 10848	CDRH2	4	5	19	14
156	TPP- 10571	CDRL2	15	15	17	16
42	TPP- 13060	CDRH2	9	20	17	11
43	TPP- 13061	CDRH2	9	20	17	11
44	TPP- 13062	CDRH2	9	20	17	11
46	TPP- 13064	CDRH2	9	10	17	11

TABLE 9-continued

Ntls and Ctls effects on antibody purity (excerpt of Table 7)						
				μg/ml pcs	% purity pcs	qualit. actvity
45	TPP- 13063	CDRH2	9	10	17	11
40	TPP- 13058	CDRH2	9	10	17	11
47	TPP- 13065	CDRH2	9	10	17	11
41	TPP- 13059	CDRH2	9	10	17	11
201	TPP- 10439	CDRL3	11	12	21	15
194	TPP- 10440	CDRL3	11	12	20	14
187	TPP- 10782	CDRL3	11	12	19	13
126	TPP- 10445	CDRH3	11	12	20	18
135	TPP- 10444	CDRH3	11	12	22	20
50	TPP- 10452	CDRH2	13	14	17	12
74	TPP- 10451	CDRH2	13	14	19	14
26	TPP- 10772	CDRH2	13	14	16	11
6	TPP- 10454	CDRH1			19	17
7	TPP- 10453	CDRH1			19	17
186	TPP- 10784	CDRL3			18	14
195	TPP- 10442	CDRL3			20	14
202	TPP- 10441	CDRL3			21	15
Cpd	N-terminal sequence ³	C-terminal sequence ⁴	μg/ml pcs	% purity pcs	qualit. actvity	
2	SGFTFGSGSG (SEQ ID NO: 93)	GSGSGM (SEQ ID NO: 94)	179	96	-	
3	SGFTFGSGSGSGS (SEQ ID NO: 95)	SGSGSGSGSM (SEQ ID NO: 96)	196	97	++	
4	SGFTFGSGSGSGGG (SEQ ID NO: 97)	GGSGGGSGSGSG (SEQ ID NO: 39)	214	96	++	
5	SGFTFGSGSGSGGGGG (SEQ ID NO: 99)	GSGSGGSGSGM (SEQ ID NO: 100)	229	93	++	
9	SGFTFGSGSGSGSGSPDGGSGG (SEQ ID NO: 105)	GSYGSNSGSGSGSM (SEQ ID NO: 106)	226	97	++	
10	SGFTFGSGSGSGSGSPDGGSGG (SEQ ID NO: 105)	GSYGSNSGSGSGSM (SEQ ID NO: 106)	265	96	++	
91	ISGSGSGSGSGSPDGGSGG (SEQ ID NO: 231)	GSYGSNSGSGSGGST (SEQ ID NO: 221)	275	99	++	

TABLE 9-continued

Ntls and Ctls effects on antibody purity (excerpt of Table 7)					
99	CAKSPDGGS GG (SEQ ID NO: 244)	GSYG (SEQ ID NO: 245)	257	100	-
100	CAKSPDGGS GG (SEQ ID NO: 244)	GSYQHWGQG (SEQ ID NO: 246)	188	99	-
169	YGS GSGSGSGSGS PDGGSGG (SEQ ID NO: 364)	GSYGS GSGSGSGGNRPSG (SEQ ID NO: 365)	78	99	++
184	CGSGSGSGSGSGPDGGSGG (SEQ ID NO: 390)	GSGSGSGSGSGSF (SEQ ID NO: 385)	100	100	Y
185	CGSGSGSGSGSGSDGGSGG (SEQ ID NO: 391)	GSGSGSGSGSGSF (SEQ ID NO: 385)	81	100	Y
189	CGSGSGSGSGSGSPDGGSGG (SEQ ID NO: 398)	GSYGS GSGSGSGSF (SEQ ID NO: 399)	102	99	Y
198	CGGSGSGSGSGSPDGGSGG (SEQ ID NO: 412)	GSYGS GSGSGSGGF (SEQ ID NO: 413)	57	100	Y
18	ISGPNPKNPNPNGG (SEQ ID NO: 121)	GSNENPNPNPGST (SEQ ID NO: 122)	290	98	+
55	ISGPNPKNPNPNPGSGG (SEQ ID NO: 170)	GSNPNEPNPNPGST (SEQ ID NO: 134)	271	95	++
93	ISGPNPKNPNPNSPDGGSGG (SEQ ID NO: 234)	GSYNPNENPNPNPGST (SEQ ID NO: 235)	286	98	+++
94	ISGPNPNPNPNPSPDGGSGG (SEQ ID NO: 236)	GSYNPNPNPNPNPGST (SEQ ID NO: 237)	318	98	+++
111	CAKVHPNPNPNPNPDPGGSGG (SEQ ID NO: 265)	GSNPNPNPNPVHDVWGQG (SEQ ID NO: 266)	296	98	++
125	CAKVHPNPNPNPSPDGGSGG (SEQ ID NO: 286)	GSYNPNPNPNPHVHDVWGQG (SEQ ID NO: 287)	320	99	++
191	CAA WNPNPNPNPNGSGG (SEQ ID NO: 402)	GSNPNPNPNPNPNVF (SEQ ID NO: 403)	248	99	++
63	ISGTYISNVNHKP DGGSGG (SEQ ID NO: 185)	GSNTKVDKKVEGST (SEQ ID NO: 186)	239	96	++
80	ISGSTYISNVNHKP DGGSGG (SEQ ID NO: 211)	GSNTKVDKKVEGGST (SEQ ID NO: 212)	214	95	++
128	CAKTQTYISNVNHKP DGGSGG (SEQ ID NO: 291)	GSNTKVDKKKA EYFQHWGQG (SEQ ID NO: 292)	291	96	Y
61	ISGTSASLAITGP DGGSGG (SEQ ID NO: 181)	GSDRFSGSKSGG ST (SEQ ID NO: 182)	334	97	++
76	ISGSTASLAITGP DGGSGG (SEQ ID NO: 204)	GSDRFSGSKSGG ST (SEQ ID NO: 205)	299	97	++
156	YGV PKEKEKEKVSTA VGG (SEQ ID NO: 340)	GSAPLEVPKEKEKEKVG (SEQ ID NO: 341)	64	98	++
42	ISVVVTSHQSPTPGGS GG (SEQ ID NO: 154)	GGSTPLKSLAST (SEQ ID NO: 155)	112	97	++
43	ISVVVTSHQAPGE GGSGG (SEQ ID NO: 145)	GGSTPLKSLAST (SEQ ID NO: 155)	141	96	++
44	ISVVVTSHQAPGE GGSGG (SEQ ID NO: 145)	GSTPKLKSLAST (SEQ ID NO: 156)	166	93	+++
46	ISVVVTSHPTPGEGGS GG (SEQ ID NO: 157)	GEKKKLKSLAST (SEQ ID NO: 146)	166	92	++
45	ISVVVTSHQSPTPGGS GG (SEQ ID NO: 154)	GEKKKLKSLAST (SEQ ID NO: 146)	135	90	++
40	ISVVVTSHQAPGSGGS GG (SEQ ID NO: 152)	GEKKKLKSLAST (SEQ ID NO: 146)	154	85	++

TABLE 9-continued

Nt1s and Ct1s effects on antibody purity (excerpt of Table 7)						
47	<u>ISVVVTSHQAPSPGSTGG</u> (SEQ ID NO: 158)	GEKKKLKSLAST (SEQ ID NO: 146)	123	83	++	
41	<u>ISVVVTSHQAPTSGGSGG</u> (SEQ ID NO: 153)	GEKKKLKSLAST (SEQ ID NO: 146)	106	79	n.d.	
201	<u>CQSYDQVKLELGHRAPDGGS</u> (SEQ ID NO: 417)	GSVNHLRSEKLTGVVF (SEQ ID NO: 405)	134	97	++	
194	<u>CQSYDQVKLELGHRPDGGS</u> (SEQ ID NO: 407)	GSNHLRSEKLTGVVF (SEQ ID NO: 408)	98	97	Y	
187	<u>CQSYDKLELGHRAPDGGS</u> (SEQ ID NO: 394)	GSVNHLRSEKGVVF (SEQ ID NO: 395)	217	95	+++	
126	<u>CAKLTQVKLELGHRPDGGS</u> (SEQ ID NO: 288)	GSNHLRSEKLTYPQHNGQG (SEQ ID NO: 289)	203	90	Y	
135	<u>CAKLTAVQVKLELGHRPDGGS</u> (SEQ ID NO: 303)	GSNHLRSEKLTYPQHNGQG (SEQ ID NO: 299)	158	88	?	
50	<u>ISGSAAVNVRA</u> PDGGS (SEQ ID NO: 160)	GSKGDKIAIGGST (SEQ ID NO: 161)	87	97	++	
74	<u>ISGSSGAAVNVRA</u> PDGGS (SEQ ID NO: 201)	GSKGDKIAIWTGGST (SEQ ID NO: 202)	142	97	++	
26	<u>ISGSAAVNVRA</u> DGGSGG (SEQ ID NO: 135)	GSGDKIAIGGST (SEQ ID NO: 136)	181	98	-	
6	SPAVVYIEILDRLHPDGGS (SEQ ID NO: 101)	GSGREVPISNGSGFVVAM (SEQ ID NO: 102)	150	76	Y	
7	SGAVVYIEILDRLHPDGGS (SEQ ID NO: 103)	GSGREVPISNGSGFVVAM (SEQ ID NO: 102)	117	70	Y	
186	<u>CQSYDGFILPIEVYGG</u> SGG (SEQ ID NO: 392)	GSKVRFDYDLFGVVF (SEQ ID NO: 393)	77	96	Y	
195	<u>CQSYDGFILPIEVYPDGG</u> SGG (SEQ ID NO: 409)	GSKVRFDYDLFGVVF (SEQ ID NO: 393)	43	97	Y	
202	<u>CQSYDGFILPIEVYFPDGGS</u> GG (SEQ ID NO: 418)	GSRKVRFDYDLFGVVF (SEQ ID NO: 419)	29	n.d.	Y	

¹The number of amino acid residues present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide;

²The number of amino acid residues present between the last amino acid of the inserted natriuretic peptide and the respective C-terminal reference amino acid residue

³The N-terminal sequence corresponds to the nearest neighboring reference aa N-terminal from the inserted natriuretic peptide plus the amino acid stretch present between said reference aa and the first amino acid residue of the inserted natriuretic peptide

⁴The C-terminal sequence corresponds the amino acid stretch present between the last amino acid residue of the inserted natriuretic peptide and the nearest neighboring reference aa C-terminal from the inserted natriuretic peptide plus and said reference aa

Example 7: IgG1, IgG2 and IgG4 Isotypes Provide Equally Suitable Antibody Scaffolds

Compounds 9, 33, 65, 91, 127 and 191 (human IgG1 TPP-10294, TPP-10277, TPP-10279, TPP-10282, TPP-10269 and TPP-10355, respectively) were generated as different IgG isotypes. Purified compound samples were tested as described in Example 3 in quadruplets in dilution series on stable hNPRA-CHO k1 cells. The activities of ANP engrafted human IgG2 and IgG4 isotype constructs (e.g. compound 9 IgG4 TPP-10992) are similar to their corresponding IgG1 isotype as graphically depicted in FIG. 12.

Example 8: Human and Non-Human IgGs Provide Equally Suitable Antibody Scaffolds

Compound 9 (human IgG1 TPP-10294 and IgG4 TPP-10992) and compound 117 (human IgG1 TPP-5665) were

generated as non-human IgG isotypes. Purified compound samples were tested as described in Example 3 in quadruplets in dilution series on stable hNPRA-CHO k1 cells. ANP engrafted rat and mouse isotype constructs, e.g. compound 9 rat IgG1 TPP-13992, showed activities similar to their corresponding human IgG isotype (FIG. 13).

Example 9: Human IgGs Comprising Varying Germline Sequences Provide Equally Suitable Antibody Scaffolds

22 additional ANP engrafted IgG4 antibodies (compounds A to S) were constructed. In each case ANP was incorporated within CDRH1. The heavy chains of these constructs comprise varying HV and CDRH3 sequences and were paired with varying lambda or kappa light chains. The structure of compounds A to S is summarized in Tables 10 and 11.

TABLE 10

Design of ANP engrafted antibody constructs A to S					
Cmpd.	Insertion Site	# aa N-term ¹	#aa C-term ²	N-terminal sequence ³	C-terminal sequence ⁴
A-P	CDRH1	23	14	SGFTFGSGSGSGSGSPDGGSGG (SEQ ID NO: 105)	GSYGSGSGSGSGSM (SEQ ID NO: 106)
Q-S	CDRH1	23	14	SGYSFGSGSGSGSGSPDGGSGG (SEQ ID NO: 449)	GSYGSGSGSGSGSI (SEQ ID NO: 450)

¹The number of amino acid residues present between the respective N-terminal reference amino acid residue and the first amino acid of the inserted natriuretic peptide;

²The number of amino acid residues present between the last amino acid of the inserted natriuretic peptide and the respective C-terminal reference amino acid residue

³The N-terminal sequence corresponds to the nearest neighboring reference aa N-terminal from the inserted natriuretic peptide plus the amino acid stretch present between said reference aa and the first amino acid residue of the inserted natriuretic peptide

⁴The C-terminal sequence corresponds to the amino acid stretch present between the last amino acid residue of the inserted natriuretic peptide and the nearest neighboring reference aa C-terminal from the inserted natriuretic peptide plus and said reference aa

TABLE 11

Design of ANP engrafted antibody constructs A to S					
Cmpd	TPP	HV	CDRH3	LV/KV	Purity
9	TPP-10992	HV3-23	KLTGAEYFQHW (SEQ ID NO: 451)	LV1-40	99
A	TPP-13944	HV3-23	KLTGAEYFQHW (SEQ ID NO: 452)	LV2-14	98
B	TPP-13945	HV3-23	KLTGAEYFQHW (SEQ ID NO: 453)	LV3-21	93
C	TPP-13941	HV3-23	KDYGDYAEYFQHW (SEQ ID NO: 454)	LV1-40	100
D	TPP-13956	HV3-23	KLTGAEYFQHW (SEQ ID NO: 455)	KV1-5	99
E	TPP-13955	HV3-23	KLTGAEYFQHW (SEQ ID NO: 456)	KV3-20	99
F	TPP-13940	HV3-23	KVLRFLEWLLYAEYFQHW (SEQ ID NO: 457)	LV1-40	98
G	TPP-13939	HV3-23	KVQLERAEYFQHW (SEQ ID NO: 458)	LV1-40	100
H	TPP-13943	HV3-23	KYNRNHAEYFQHW (SEQ ID NO: 459)	LV1-40	54
I	TPP-13942	HV3-23	KYNWNDAEYFQHW (SEQ ID NO: 460)	LV1-40	99
J	TPP-14684	HV3-23	RGATFALDW (SEQ ID NO: 461)	KV3-20	97
K	TPP-13958	HV3-23	RGRLPDVW (SEQ ID NO: 462)	KV1-5	99
L	TPP-13957	HV3-23	RGRLPDVW (SEQ ID NO: 462)	KV3-20	97
M	TPP-13948	HV3-23	RGRLPDVW (SEQ ID NO: 462)	LV1-40	98
N	TPP-14289	HV3-23	RGRLPDVW (SEQ ID NO: 462)	LV1-47	
O	TPP-13946	HV3-23	RGRLPDVW (SEQ ID NO: 462)	LV2-14	97
P	TPP-13947	HV3-23	RGRLPDVW (SEQ ID NO: 462)	LV3-21	96

TABLE 11-continued

Design of ANP engrafted antibody constructs A to S					
Cmpd	TPP	HV	CDRH3	LV/KV	Purity
Q	TPP-13952	HV5-51	RGRLPDVW (SEQ ID NO: 462)	LV2-14	99
R	TPP-13953	HV5-51	RGRLPDVW (SEQ ID NO: 462)	LV3-21	98
S	TPP-13962	HV5-51	RGRLPDVW (SEQ ID NO: 462)	KV1-5	99

Purified compound samples of IgG scaffold constructs A to S comprising varying germline sequences were tested as described in Example 3 in quadruplets in dilution series on stable hNPRA-CHO k1 cells. Exemplary activity data are graphically depicted in FIG. 14.

Example 10: CNP Engrafted IgG Protects Against Induced Endothelial Barrier Permeability

Endothelial monolayer permeability was assayed by real-time impedance measurement with an xCELLigence RTCA system utilizing microtiter well plates covered with micro-electrodes (E-Plates). Relative impedance changes are expressed as unitless Cell Index (CI) values.

Primary Human Pulmonary Artery Endothelial Cells (HPAECs) were seeded at low passages in collagen pre-coated E-Plates. After tight monolayer and cell barrier formation with constant CI values, HPAECs were pre-treated with the indicated concentrations of compound TPP-12899 or the respective negative control antibody construct TPP-5657, followed by compromising the EC barrier with the disruptive agonists LPS (200 ng/ml), IL-113 (0.5 ng/ml), or thrombin (2 U/ml). CI were recorded every 10 min to monitor effects on cell growth and monolayer permeability. All cell indices were normalized at the last recording point before test substance application (=normalized CI).

The experiments were performed with n=4 with 3 technical triplicates each. Results were expressed as mean±SEM. Data were statistically analyzed using one-way ANOVA followed by Sidak's multiple post-test; p-values<0.05 were considered as significant.

FIG. 15 graphically depicts the effects on endothelial monolayer permeability expressed as Cell Index values. As shown in FIG. 15, pre-treatment of human endothelial monolayer cultures with TPP-12899 protected against induced endothelial barrier permeability in a dose-dependent manner. This was independent of the applied barrier disruptive agent; both, with fast and strong acting thrombin as well as with long-lasting pro-inflammatory stimuli LPS and IL-113 significant effects were observed. The respective negative control showed no effect.

Example 11: Long Term Effects of ANP Engrafted IgG in a Chronic Heart Failure Rat Model (TGR(mRenR2)27)

The TGR(mRenR2)27 rat model shows hypertension and endothelial dysfunction, as well as end-organ damage. Male renin-transgenic rats (Ganten D., Nature, 1990; 344(6266): 541-4) at the age of 8 weeks were used. The nonselective inhibitor of nitric oxide synthetases L-NAME (N^ω-Nitro-

L-arginine methyl ester) was chronically administered via the drinking water (20 mg/l) in all study groups to induce endothelial dysfunction. TPP-13992, the rat IgG1 counterpart of TPP-10294 used in Example 8 and TPP-10155, a rat

IgG1 isotype control antibody were administered once weekly intraperitoneally. Body weight and survival were assessed. The placebo group was treated with vehicle (PBS) and the healthy control group was treated with captopril-food from weaning on. Food and water were given ad libitum. Daily observation of the behavior and general health status of the animals was performed. At the end of the experiment (week 14), the rats were anaesthetized. The rats were then exsanguinated and the heart was removed from the thoracic cavity for analysis. Urine was collected at the end of the study to determine different urine parameters, e.g. urinary protein creatinine ratio. FIG. 16 graphically depicts the therapeutic effects of TPP-13992 on survival, body weight gain, urinary protein/creatinine ratio and left atrial weight.

Example 12: Hemodynamic Effects of ANP Engrafted IgG in Healthy Beagle Dogs

The effects of TPP-10992 on cardiovascular and ECG parameters after single subcutaneous administration were assessed in a primary pharmacodynamic study in conscious telemetered beagle dogs.

Telemetry devices (DSITM, USA) were surgically implanted to measure blood pressure as well as heart rate, followed by a recovery period to allow wound closure. On the day of the study, telemetry sensors were activated for continuous hemodynamic measurements. The transmitted signals were collected by telemetry receivers located in the animal facility. All collected data were processed by a data acquisition program and averaged over a predefined period of 12 h. As vehicle for TPP-10992 NaCl (0.9%) was used and doses of 0.1 mg/kg, 0.3 mg/kg and 1.0 mg/kg body-weight were applied via subcutaneous injection.

The results are graphically depicted in FIG. 17. In healthy dogs, TPP-10992 showed a dose-dependent and long-lasting (>5d) reduction in blood pressure which was significant at 1.0 mg/kg s.c. (compared to placebo). No effects on heart rate were observable.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 462

<210> SEQ ID NO 1

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 1

Ser Tyr Ala Met Ser Trp Val Arg Gln Ala
1 5 10

<210> SEQ ID NO 2

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 2

Thr Tyr Ile Ser Asn Val Asn His Lys Pro
1 5 10

<210> SEQ ID NO 3

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 3

Ser Asn Thr Lys Val Asp Lys Lys Val
1 5

<210> SEQ ID NO 4

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 4

Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly
1 5 10

<210> SEQ ID NO 5

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 5

Asp Arg Phe Ser Gly Ser Lys Ser Gly
1 5

<210> SEQ ID NO 6

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 6

Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu Thr Ala Pro
1 5 10 15

-continued

```
<210> SEQ ID NO 7
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 7
```

Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly
1 5 10

```
<210> SEQ ID NO 8
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence
```

<400> SEQUENCE: 8
Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly

212

```
<210> SEQ ID NO 9
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence
```

<400> SEQUENCE: 9
Ser Val Val Val Thr Ser His Gln Ala Pro Gly Glu
1 2 3 4 5 6 7 8 9 10

```
<210> SEQ ID NO 10
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence
```

<400> SEQUENCE: 10
Gly Glu Lys Lys Lys Leu Lys Ser Leu Ala

```
<210> SEQ ID NO 11
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<221> OTHER INFORMATION: linker sequence
```

<400> SEQUENCE: 11
Gln Val Lys Leu Glu Leu Gly His Arg Ala

```
<210> SEQ_ID NO 12
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER_INFORMATION: linker sequence
```

<400> SEQUENCE: 13

Val Asn His Leu Arg Ser Glu Lys Leu Thr

-continued

1 5 10

<210> SEQ ID NO 13
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 13

Ala Val Val Asn Val Arg Ala
1 5

<210> SEQ ID NO 14
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 14

Lys Gly Asp Lys Ile Ala Ile
1 5

<210> SEQ ID NO 15
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 15

Val Pro Lys Glu Lys Glu Lys Glu Lys Val
1 5 10

<210> SEQ ID NO 16
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 16

Ala Thr Lys Ala Val Ser Val Leu Lys Gly Asp Gly
1 5 10

<210> SEQ ID NO 17
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 17

Gln Gly Ile Ile Asn Phe Glu Gln Lys
1 5

<210> SEQ ID NO 18
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 18

Gly Pro Val Lys Val Trp Gly Ser Ile Lys Gly
1 5 10

<210> SEQ ID NO 19
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 19

Tyr Glu Lys Glu Lys Glu Lys
1 5

<210> SEQ ID NO 20
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 20

Gly Gly Ser Thr Pro Leu Lys Ser Leu Ala
1 5 10

<210> SEQ ID NO 21
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 21

Gly Ile Thr Gly Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly
1 5 10

<210> SEQ ID NO 22
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: linker sequence

<400> SEQUENCE: 22

Ser Tyr Ser Tyr Thr Tyr Asn Tyr Ala Glu Tyr Phe Gln His Trp Gly
1 5 10 15

Gln

<210> SEQ ID NO 23
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly
1 5 10 15

Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
20 25

<210> SEQ ID NO 24
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser
1 5 10 15

-continued

Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg
20 25

<210> SEQ ID NO 25
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser
1 5 10 15

Met Ser Gly Leu Gly Cys
20

<210> SEQ ID NO 26
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 26

Gly Phe Thr Phe Gly Ser Gly Ser Gly Gly Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 27
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 27

Gly Phe Thr Phe Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser
1 5 10 15

Pro Asp Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 28
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 28

Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Pro Asp Gly Gly
1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 29
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 29

Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

-continued

<210> SEQ ID NO 30
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 30

Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Gly Ser Gly
1 5 10 15

Gly

<210> SEQ ID NO 31
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 31

Ser Gly Pro Asn Pro Asn Pro Asn Pro Asn Ser Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

<210> SEQ ID NO 32
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 32

Ala Lys Val His Pro Asn Pro Asn Pro Asn Ser Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

<210> SEQ ID NO 33
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 33

Ala Ala Trp Asn Pro Asn Pro Asn Pro Asn Pro Asn Gly Gly
1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 34
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 34

Ala Lys Gly Ile Thr Gly Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

<210> SEQ ID NO 35

-continued

<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 35

Ser Gly Ser Thr Tyr Ile Ser Asn Val Asn His Lys Pro Asp Gly Gly
1 5 10 15

Gly Gly

<210> SEQ ID NO 36
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 36

Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Pro Asp Gly Gly Ser
1 5 10 15

Gly Gly

<210> SEQ ID NO 37
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 37

Gly Val Pro Lys Glu Lys Glu Lys Glu Lys Val Ser Thr Ala Val Gly
1 5 10 15

Gly

<210> SEQ ID NO 38
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence (without ref aa)

<400> SEQUENCE: 38

Ser Val Val Val Thr Ser His Gln Ala Pro Gly Glu Gly Ser Gly
1 5 10 15

Gly

<210> SEQ ID NO 39
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 39

Gly Gly Ser Gly Gly Ser Gly Ser Gly Ser Gly
1 5 10

<210> SEQ ID NO 40
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

-continued

<400> SEQUENCE: 40

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly
 1 5 10

<210> SEQ ID NO 41
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 41

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Asn Arg Pro
 1 5 10 15

Ser

<210> SEQ ID NO 42
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 42

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser
 1 5 10 15

<210> SEQ ID NO 43
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 43

Gly Ser Asn Pro Asn Glu Asn Pro Asn Pro Asn Pro Gly Ser
 1 5 10

<210> SEQ ID NO 44
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 44

Gly Ser Tyr Asn Pro Asn Pro Asn Pro Asn Pro Asn Pro Gly Ser
 1 5 10 15

<210> SEQ ID NO 45
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 45

Gly Ser Tyr Asn Pro Asn Pro Asn Pro Asn Pro His Val Asp Val Trp
 1 5 10 15

Gly Gln

<210> SEQ ID NO 46
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial

US 12,390,508 B2

119**120**

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 46

Gly Ser Asn Pro Asn Pro Asn Pro Asn Pro Asn Val
 1 5 10

<210> SEQ ID NO 47
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 47

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Ala Glu Tyr Phe Gln His Trp
 1 5 10 15

Gly Gln

<210> SEQ ID NO 48
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 48

Gly Ser Asn Thr Lys Val Asp Lys Lys Val Glu Gly Gly Ser
 1 5 10

<210> SEQ ID NO 49
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 49

Gly Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Gly Ser
 1 5 10

<210> SEQ ID NO 50
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 50

Gly Ser Ala Pro Leu Glu Val Pro Lys Glu Lys Glu Lys Glu Lys Val
 1 5 10 15

<210> SEQ ID NO 51
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal Sequence (without ref aa)

<400> SEQUENCE: 51

Gly Gly Ser Thr Pro Leu Lys Ser Leu Ala Ser
 1 5 10

<210> SEQ ID NO 52
 <211> LENGTH: 54
 <212> TYPE: PRT

-continued

<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 52

Gly	Phe	Thr	Phe	Gly	Ser	Gly	Ser	Gly	Gly	Ser	Gly	Gly	Ser		
1				5			10			15					
Leu	Arg	Arg	Ser	Ser	Cys	Phe	Gly	Gly	Arg	Met	Asp	Arg	Ile	Gly	Ala
	20					25			30						
Gln	Ser	Gly	Leu	Gly	Cys	Asn	Ser	Phe	Arg	Tyr	Gly	Gly	Ser	Gly	Gly
	35					40			45						
Ser	Gly	Ser	Gly	Ser	Gly										
	50														

<210> SEQ ID NO 53

<211> LENGTH: 65

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 53

Gly	Phe	Thr	Phe	Gly	Ser										
1				5			10		15						
Pro	Asp	Gly	Gly	Ser	Gly	Gly	Ser	Leu	Arg	Arg	Ser	Ser	Cys	Phe	Gly
	20						25		30						
Gly	Arg	Met	Asp	Arg	Ile	Gly	Ala	Gln	Ser	Gly	Leu	Gly	Cys	Asn	Ser
	35					40			45						
Phe	Arg	Tyr	Gly	Ser	Tyr	Gly	Ser								
	50					55			60						

Gly
65

<210> SEQ ID NO 54

<211> LENGTH: 64

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 54

Gly	Ser	Pro	Asp	Gly	Gly										
1				5			10		15						
Ser	Gly	Gly	Ser	Leu	Arg	Arg	Ser	Ser	Cys	Phe	Gly	Gly	Arg	Met	Asp
	20						25			30					
Arg	Ile	Gly	Ala	Gln	Ser	Gly	Leu	Gly	Cys	Asn	Ser	Phe	Arg	Tyr	Gly
	35						40		45						
Ser	Tyr	Gly	Ser	Gly	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Asn	Arg	Pro	Ser
	50					55			60						

<210> SEQ ID NO 55

<211> LENGTH: 63

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 55

-continued

Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Pro Asp Gly
 1 5 10 15

Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
 20 25 30

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 35 40 45

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser
 50 55 60

<210> SEQ ID NO 56

<211> LENGTH: 59

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence (wo
ref aas)

<400> SEQUENCE: 56

Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Asn Pro Gly Ser Gly
 1 5 10 15

Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile
 20 25 30

Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly Ser Asn
 35 40 45

Pro Asn Glu Asn Pro Asn Pro Asn Pro Gly Ser
 50 55

<210> SEQ ID NO 57

<211> LENGTH: 63

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 57

Ser Gly Pro Asn Pro Asn Pro Asn Pro Asn Ser Pro Asp Gly
 1 5 10 15

Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
 20 25 30

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 35 40 45

Gly Ser Tyr Asn Pro Asn Pro Asn Pro Asn Pro Asn Pro Gly Ser
 50 55 60

<210> SEQ ID NO 58

<211> LENGTH: 66

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 58

Ala Lys Val His Pro Asn Pro Asn Pro Asn Ser Pro Asp Gly
 1 5 10 15

Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
 20 25 30

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 35 40 45

Gly Ser Tyr Asn Pro Asn Pro Asn Pro His Val Asp Val Trp

US 12,390,508 B2

125**126**

-continued

50	55	60
----	----	----

Gly Gln
65

<210> SEQ ID NO 59
<211> LENGTH: 61
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 59

Ala Ala Trp Asn Pro Asn Pro Asn Pro Asn Pro Asn Gly Gly	1	15
5	10	
Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp	20	30
25	30	
Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly	35	45
40	45	
Ser Asn Pro Asn Pro Asn Pro Asn Pro Asn Pro Asn Val	50	60
55	60	

<210> SEQ ID NO 60
<211> LENGTH: 66
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 60

Ala Lys Gly Ile Thr Gly Thr Lys Tyr Gln Ser Ser Pro Asp Gly	1	15
5	10	15
Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met	20	30
25	30	
Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr	35	45
40	45	
Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Ala Glu Tyr Phe Gln His Trp	50	60
55	60	

Gly Gln
65

<210> SEQ ID NO 61
<211> LENGTH: 61
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 61

Ser Gly Ser Thr Tyr Ile Ser Asn Val Asn His Lys Pro Asp Gly Gly	1	15
5	10	15
Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp	20	30
25	30	
Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly	35	45
40	45	
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Gly Gly Ser	50	60
55	60	

<210> SEQ ID NO 62

-continued

<211> LENGTH: 59
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 62

Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Pro Asp Gly Gly Ser
1 5 10 15
Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg
20 25 30
Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly Ser
35 40 45
Asp Arg Phe Ser Gly Ser Lys Ser Gly Gly Ser
50 55

<210> SEQ ID NO 63
<211> LENGTH: 61
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 63

Gly Val Pro Lys Glu Lys Glu Lys Val Ser Thr Ala Val Gly
1 5 10 15
Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile
20 25 30
Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly Ser Ala
35 40 45
Pro Leu Glu Val Pro Lys Glu Lys Glu Lys Val
50 55 60

<210> SEQ ID NO 64
<211> LENGTH: 56
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal Sequence-NP-C-terminal Sequence
(without ref aas)

<400> SEQUENCE: 64

Ser Val Val Val Thr Ser His Gln Ala Pro Gly Glu Gly Ser Gly
1 5 10 15
Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile
20 25 30
Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly Ser
35 40 45
Thr Pro Leu Lys Ser Leu Ala Ser
50 55

<210> SEQ ID NO 65
<211> LENGTH: 447
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 65

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

US 12,390,508 B2

129**130**

-continued

20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Leu Thr Gly Ala Glu Tyr Phe Gln His Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
 180 185 190

Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
 195 200 205

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
 210 215 220

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 245 250 255

Thr Pro Glu Val Thr Cys Val Val Asp Val Ser His Glu Asp Pro
 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 290 295 300

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
 325 330 335

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 340 345 350

Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
 355 360 365

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 370 375 380

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 385 390 395 400

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
 405 410 415

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 420 425 430

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
 435 440 445

-continued

<210> SEQ ID NO 66
<211> LENGTH: 217
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 66

Gln	Ser	Val	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ala	Pro	Gly	Gln
1					5				10			15			

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly

20				25					30						
----	--	--	--	----	--	--	--	--	----	--	--	--	--	--	--

Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu

35				40				45							
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--	--

Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe

50				55				60							
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--	--

Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu

65				70			75		80						
----	--	--	--	----	--	--	----	--	----	--	--	--	--	--	--

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser

85				90			95								
----	--	--	--	----	--	--	----	--	--	--	--	--	--	--	--

Leu Ser Gly Val Val Phe Gly Gly Thr Lys Leu Thr Val Leu Gly

100				105			110								
-----	--	--	--	-----	--	--	-----	--	--	--	--	--	--	--	--

Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115				120			125								
-----	--	--	--	-----	--	--	-----	--	--	--	--	--	--	--	--

Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe

130				135			140								
-----	--	--	--	-----	--	--	-----	--	--	--	--	--	--	--	--

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val

145				150			155		160						
-----	--	--	--	-----	--	--	-----	--	-----	--	--	--	--	--	--

Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys

165				170			175								
-----	--	--	--	-----	--	--	-----	--	--	--	--	--	--	--	--

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser

180				185			190								
-----	--	--	--	-----	--	--	-----	--	--	--	--	--	--	--	--

His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu

195				200			205								
-----	--	--	--	-----	--	--	-----	--	--	--	--	--	--	--	--

Lys Thr Val Ala Pro Thr Glu Cys Ser

210				215											
-----	--	--	--	-----	--	--	--	--	--	--	--	--	--	--	--

<210> SEQ ID NO 67
<211> LENGTH: 499
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 67

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1					5				10			15			

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20				25			30								
----	--	--	--	----	--	--	----	--	--	--	--	--	--	--	--

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35				40			45								
----	--	--	--	----	--	--	----	--	--	--	--	--	--	--	--

Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val

50				55			60								
----	--	--	--	----	--	--	----	--	--	--	--	--	--	--	--

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65				70			75		80						
----	--	--	--	----	--	--	----	--	----	--	--	--	--	--	--

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85				90			95								
----	--	--	--	----	--	--	----	--	--	--	--	--	--	--	--

-continued

Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly
 100 105 110
 Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Ile
 115 120 125
 Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 130 135 140
 Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp
 145 150 155 160
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
 165 170 175
 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 180 185 190
 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
 195 200 205
 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 210 215 220
 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 225 230 235 240
 Val Pro Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
 245 250 255
 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
 260 265 270
 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 275 280 285
 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 290 295 300
 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 305 310 315 320
 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 325 330 335
 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 340 345 350
 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 355 360 365
 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 370 375 380
 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 385 390 395 400
 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 405 410 415
 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 420 425 430
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 435 440 445
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 450 455 460
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 465 470 475 480
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 485 490 495
 Ser Pro Gly

-continued

<211> LENGTH: 499
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: NP engrafted HC
 <400> SEQUENCE: 68

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5				10				15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
						20			25				30		
Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35		40				45		
Ser	Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
							50		55			60			
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
							65		70		75		80		
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
							85		90				95		
Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser	Pro	Asp	Gly
							100		105				110		
Gly	Ser	Gly	Gly	Ser	Leu	Arg	Arg	Ser	Ser	Cys	Phe	Gly	Gly	Arg	Met
							115		120			125			
Asp	Arg	Ile	Gly	Ala	Gln	Ser	Gly	Leu	Gly	Cys	Asn	Ser	Phe	Arg	Tyr
							130		135			140			
Gly	Ser	Tyr	Ser	Tyr	Thr	Tyr	Asn	Tyr	Glu	Trp	His	Val	Asp	Val	Trp
							145		150			155			160
Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro
							165		170			175			
Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr
							180		185			190			
Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr
							195		200			205			
Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro
							210		215			220			
Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr
							225		230			235			240
Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn
							245		250			255			
His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser
							260		265			270			
Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
							275		280			285			
Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
							290		295			300			
Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
							305		310			315			320
His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu
							325		330			335			
Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr
							340		345			350			
Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn
							355		360			365			
Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro
							370		375			380			

-continued

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 385 390 395 400

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 405 410 415

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 420 425 430

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 435 440 445

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 450 455 460

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 465 470 475 480

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 485 490 495

Ser Pro Gly

<210> SEQ ID NO 69

<211> LENGTH: 504

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 69

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser
 50 55 60

Pro Asp Gly Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly
 65 70 75 80

Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser
 85 90 95

Phe Arg Tyr Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser
 100 105 110

Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
 115 120 125

Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
 130 135 140

Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu
 145 150 155 160

Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
 165 170 175

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
 180 185 190

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
 195 200 205

Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
 210 215 220

Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
 225 230 235 240

US 12,390,508 B2

139**140**

-continued

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
245 250 255

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
260 265 270

Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
275 280 285

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
290 295 300

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
305 310 315 320

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
325 330 335

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
340 345 350

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
355 360 365

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
370 375 380

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
385 390 395 400

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
405 410 415

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
420 425 430

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
435 440 445

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
450 455 460

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
465 470 475 480

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
485 490 495

Lys Ser Leu Ser Leu Ser Pro Gly
500

<210> SEQ ID NO 70
<211> LENGTH: 504
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 70

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Pro Asn Pro Asn Pro Asn Pro Asn Ser
50 55 60

Pro Asp Gly Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly
65 70 75 80

Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser
85 90 95

US 12,390,508 B2

141**142**

-continued

Phe Arg Tyr Gly Ser Tyr Asn Pro Pro Asn Pro Asn Pro
100 105 110

Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
115 120 125

Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
130 135 140

Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu
145 150 155 160

Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
165 170 175

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
180 185 190

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
195 200 205

Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
210 215 220

Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
225 230 235 240

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
245 250 255

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
260 265 270

Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
275 280 285

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
290 295 300

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
305 310 315 320

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
325 330 335

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
340 345 350

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
355 360 365

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
370 375 380

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
385 390 395 400

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
405 410 415

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
420 425 430

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
435 440 445

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
450 455 460

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
465 470 475 480

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
485 490 495

Lys Ser Leu Ser Leu Ser Pro Gly
500

-continued

```

<210> SEQ ID NO 71
<211> LENGTH: 499
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 71

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1           5          10          15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20          25          30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35          40          45

Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50          55          60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65          70          75          80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85          90          95

Ala Lys Val His Pro Asn Pro Asn Pro Asn Ser Pro Asp Gly
100         105         110

Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
115         120         125

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
130         135         140

Gly Ser Tyr Asn Pro Asn Pro Asn Pro His Val Asp Val Trp
145         150         155         160

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
165         170         175

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
180         185         190

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
195         200         205

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
210         215         220

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
225         230         235         240

Val Pro Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
245         250         255

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
260         265         270

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
275         280         285

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290         295         300

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
305         310         315         320

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
325         330         335

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
340         345         350

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
355         360         365

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

```

US 12,390,508 B2

145

-continued

370	375	380
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln		
385	390	395
400		
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val		
405	410	415
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val		
420	425	430
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro		
435	440	445
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr		
450	455	460
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val		
465	470	475
480		
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu		
485	490	495

Ser Pro Gly

<210> SEQ ID NO 72
<211> LENGTH: 504
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 72

Glu Val Gln Leu Leu Glu Ser Gly Gly	10	15
1	5	
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Gly		
20	25	30
Ser Gly Ser Gly Ser Gly Ser Pro Asp Gly Gly		
35	40	45
Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly		
50	55	60
Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly Ser Tyr Gly		
65	70	75
80		
Ser Gly Ser Gly Ser Gly Ser Gly Met Ser Trp Val Arg Gln		
85	90	95
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly		
100	105	110
Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser		
115	120	125
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg		
130	135	140
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu		
145	150	155
160		
Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala		
165	170	175
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser		
180	185	190
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe		
195	200	205
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly		
210	215	220
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu		
225	230	235
240		

US 12,390,508 B2

147

-continued

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
245 250 255

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
260 265 270

Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
275 280 285

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
290 295 300

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
305 310 315 320

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
325 330 335

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
340 345 350

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
355 360 365

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
370 375 380

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
385 390 395 400

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
405 410 415

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
420 425 430

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
435 440 445

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
450 455 460

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
465 470 475 480

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
485 490 495

Lys Ser Leu Ser Leu Ser Pro Gly
500

<210> SEQ ID NO 73
<211> LENGTH: 500
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 73

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Asn Pro
50 55 60

Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
65 70 75 80

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
85 90 95

148

US 12,390,508 B2

149**150**

-continued

Gly Ser Asn Pro Asn Glu Asn Pro Asn Pro Gly Ser Thr Tyr
 100 105 110

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 115 120 125

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 130 135 140

Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu Tyr Phe Gln His
 145 150 155 160

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
 165 170 175

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
 180 185 190

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
 195 200 205

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
 210 215 220

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
 225 230 235 240

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
 245 250 255

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
 260 265 270

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
 275 280 285

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 290 295 300

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 305 310 315 320

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 325 330 335

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 340 345 350

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 355 360 365

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 370 375 380

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 385 390 395 400

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 405 410 415

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 420 425 430

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 435 440 445

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 450 455 460

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 465 470 475 480

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 485 490 495

Leu Ser Pro Gly
 500

-continued

<210> SEQ ID NO 74
 <211> LENGTH: 502
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: NP engrafted HC

 <400> SEQUENCE: 74

 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

 Ser Ala Ile Ser Gly Ser Thr Tyr Ile Ser Asn Val Asn His Lys Pro
 50 55 60

 Asp Gly Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly
 65 70 75 80

 Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe
 85 90 95

 Arg Tyr Gly Ser Asn Thr Lys Val Asp Lys Lys Val Glu Gly Ser
 100 105 110

 Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
 115 120 125

 Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
 130 135 140

 Asp Thr Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu Tyr Phe
 145 150 155 160

 Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
 165 170 175

 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
 180 185 190

 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
 195 200 205

 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
 210 215 220

 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
 225 230 235 240

 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
 245 250 255

 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
 260 265 270

 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 275 280 285

 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 290 295 300

 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 305 310 315 320

 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 325 330 335

 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 340 345 350

 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 355 360 365

US 12,390,508 B2

153**154**

-continued

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Val Ser Asn Lys Ala Leu
 370 375 380

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 385 390 395 400

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
 405 410 415

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 420 425 430

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 435 440 445

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 450 455 460

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 465 470 475 480

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 485 490 495

Leu Ser Leu Ser Pro Gly
 500

<210> SEQ ID NO 75

<211> LENGTH: 500

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 75

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Pro Asp
 50 55 60

Gly Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg
 65 70 75 80

Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg
 85 90 95

Tyr Gly Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Gly Ser Thr Tyr
 100 105 110

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 115 120 125

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 130 135 140

Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu Tyr Phe Gln His
 145 150 155 160

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
 165 170 175

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
 180 185 190

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
 195 200 205

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
 210 215 220

US 12,390,508 B2

155**156**

-continued

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
225 230 235 240

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
245 250 255

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
260 265 270

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
275 280 285

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
290 295 300

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
305 310 315 320

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
325 330 335

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
340 345 350

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
355 360 365

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
370 375 380

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
385 390 395 400

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
405 410 415

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
420 425 430

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
435 440 445

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
450 455 460

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
465 470 475 480

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
485 490 495

Leu Ser Pro Gly
500

<210> SEQ ID NO 76

<211> LENGTH: 501

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 76

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Gly
20 25 30

Ser Gly Ser Gly Ser Gly Ser Pro Asp Gly Gly Ser Gly Gly
35 40 45

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly
50 55 60

Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly Ser Tyr Gly
65 70 75 80

US 12,390,508 B2

157

-continued

Ser Gly Ser Gly Ser Gly Ser Gly Met Ser Trp Val Arg Gln
 85 90 95

 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly
 100 105 110

 Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
 115 120 125

 Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
 130 135 140

 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu
 145 150 155 160

 Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
 165 170 175

 Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
 180 185 190

 Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
 195 200 205

 Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
 210 215 220

 Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
 225 230 235 240

 Ser Ser Val Val Thr Val Pro Ser Ser Leu Gly Thr Lys Thr Tyr
 245 250 255

 Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg
 260 265 270

 Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
 275 280 285

 Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 290 295 300

 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 305 310 315 320

 Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
 325 330 335

 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
 340 345 350

 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 355 360 365

 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
 370 375 380

 Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 385 390 395 400

 Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
 405 410 415

 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 420 425 430

 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 435 440 445

 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
 450 455 460

 Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
 465 470 475 480

 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 485 490 495

 Ser Leu Ser Leu Gly

US 12,390,508 B2

159**160**

-continued

500

<210> SEQ ID NO 77
<211> LENGTH: 493
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 77

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly			
1																		
														10	15			
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Gly	Ser	Gly			
														20	25	30		
Ser	Gly	Ser	Gly	Gly	Ser	Gly	Gly	Ser	Leu	Arg	Arg	Ser	Ser	Cys	Phe			
															35	40	45	
Gly	Gly	Arg	Met	Asp	Arg	Ile	Gly	Ala	Gln	Ser	Gly	Leu	Gly	Cys	Asn			
															50	55	60	
Ser	Phe	Arg	Tyr	Gly	Gly	Ser	Gly	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Met			
															65	70	75	80
Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	Ser	Ala			
															85	90	95	
Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	Lys	Gly			
															100	105	110	
Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln			
															115	120	125	
Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Lys			
															130	135	140	
Leu	Thr	Gly	Ala	Glu	Tyr	Phe	Gln	His	Trp	Gly	Gln	Gly	Thr	Leu	Val			
															145	150	155	160
Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala			
															165	170	175	
Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu			
															180	185	190	
Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly			
															195	200	205	
Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser			
															210	215	220	
Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu			
															225	230	235	240
Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr			
															245	250	255	
Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr			
															260	265	270	
Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe			
															275	280	285	
Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro			
															290	295	300	
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val			
															305	310	315	320
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr			
															325	330	335	
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val			
															340	345	350	
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Glu	Tyr	Lys	Cys				

US 12,390,508 B2

161**162**

-continued

355 360 365

Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
 370 375 380

Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
 385 390 395 400

Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
 405 410 415

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
 420 425 430

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
 435 440 445

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
 450 455 460

Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
 465 470 475 480

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
 485 490

<210> SEQ ID NO 78

<211> LENGTH: 497

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 78

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Val Val Val Thr Ser His Gln Ala Pro Gly Glu Gly
 50 55 60

Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
 65 70 75 80

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 85 90 95

Gly Gly Ser Thr Pro Leu Lys Ser Leu Ala Ser Thr Tyr Tyr Ala Asp
 100 105 110

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
 115 120 125

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 130 135 140

Tyr Cys Ala Lys Leu Thr Gly Ala Glu Tyr Phe Gln His Trp Gly Gln
 145 150 155 160

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 165 170 175

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 180 185 190

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 195 200 205

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 210 215 220

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro

US 12,390,508 B2

163

-continued

225	230	235	240
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys			
245	250	255	
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp			
260	265	270	
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly			
275	280	285	
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile			
290	295	300	
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu			
305	310	315	320
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His			
325	330	335	
Asn Ala Lys Thr Lys Pro Arg Glu Gln Tyr Asn Ser Thr Tyr Arg			
340	345	350	
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys			
355	360	365	
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu			
370	375	380	
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr			
385	390	395	400
Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu			
405	410	415	
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp			
420	425	430	
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val			
435	440	445	
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp			
450	455	460	
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His			
465	470	475	480
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro			
485	490	495	

Gly

<210> SEQ ID NO 79
<211> LENGTH: 499
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 79

Glu Val Gln Leu Leu Glu Ser Gly Gly	Leu Val Gln Pro Gly Gly
1 5	10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr	
20 25	30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly	Leu Glu Trp Val
35 40	45
Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val	
50 55	60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr	
65 70	75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90	95

164

US 12,390,508 B2

165

-continued

Ala Lys Gly Ile Thr Gly Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly
 100 105 110
 Gly Ser Gly Gly Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
 115 120 125
 Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 130 135 140
 Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Ala Glu Tyr Phe Gln His Trp
 145 150 155 160
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
 165 170 175
 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 180 185 190
 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
 195 200 205
 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 210 215 220
 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 225 230 235 240
 Val Pro Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
 245 250 255
 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
 260 265 270
 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 275 280 285
 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 290 295 300
 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 305 310 315 320
 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 325 330 335
 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 340 345 350
 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 355 360 365
 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 370 375 380
 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 385 390 395 400
 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 405 410 415
 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 420 425 430
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 435 440 445
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 450 455 460
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 465 470 475 480
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 485 490 495
 Ser Pro Gly

US 12,390,508 B2

167

-continued

<210> SEQ ID NO 80
 <211> LENGTH: 267
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: NP engrafted LC

 <400> SEQUENCE: 80

 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
 1 5 10 15

 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
 20 25 30

 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45

 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
 50 55 60

 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
 65 70 75 80

 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asn Pro Asn
 85 90 95

 Pro Asn Pro Asn Pro Asn Pro Asn Gly Gly Ser Gly Gly Ser Leu Arg
 100 105 110

 Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser
 115 120 125

 Gly Leu Gly Cys Asn Ser Phe Arg Tyr Gly Ser Asn Pro Asn Pro Asn
 130 135 140

 Pro Asn Pro Asn Pro Asn Val Phe Gly Ser Gly Thr Lys Val Thr Val
 145 150 155 160

 Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser
 165 170 175

 Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser
 180 185 190

 Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser
 195 200 205

 Pro Val Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gln Ser Asn
 210 215 220

 Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp
 225 230 235 240

 Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr
 245 250 255

 Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
 260 265

<210> SEQ ID NO 81
 <211> LENGTH: 274
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: NP engrafted LC

 <400> SEQUENCE: 81

 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
 1 5 10 15

 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
 20 25 30

 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45

168

US 12,390,508 B2

169**170**

-continued

Leu	Ile	Tyr	Gly	Ser	Pro										
50			55			60									
Asp	Gly	Gly	Ser	Gly	Gly	Ser	Leu	Arg	Arg	Ser	Ser	Cys	Phe	Gly	Gly
65				70			75			80					
Arg	Met	Asp	Arg	Ile	Gly	Ala	Gln	Ser	Gly	Leu	Gly	Cys	Asn	Ser	Phe
				85			90			95					
Arg	Tyr	Gly	Ser	Tyr	Gly	Ser	Gly	Gly	Ser	Gly	Ser	Gly	Asn		
				100			105			110					
Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Lys	Ser	Gly	Thr
				115			120			125					
Ser	Ala	Ser	Leu	Ala	Ile	Thr	Gly	Leu	Gln	Ala	Glu	Asp	Glu	Ala	Asp
	130				135			140							
Tyr	Tyr	Cys	Gln	Ser	Tyr	Asp	Ser	Ser	Leu	Ser	Gly	Val	Val	Phe	Gly
145					150			155			160				
Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu	Gly	Gln	Pro	Lys	Ala	Ala	Pro	Ser
				165			170			175					
Val	Thr	Leu	Phe	Pro	Pro	Ser	Ser	Glu	Glu	Leu	Gln	Ala	Asn	Lys	Ala
				180			185			190					
Thr	Leu	Val	Cys	Leu	Ile	Ser	Asp	Phe	Tyr	Pro	Gly	Ala	Val	Thr	Val
				195			200			205					
Ala	Trp	Lys	Ala	Asp	Ser	Ser	Pro	Val	Lys	Ala	Gly	Val	Glu	Thr	Thr
				210			215			220					
Thr	Pro	Ser	Lys	Gln	Ser	Asn	Asn	Lys	Tyr	Ala	Ala	Ser	Ser	Tyr	Leu
225					230			235			240				
Ser	Leu	Thr	Pro	Glu	Gln	Trp	Lys	Ser	His	Arg	Ser	Tyr	Ser	Cys	Gln
				245			250			255					
Val	Thr	His	Glu	Gly	Ser	Thr	Val	Glu	Lys	Thr	Val	Ala	Pro	Thr	Glu
				260			265			270					

Cys Ser

<210> SEQ ID NO 82
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC encoding construct

<400> SEQUENCE: 82

```
gaagtgcagc tgctggaaag cggcgaggc ctgggtcagc ctggcgatc tctgagactg      60
agctgtgcgc ccagcgccctt caccttcagc agctacgcca ttagctgggt gcgccaggcc    120
cctggaaaag gccttggaatg ggtgtccgcc atctctggca gcccggccag cacctactac   180
ccccgattctg tgaaggggccg gttcaccatc agccgggaca acagcaagaa caccctgtac   240
ctgcagatga acagcctgcg ggccgaggac accggcggtt actactgtac aagcgtgcac   300
caggaaacaa agaagtacca gacggcccc gacggcgccgca gtggcgaaag tctgagaaga   360
agctcc                                              366
```

<210> SEQ ID NO 83
<211> LENGTH: 525
<212> TYPE: DNA
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC encoding construct

<400> SEQUENCE: 83

```
gaagttcagc tgctggaaatc tggcgccgga ctgggtcaac ctggcgatc tctgagactg      60
```

-continued

actgtgtggcc ccageggcgt tacatggc ageggctctg gatctggctc cggaaacggg 120
tctccgtatgt gtggaaagcg aggccagcctg agaagaagca gctgtttcg cgccagaatg 180
gacagaatcg gcccataatc tggccgtggc tgcaacacgt ttagatacgg cagctacggc 240
tccggcagtgttccggtag tggctctgga atgagctggg ttgcacaggc ccctggcaaa 300
ggcccttgaat ggggtgtccgc catttctggc agcggaggct ctacctacta cgccgatagc 360
gtgaaggggca gattcaccat cagccggac aacagcaaga acacctgtta cctgcagatg 420
aactccctgtt gagccgagga caccggcgtg tactattgcg ccaaactgac aggcggccgag 480
tacttccacgtt atggggaca ggaaacctgtt gtcacagatctt cttca 525

<210> SEQ ID NO 84
<211> LENGTH: 333
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 84

cagtcgtgc tgacacagcc tccttagtgtg tctggcgccc ctggccagag agtgaccatc	60
agctgttaccc gcagcagctc caacatcgga gccggctatg acgtgactg gtatcagcag	120
ctgcctggca cccggggccaa actgtgtatc tacggcaaca gcaacccggcc cagccggctg	180
cccgatagat ttccggcag caagagccgc accagcgcca gcctggctat tactggactg	240
caggccgagg acgaggccga ctactactgc cagagctacg acagcagcct gagccggctg	300
atattttaaacq qccqaaacaaa qctgaccatgt cta	333

<210> SEQ ID NO 85
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 85

<210> SEQ ID NO 86
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

-100- SEQUENCE - 86

-continued

<210> SEQ ID NO 87
 <211> LENGTH: 329
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <400> SEQUENCE: 87

Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	
1					5							10				15
Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	
		20						25					30			
Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	
				35			40				45					
Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	
		50				55				60						
Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	
		65				70			75			80				
Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	
		85					90				95					
Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	
		100				105				110						
Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	
		115				120				125						
Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	
		130				135				140						
Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	
		145				150			155			160				
Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	
		165				170			175							
Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	
		180				185				190						
His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	
		195				200				205						
Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	
		210				215				220						
Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	
		225				230			235			240				
Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	
		245				250			255			255				
Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	
		260				265				270						
Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	
		275				280				285						
Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	
		290				295				300						
Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	
		305				310				315			320			
Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly								
		325														

<210> SEQ ID NO 88
 <211> LENGTH: 99
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <400> SEQUENCE: 88

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln

US 12,390,508 B2

175

176

-continued

1	5	10	15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly			
20	25	30	
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu			
35	40	45	
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe			
50	55	60	
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu			
65	70	75	80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser			
85	90	95	
Leu Ser Gly			

<210> SEQ ID NO 89

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 89

1	5	10	15
Val Val Phe Gly Gly Thr Lys Leu Thr Val Leu			

<210> SEQ ID NO 90

<211> LENGTH: 106

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 90

1	5	10	15
Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser			

20	25	30	
Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp			

35	40	45	
Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro			

50	55	60	
Val Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gln Ser Asn Asn			

65	70	75	80
Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys			

85	90	95	
Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val			

100	105		
Glu Lys Thr Val Ala Pro Thr Glu Cys Ser			

<210> SEQ ID NO 91

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP variant

<220> FEATURE:

<221> NAME/KEY: VARIANT

<222> LOCATION: (1)..(1)

<223> OTHER INFORMATION: Xaa = Gly or Ser

<220> FEATURE:

<221> NAME/KEY: VARIANT

<222> LOCATION: (5)..(5)

<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<220> FEATURE:

<221> NAME/KEY: VARIANT

<222> LOCATION: (6)..(6)

<223> OTHER INFORMATION: Xaa = Arg or Lys

<220> FEATURE:

-continued

<221> NAME/KEY: VARIANT
 <222> LOCATION: (7)..(7)
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
 <220> FEATURE:
 <221> NAME/KEY: VARIANT
 <222> LOCATION: (11)..(11)
 <223> OTHER INFORMATION: Xaa = Gly or Ser
 <220> FEATURE:
 <221> NAME/KEY: VARIANT
 <222> LOCATION: (12)..(12)
 <223> OTHER INFORMATION: Xaa = Ala or Ser
 <220> FEATURE:
 <221> NAME/KEY: VARIANT
 <222> LOCATION: (13)..(13)
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
 <220> FEATURE:
 <221> NAME/KEY: VARIANT
 <222> LOCATION: (15)..(15)
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

 <400> SEQUENCE: 91

Xaa Cys Phe Gly Xaa Xaa Xaa Asp Arg Ile Xaa Xaa Xaa Ser Xaa Leu
 1 5 10 15

Gly Cys

<210> SEQ ID NO 92
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 92

Ser Gly Phe Thr Phe Ser Ser
 1 5

<210> SEQ ID NO 93
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 93

Ser Gly Phe Thr Phe Gly Ser Gly Ser Gly
 1 5 10

<210> SEQ ID NO 94
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 94

Gly Ser Gly Ser Gly Met
 1 5

<210> SEQ ID NO 95
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 95

Ser Gly Phe Thr Phe Gly Ser Gly Ser Gly Ser
 1 5 10

-continued

<210> SEQ ID NO 96
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 96

Ser Gly Ser Gly Ser Gly Ser Gly Met
1 5

<210> SEQ ID NO 97
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 97

Ser Gly Phe Thr Phe Gly Ser Gly Ser Gly Gly Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 98
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 98

Gly Gly Ser Gly Gly Ser Gly Ser Gly Met
1 5 10

<210> SEQ ID NO 99
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 99

Ser Gly Phe Thr Phe Gly Ser Gly Ser Gly Ser Gly Gly Gly
1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 100
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 100

Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Met
1 5 10

<210> SEQ ID NO 101
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 101

Ser Pro Ala Val Val Tyr Ile Glu Ile Leu Asp Arg His Pro Asp Gly
1 5 10 15

US 12,390,508 B2

181**182**

-continued

Gly Ser Gly Gly
20

<210> SEQ ID NO 102
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 102

Gly Ser Gly Arg Glu Val Pro Ile Ser Asn Gly Ser Gly Phe Val Val
1 5 10 15

Ala Met

<210> SEQ ID NO 103
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 103

Ser Gly Ala Val Val Tyr Ile Glu Ile Leu Asp Arg His Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

<210> SEQ ID NO 104
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 104

Ser Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu
1 5 10 15

Leu Thr Ala Pro Arg
20

<210> SEQ ID NO 105
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 105

Ser Gly Phe Thr Phe Gly Ser Gly Ser Gly Ser Gly Ser Gly
1 5 10 15

Ser Pro Asp Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 106
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 106

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Met
1 5 10 15

-continued

<210> SEQ ID NO 107
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 107

Ser Gly Phe Thr Phe Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys
1 5 10 15
Leu Arg Ala Leu Leu Thr Ala Pro Arg
20 25

<210> SEQ ID NO 108
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 108

Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Met
1 5 10

<210> SEQ ID NO 109
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 109

Ile Ser Gly Ser
1

<210> SEQ ID NO 110
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 110

Gly Gly Ser Thr
1

<210> SEQ ID NO 111
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 111

Ile Ser Gly Ser Gly Ser Gly Ser
1 5

<210> SEQ ID NO 112
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 112

-continued

Gly Ser Gly Ser Gly Ser Thr
1 5

<210> SEQ ID NO 113
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 113

Ile Ser Gly Ser Gly Ser Gly Ser Gly
1 5

<210> SEQ ID NO 114
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 114

Gly Ser Ser Gly Ser Gly Ser Gly Ser Thr
1 5 10

<210> SEQ ID NO 115
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 115

Ile Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly
1 5 10

<210> SEQ ID NO 116
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 116

Gly Ser Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr
1 5 10

<210> SEQ ID NO 117
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 117

Ile Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly
1 5 10

<210> SEQ ID NO 118
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 118

Gly Glu Lys Glu Lys Glu Lys Val Ser Thr Ala Val Gly Ser Thr

-continued

1	5	10	15
---	---	----	----

<210> SEQ ID NO 119
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 119

Ile Ser Gly Ser Ala Val Val Asn Gly Gly Ser Gly Gly
1 5 10

<210> SEQ ID NO 120
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 120

Gly Lys Ile Ala Ile Gly Gly Ser Thr
1 5

<210> SEQ ID NO 121
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 121

Ile Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Gly Gly
1 5 10

<210> SEQ ID NO 122
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 122

Gly Ser Asn Glu Asn Pro Asn Pro Asn Pro Gly Ser Thr
1 5 10

<210> SEQ ID NO 123
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 123

Ile Ser Gly Ser Val Val Val Thr Ser His Gly Gly Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 124
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 124

Gly Gly Ser Gly Ser Gly Ser Gly Ser Thr
1 5 10

-continued

<210> SEQ ID NO 125
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 125

Ile Ser Gly Ser Ala Val Val Asn Val Arg Gly Gly Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 126
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 126

Gly Gly Asp Lys Ile Ala Ile Gly Gly Ser Thr
1 5 10

<210> SEQ ID NO 127
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 127

Ile Ser Gly Ser Gly Ser Gly Ser Gly Ser Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 128
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 128

Ile Ser Gly Leu Ala Val Gln Ile Arg Arg Gly Gly Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 129
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 129

Gly Gly Ser Gly Arg Glu Thr Leu Thr Leu Tyr Val Gly Ser Thr
1 5 10 15

<210> SEQ ID NO 130
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 130

Ile Ser Gly Ser Ala Val Val Asn Val Arg Ala Gly Gly Ser Gly Gly
1 5 10 15

-continued

<210> SEQ ID NO 131
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 131

Ile Ser Gly Ser Tyr Ala Met Ser Trp Val Arg Gly Gly Ser Gly Gly		
1	5	10
		15

<210> SEQ ID NO 132
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 132

Gly Ser Tyr Ala Met Ser Trp Val Arg Gln Gly Ser Thr		
1	5	10

<210> SEQ ID NO 133
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 133

Ile Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Asn Pro Gly Gly		
1	5	10
		15

<210> SEQ ID NO 134
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 134

Gly Ser Asn Pro Asn Glu Asn Pro Asn Pro Asn Pro Gly Ser Thr		
1	5	10
		15

<210> SEQ ID NO 135
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 135

Ile Ser Gly Ser Ala Val Val Asn Val Arg Ala Asp Gly Gly Ser Gly		
1	5	10
		15

Gly

<210> SEQ ID NO 136
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 136

Gly Ser Gly Asp Lys Ile Ala Ile Gly Gly Ser Thr		
1	5	10

-continued

<210> SEQ ID NO 137
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 137

Ile	Ser	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Ser	Pro	Asp	Gly	Gly	Ser	Gly
1															
		5				10								15	

Gly

<210> SEQ ID NO 138
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 138

Ile	Ser	Gly												
1														
		5				10							15	

Gly

<210> SEQ ID NO 139
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 139

Ile	Ser	Gly	Ser	Val	Val	Val	Thr	Ser	His	Gln	Ala	Pro	Gly	Ser	Gly
1															
		5				10								15	

Gly

<210> SEQ ID NO 140
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 140

Gly	Ser	Gly	Glu	Lys	Lys	Lys	Leu	Lys	Ser	Leu	Ala	Tyr	Gly	Ser	Thr
1															
		5				10								15	

<210> SEQ ID NO 141
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 141

Ile	Ser	Gly	Arg	Tyr	Asn	Ile	Leu	Lys	Ile	Gln	Lys	Val	Gly	Ser	Gly
1															
		5				10								15	

Gly

<210> SEQ ID NO 142
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial

-continued

<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 142

Gly Gly Ser Gly Glu Tyr Leu Thr Tyr Gln Ile Met Gly Ser Thr
1 5 10 15

<210> SEQ ID NO 143
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 143

Ile Ser Gly Arg Gln Leu Leu Phe Cys Arg Val Thr Leu Gly Ser Gly
1 5 10 15

Gly

<210> SEQ ID NO 144
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 144

Gly Gly Ser Gly Glu Gln Ala Tyr Pro Glu Tyr Leu Ile Thr Tyr Gly
1 5 10 15

Ser Thr

<210> SEQ ID NO 145
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 145

Ile Ser Val Val Val Thr Ser His Gln Ala Pro Gly Glu Gly Ser
1 5 10 15

Gly Gly

<210> SEQ ID NO 146
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 146

Gly Glu Lys Lys Lys Leu Lys Ser Leu Ala Ser Thr
1 5 10

<210> SEQ ID NO 147
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 147

Ile Ser Gly Val Val Thr Ser His Gln Ala Pro Gly Glu Gly Ser
1 5 10 15

-continued

Gly Gly

<210> SEQ ID NO 148
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 148

Gly Glu Lys Lys Lys Leu Lys Ser Leu Gly Ser Thr
1 5 10

<210> SEQ ID NO 149
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 149

Gly Glu Lys Lys Lys Leu Lys Ser Gly Gly Ser Thr
1 5 10

<210> SEQ ID NO 150
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 150

Ile Ser Gly Ser Val Thr Ser His Gln Ala Pro Gly Glu Gly Ser
1 5 10 15

Gly Gly

<210> SEQ ID NO 151
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 151

Gly Glu Lys Lys Lys Gly Lys Ser Gly Gly Ser Thr
1 5 10

<210> SEQ ID NO 152
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 152

Ile Ser Val Val Val Thr Ser His Gln Ala Pro Gly Ser Gly Ser
1 5 10 15

Gly Gly

<210> SEQ ID NO 153
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

US 12,390,508 B2

199**200**

-continued

<400> SEQUENCE: 153

Ile	Ser	Val	Val	Val	Thr	Ser	His	Gln	Ala	Pro	Thr	Ser	Gly	Gly	Ser
1															15
5 10															

Gly Gly

<210> SEQ_ID NO 154

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 154

Ile	Ser	Val	Val	Val	Thr	Ser	His	Gln	Ser	Pro	Thr	Pro	Gly	Gly	Ser
1															15
5 10															

Gly Gly

<210> SEQ_ID NO 155

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 155

Gly	Gly	Ser	Thr	Pro	Leu	Lys	Ser	Leu	Ala	Ser	Thr
1											
5 10											

<210> SEQ_ID NO 156

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 156

Gly	Ser	Thr	Pro	Lys	Leu	Lys	Ser	Leu	Ala	Ser	Thr
1											
5 10											

<210> SEQ_ID NO 157

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 157

Ile	Ser	Val	Val	Val	Thr	Ser	His	Pro	Thr	Pro	Gly	Glu	Gly	Ser
1														15
5 10														

Gly Gly

<210> SEQ_ID NO 158

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 158

Ile	Ser	Val	Val	Val	Thr	Ser	His	Gln	Ala	Pro	Ser	Pro	Gly	Ser	Thr
1														15	
5 10															

Gly Gly

-continued

<210> SEQ ID NO 159
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 159

Ile Ser Val Val Val Thr Ser His Gln Ala Asn Gly Ser Gly Gly Ser
1 5 10 15

Gly Gly

<210> SEQ ID NO 160
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 160

Ile Ser Gly Ser Ala Val Val Asn Val Arg Ala Pro Asp Gly Gly Ser
1 5 10 15

Gly Gly

<210> SEQ ID NO 161
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 161

Gly Ser Lys Gly Asp Lys Ile Ala Ile Gly Gly Ser Thr
1 5 10

<210> SEQ ID NO 162
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 162

Ile Ser Thr Ser Ala Ser Leu Ala Ile Thr Gly Pro Asp Gly Gly Ser
1 5 10 15

Gly Gly

<210> SEQ ID NO 163
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 163

Gly Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Ser Thr
1 5 10

<210> SEQ ID NO 164
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 164

-continued

Ile Ser Gly Phe Ile Leu Pro Ile Glu Val Tyr Pro Asp Gly Gly Ser
 1 5 10 15

Gly Gly

<210> SEQ ID NO 165
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 165

Gly Ser Lys Val Arg Phe Asp Tyr Asp Leu Phe Ser Thr
 1 5 10

<210> SEQ ID NO 166
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 166

Ile Ser Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu Thr Ala
 1 5 10 15

Pro Gly

<210> SEQ ID NO 167
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 167

Gly Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr
 1 5 10

<210> SEQ ID NO 168
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 168

Ile Ser Gly Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Gly Gly Ser
 1 5 10 15

Gly Gly

<210> SEQ ID NO 169
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 169

Gly Ser Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Gly Ser Thr
 1 5 10 15

<210> SEQ ID NO 170
 <211> LENGTH: 18
 <212> TYPE: PRT

-continued

<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
<400> SEQUENCE: 170

```
Ile Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Asn Pro Gly Ser
1           5           10           15

Gly Gly
```

<210> SEQ ID NO 171
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
<400> SEQUENCE: 171

```
Ile His Pro Leu Gln Asn Arg Trp Ala Leu Trp Phe Phe Lys Gly Ser
1           5           10           15

Gly Gly
```

<210> SEQ ID NO 172
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)
<400> SEQUENCE: 172

```
Gly Gly Ser Gly Asn Leu Arg Leu Ile Ser Lys Phe Asp Thr Val Thr
1           5           10           15
```

<210> SEQ ID NO 173
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
<400> SEQUENCE: 173

```
Ile Ser Gly Ser Val Thr Ile Phe Ser Leu Ala Thr Asn Glu Gly Ser
1           5           10           15
```

Gly Gly

<210> SEQ ID NO 174
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)
<400> SEQUENCE: 174

```
Gly Gly Ser Gly Lys Thr Thr Trp His Arg Ile Ser Val Phe Gly Gly
1           5           10           15
```

Ser Thr

<210> SEQ ID NO 175
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
<400> SEQUENCE: 175

-continued

Ile Tyr Leu Glu Gly Lys Ile Asp Tyr Gly Glu Tyr Met Asp Gly Ser
 1 5 10 15

Gly Gly

<210> SEQ ID NO 176
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)
 <400> SEQUENCE: 176

Gly Gly Ser Asn Val Arg Arg Gln Ala Thr Thr Ile Ile Ala Asp Asn
 1 5 10 15

Ile Thr

<210> SEQ ID NO 177
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)
 <400> SEQUENCE: 177

Ile Ser Gly Ser Val Gln Gly Ile Ile Asn Phe Glu Gln Lys Gly Ser
 1 5 10 15

Gly Gly

<210> SEQ ID NO 178
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 178

Gly Gly Ser Gly Pro Val Lys Val Trp Gly Ser Ile Lys Gly Gly Gly
 1 5 10 15

Ser Thr

<210> SEQ ID NO 179
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 179

Ile Ser Gly Val Val Val Thr Ser His Gln Ala Pro Gly Glu Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 180
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 180

Gly Glu Lys Lys Lys Leu Lys Ser Leu Ala Gly Ser Thr
 1 5 10

-continued

<210> SEQ ID NO 181
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 181

Ile Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Pro Asp Gly Gly
1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 182
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 182

Gly Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Gly Ser Thr
1 5 10

<210> SEQ ID NO 183
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 183

Ile Ser Gly Ser Gly Ser Gly Ser Gly Ser Pro Asp Gly Gly
1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 184
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 184

Gly Ser Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr
1 5 10

<210> SEQ ID NO 185
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 185

Ile Ser Gly Thr Tyr Ile Ser Asn Val Asn His Lys Pro Asp Gly Gly
1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 186
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 186

Gly Ser Asn Thr Lys Val Asp Lys Lys Val Glu Gly Ser Thr
 1 5 10

<210> SEQ ID NO 187
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 187

Ile Ser Gly Gly Phe Ile Leu Pro Ile Glu Val Tyr Pro Asp Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 188
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 188

Gly Ser Lys Val Arg Phe Asp Tyr Asp Leu Phe Gly Ser Thr
 1 5 10

<210> SEQ ID NO 189
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 189

Ile Ser Gly Ser Val Val Val Thr Ser His Gln Ala Pro Gly Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 190
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 190

Gly Glu Lys Lys Lys Leu Lys Ser Leu Ala Tyr Gly Ser Thr
 1 5 10

<210> SEQ ID NO 191
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 191

Gly Glu Lys Pro Lys Pro Lys Pro Leu Ala Tyr Gly Ser Thr
 1 5 10

<210> SEQ ID NO 192
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 192

Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr
 1 5 10

<210> SEQ ID NO 193

<211> LENGTH: 19

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 193

Ile Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Asn Pro Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 194

<211> LENGTH: 19

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 194

Ile Ser Gly Asp Ile Tyr Leu Ala Ile Asn Ile Thr Asn Gly Glu Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 195

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 195

Gly Gly Ser Gly Asp Ile Tyr Leu Ala Ile Asn Ile Thr Asn Gly Glu
 1 5 10 15

Ser Thr

<210> SEQ ID NO 196

<211> LENGTH: 19

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 196

Ile Ser Gly Ser Ala Thr Lys Ala Val Ser Val Leu Lys Gly Asp Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 197

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 197

Gly Gly Ser Gly Val Gln Gly Ile Ile Asn Phe Glu Gln Lys Gly Gly
 1 5 10 15

-continued

Ser Thr

<210> SEQ ID NO 198
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 198

Ile Ser Gly Ser Val Pro Lys Glu Lys Glu Lys Val Ser Thr		
1	5	10
		15

Ala Val Gly Gly	
20	

<210> SEQ ID NO 199
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 199

Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr		
1	5	10

<210> SEQ ID NO 200
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 200

Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr		
1	5	10
		15

<210> SEQ ID NO 201
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 201

Ile Ser Gly Ser Ser Gly Ala Val Val Asn Val Arg Ala Pro Asp Gly		
1	5	10
		15

Gly Ser Gly Gly	
20	

<210> SEQ ID NO 202
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 202

Gly Ser Lys Gly Asp Lys Ile Ala Ile Trp Thr Thr Gly Ser Thr		
1	5	10
		15

<210> SEQ ID NO 203
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 203

Ile	Ser	Gly	Ser	Tyr	Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Asp	Gly
1				5				10					15		

Gly Ser Gly Gly
20

<210> SEQ ID NO 204
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 204

Ile	Ser	Gly	Ser	Thr	Ser	Ala	Ser	Leu	Ala	Ile	Thr	Gly	Pro	Asp	Gly
1				5				10				15			

Gly Ser Gly Gly
20

<210> SEQ ID NO 205
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 205

Gly	Ser	Asp	Arg	Phe	Ser	Gly	Ser	Lys	Ser	Gly	Gly	Ser	Thr		
1				5				10			15				

<210> SEQ ID NO 206
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 206

Ile	Ser	Gly	Pro	Asp	Gly										
1				5				10			15				

Gly Ser Gly Gly
20

<210> SEQ ID NO 207
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 207

Ser	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Ser	Ser	Pro	Asp	Gly	Gly		
1				5				10			15				

Ser Gly Gly

<210> SEQ ID NO 208
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

US 12,390,508 B2

219**220**

-continued

<400> SEQUENCE: 208

```
Gly Ser Tyr Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr
1           5          10          15
```

<210> SEQ ID NO 209

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 209

```
Ile Ser Thr Gln Thr Tyr Ile Ser Asn Val Asn His Lys Pro Asp Gly
1           5          10          15
```

Gly Ser Gly Gly

20

<210> SEQ ID NO 210

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 210

```
Gly Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Thr
1           5          10          15
```

<210> SEQ ID NO 211

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 211

```
Ile Ser Gly Ser Thr Tyr Ile Ser Asn Val Asn His Lys Pro Asp Gly
1           5          10          15
```

Gly Ser Gly Gly

20

<210> SEQ ID NO 212

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 212

```
Gly Ser Asn Thr Lys Val Asp Lys Lys Val Glu Gly Ser Thr
1           5          10          15
```

<210> SEQ ID NO 213

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 213

```
Ile Ser Gly Pro Asn Pro Asn Pro Asn Pro Asn Pro Asn Pro Asp Gly
1           5          10          15
```

Gly Ser Gly Gly

20

-continued

<210> SEQ ID NO 214
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 214

Gly Ser Asn Pro Asn Pro Asn Pro Asn Pro Gly Ser Thr
1 5 10 15

<210> SEQ ID NO 215
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 215

Ile Ser Ala Val Gln Val Lys Leu Glu Leu Gly His Arg Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

<210> SEQ ID NO 216
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 216

Gly Ser Asn His Leu Arg Ser Glu Lys Leu Thr Phe Asn Ser Thr
1 5 10 15

<210> SEQ ID NO 217
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 217

Ile Ser Gly Phe Ile Leu Pro Ile Glu Val Tyr Phe Lys Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

<210> SEQ ID NO 218
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 218

Gly Ser Pro Arg Lys Val Arg Phe Asp Tyr Asp Leu Phe Ser Thr
1 5 10 15

<210> SEQ ID NO 219
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

-continued

<400> SEQUENCE: 219

Ile Ser Gly Ser Gly Phe Ile Leu Pro Ile Glu Val Tyr Pro Asp Gly			
1	5	10	15

Gly Ser Gly Gly		
20		

<210> SEQ ID NO 220

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 220

Gly Ser Lys Val Arg Phe Asp Tyr Asp Leu Phe Gly Gly Ser Thr			
1	5	10	15

<210> SEQ ID NO 221

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 221

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr			
1	5	10	15

<210> SEQ ID NO 222

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 222

Ile Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu			
1	5	10	15

Thr Ala Pro Arg		
20		

<210> SEQ ID NO 223

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 223

Gly Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Ser Thr			
1	5	10	15

<210> SEQ ID NO 224

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 224

Ile Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu			
1	5	10	15

Thr Ala Pro Gly		
20		

-continued

<210> SEQ ID NO 225
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 225

Gly Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Thr
1 5 10 15

<210> SEQ ID NO 226
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 226

Ile Ser Gly Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 227
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 227

Gly Ser Lys Thr His Thr Ser Pro Pro Ser Pro Gly Gly Ser Thr
1 5 10 15

<210> SEQ ID NO 228
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 228

Ile Ser Gly Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 229
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 229

Gly Ser Tyr Ser Ser Tyr Ala Met Ser Trp Val Arg Gly Gly Ser Thr
1 5 10 15

<210> SEQ ID NO 230
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

-continued

<400> SEQUENCE: 230

```
Gly Ser Tyr Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Gly Ser Thr
1           5           10           15
```

<210> SEQ ID NO 231

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 231

```
Ile Ser Gly Ser Gly Ser Gly Ser Gly Ser Pro Asp
1           5           10           15
```

Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 232

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 232

```
Ile Ser Gly Ser Pro Asn Pro Asn Pro Asn Pro Ser Pro Asp
1           5           10           15
```

Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 233

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 233

```
Gly Ser Tyr Pro Asn Pro Asn Pro Asn Pro Ser Gly Ser Thr
1           5           10           15
```

<210> SEQ ID NO 234

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 234

```
Ile Ser Gly Pro Asn Pro Asn Lys Asn Pro Asn Pro Ser Pro Asp
1           5           10           15
```

Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 235

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 235

```
Gly Ser Tyr Asn Pro Asn Glu Asn Pro Asn Pro Asn Pro Gly Ser Thr
1           5           10           15
```

-continued

<210> SEQ ID NO 236
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 236

Ile	Ser	Gly	Pro	Asn	Pro	Asn	Pro	Asn	Pro	Asn	Ser	Pro	Asp
1			5			10					15		
Gly	Gly	Ser	Gly	Gly									
					20								

<210> SEQ ID NO 237
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 237

Gly	Ser	Tyr	Asn	Pro	Asn	Pro	Asn	Pro	Gly	Ser	Thr
1			5			10			15		

<210> SEQ ID NO 238
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 238

Ile	Ser	Gly	Ser	Val	Val	Val	Thr	Ser	His	Gln	Ala	Pro	Gly	Ser
1				5			10			15				

Gly

Gly	Ser	Gly	Gly
	20		

<210> SEQ ID NO 239
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 239

Ile	Ser	Gly	Ser	Val	Val	Tyr	Ile	Glu	Ile	Leu	Asp	Arg	His	Pro	Asp
1				5		10			15						

Gly

Gly	Ser	Gly	Gly
	20		

<210> SEQ ID NO 240
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 240

Gly	Ser	Gly	Arg	Glu	Val	Pro	Ile	Ser	Asn	Gly	Ser	Gly	Ser	Thr
1				5		10			15					

<210> SEQ ID NO 241
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 241

Ile	Ser	Gly	Ala	Val	Val	Tyr	Ile	Glu	Ile	Leu	Asp	Arg	His	Pro	Asp
1				5				10				15			
Gly Gly Ser Gly Gly															
20															

<210> SEQ ID NO 242
 <211> LENGTH: 21
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 242

Ile	Ser	Pro	Ala	Val	Val	Tyr	Ile	Glu	Ile	Leu	Asp	Arg	His	Pro	Asp
1				5				10				15			
Gly Gly Ser Gly Gly															
20															

<210> SEQ ID NO 243
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 243

Gly	Ser	Gly	Arg	Glu	Val	Pro	Ile	Ser	Asn	Gly	Ser	Gly	Phe	Ser	Thr
1				5				10				15			

<210> SEQ ID NO 244
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 244

Cys	Ala	Lys	Ser	Pro	Asp	Gly	Gly	Ser	Gly	Gly
1				5				10		

<210> SEQ ID NO 245
 <211> LENGTH: 4
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 245

Gly	Ser	Tyr	Gly
1			

<210> SEQ ID NO 246
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 246

Gly	Ser	Tyr	Gln	His	Trp	Gly	Gln	Gly
1				5				

-continued

<210> SEQ ID NO 247
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 247

Cys Ala Lys Val His Gln Glu Thr Gly Gly Ser Gly Gly
1 5 10

<210> SEQ ID NO 248
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 248

Gly Ser Trp His Val Gln His Trp Gly Gln Gly
1 5 10

<210> SEQ ID NO 249
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 249

Cys Ala Lys Val His Gln Glu Thr Pro Asp Gly Gly Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 250
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 250

Gly Ser Tyr Glu Trp His Val Gln His Trp Gly Gln Gly
1 5 10

<210> SEQ ID NO 251
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 251

Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Gly Gly
1 5 10 15

<210> SEQ ID NO 252
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 252

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp
1 5 10 15

Gly Gln Gly

-continued

<210> SEQ ID NO 253
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 253

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Ser	Ser	Pro	Asp	Gly	Gly	Ser	Gly
1															
														15	

Gly

<210> SEQ ID NO 254
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 254

Gly	Ser	Tyr	Ser	Tyr	Glu	Trp	His	Val	Asp	Val	Trp	Gly	Gln	Gly
1														
														15

<210> SEQ ID NO 255
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 255

Cys	Ala	Lys	Thr	His	Thr	Ser	Pro	Pro	Ser	Pro	Asp	Gly	Gly	Ser	Gly
1															
														15	

Gly

<210> SEQ ID NO 256
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 256

Gly	Ser	Ser	Pro	Pro	Ser	Pro	Tyr	Phe	Gln	His	Trp	Gly	Gln	Gly
1														
														15

<210> SEQ ID NO 257
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 257

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Ser	Ser	Pro	Asp	Gly	Gly	Ser
1															
															15

Gly Gly

<210> SEQ ID NO 258
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

-continued

<400> SEQUENCE: 258

Gly	Ser	Tyr	Ser	Asn	Tyr	Glu	Trp	His	Val	Asp	Val	Trp	Gly	Gln	Gly
1															
													15		

<210> SEQ ID NO 259
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 259

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser	Pro	Asp
1															
												10			15

Gly Gly

<210> SEQ ID NO 260
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 260

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Ser	Ser	Pro	Asp	Gly	Gly
1															
												10			15

Ser Gly Gly

<210> SEQ ID NO 261
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 261

Gly	Ser	Tyr	Ser	Tyr	Asn	Tyr	Glu	Trp	His	Val	Asp	Val	Trp	Gly	Gln
1															
														15	

Gly

<210> SEQ ID NO 262
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 262

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser	Gly	Gly
1															
												10			15

Ser Gly Gly

<210> SEQ ID NO 263
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 263

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Gln	Ser	Ser	Pro	Asp	Gly
1															
												10			15

-continued

Gly Ser Gly Gly
20

<210> SEQ ID NO 264
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 264

Gly Ser Tyr Ser Tyr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly
1 5 10 15

Gln Gly

<210> SEQ ID NO 265
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 265

Cys Ala Lys Val His Pro Asn Pro Asn Pro Asn Pro Asp Gly
1 5 10 15

Gly Ser Gly Gly
20

<210> SEQ ID NO 266
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 266

Gly Ser Asn Pro Asn Pro Asn Pro Asn His Val Asp Val Trp Gly
1 5 10 15

Gln Gly

<210> SEQ ID NO 267
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 267

Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly
20

<210> SEQ ID NO 268
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 268

Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly

-continued

20

<210> SEQ ID NO 269
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 269

Cys	Ala	Lys	Leu	Thr	Val	Val	Val	Thr	Ser	Gln	Ala	Pro	Gly	Glu
1														
													10	15

Gly	Gly	Ser	Gly	Gly
20				

<210> SEQ ID NO 270
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 270

Gly	Glu	Lys	Lys	Lys	Leu	Lys	Ser	Leu	Ala	Tyr	Phe	Gln	His	Trp	Gly
1															
														10	15

Gln Gly

<210> SEQ ID NO 271
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 271

Cys	Ala	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Ser	Pro	Asp
1															
														10	15

Gly	Gly	Ser	Gly	Gly
20				

<210> SEQ ID NO 272
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 272

Gly	Ser	Lys	Thr	His	Thr	Ser	Pro	Pro	Ser	Pro	Tyr	Phe	Gln	His	Trp	
1																
														5	10	15

Gly Gln Gly

<210> SEQ ID NO 273
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 273

Cys	Ala	Lys	Val	Glu	Thr	Lys	Tyr	Gln	Ser	Ser	Pro	Asp	Gly	Gly		
1																
														5	10	15

Ser Gly Gly

-continued

<210> SEQ ID NO 274
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 274

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Val Gln His Trp Gly Gln
1 5 10 15

Gly

<210> SEQ ID NO 275
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 275

Cys Ala Lys Val His Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly Gly
1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 276
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 276

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr His Val Gln His Trp Gly Gln
1 5 10 15

Gly

<210> SEQ ID NO 277
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 277

Cys Ala Lys Leu Thr Val Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 278
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 278

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Gln His Trp
1 5 10 15

Gly Gln Gly

<210> SEQ ID NO 279
<211> LENGTH: 21

-continued

<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 279

Cys Ala Lys Leu Thr Ala Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 280
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 280

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Asn Tyr Phe Gln His Trp
1 5 10 15

Gly Gln Gly

<210> SEQ ID NO 281
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 281

Cys Ala Lys Gly Ile Thr Gly Thr Lys Lys Tyr Gln Ser Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 282
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 282

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Ala Glu Tyr Phe Gln His Trp
1 5 10 15

Gly Gln Gly

<210> SEQ ID NO 283
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 283

Gly Ser Tyr Asp Tyr Val Trp Gly Ser Tyr Ala Tyr Phe Gln His Trp
1 5 10 15

Gly Gln Gly

<210> SEQ ID NO 284
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 284

```
Cys Ala Lys Leu Thr Ser Val Val Val Thr Ser His Gln Ala Pro Gly
1           5           10          15
Gly Gly Ser Gly Gly
20
```

<210> SEQ ID NO 285
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 285

```
Gly Glu Lys Lys Leu Lys Ser Leu Ala Tyr Tyr Phe Gln His Trp
1           5           10          15
Gly Gln Gly
```

<210> SEQ ID NO 286
 <211> LENGTH: 21
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 286

```
Cys Ala Lys Val His Pro Asn Pro Asn Pro Asn Ser Pro Asp
1           5           10          15
Gly Gly Ser Gly Gly
20
```

<210> SEQ ID NO 287
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 287

```
Gly Ser Tyr Asn Pro Asn Pro Asn Pro His Val Asp Val Trp
1           5           10          15
```

Gly Gln Gly

<210> SEQ ID NO 288
 <211> LENGTH: 21
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 288

```
Cys Ala Lys Leu Thr Gln Val Lys Leu Glu Leu Gly His Arg Pro Asp
1           5           10          15
```

Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 289
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:

US 12,390,508 B2

249**250**

-continued

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 289

Gly	Ser	Asn	His	Leu	Arg	Ser	Glu	Lys	Leu	Thr	Tyr	Phe	Gln	His	Trp
1				5				10					15		

Gly Gln Gly

<210> SEQ ID NO 290

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 290

Cys	Ala	Lys	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser	Pro	Asp
1					5			10				15			

Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 291

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 291

Cys	Ala	Lys	Thr	Gln	Thr	Tyr	Ile	Ser	Asn	Val	Asn	His	Lys	Pro	Asp
1					5			10			15				

Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 292

<211> LENGTH: 19

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 292

Gly	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Ala	Glu	Tyr	Phe	Gln	His	Trp
1					5			10					15		

Gly Gln Gly

<210> SEQ ID NO 293

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 293

Gly	Ser	Tyr	Ser	Tyr	Thr	Thr	Tyr	Asn	Tyr	Glu	Trp	His	Val	Asp	Val
1					5			10				15			

Trp Gly Gln Gly

20

<210> SEQ ID NO 294

<211> LENGTH: 22

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

-continued

<400> SEQUENCE: 294

```
Cys Ala Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro
1           5          10          15
Asp Gly Gly Ser Gly Gly
20
```

```
<210> SEQ ID NO 295
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)
```

<400> SEQUENCE: 295

```
Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val His
1           5          10          15
```

```
Trp Gly Gln Gly
20
```

```
<210> SEQ ID NO 296
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
```

<400> SEQUENCE: 296

```
Cys Ala Lys Leu Thr Ala Glu Glu Trp Lys Lys Lys Tyr Glu Lys Glu
1           5          10          15
```

```
Lys Glu Lys Asn Lys Gly Ser
20
```

```
<210> SEQ ID NO 297
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)
```

<400> SEQUENCE: 297

```
Gly Gly Ser Gly Gly Ser Gly Gly Ala Glu Tyr Phe Gln
1           5          10          15
```

```
His Trp Gly Gln Gly
20
```

```
<210> SEQ ID NO 298
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
```

<400> SEQUENCE: 298

```
Cys Ala Asp Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg
1           5          10          15
```

```
Ala Leu Leu Thr Ala Pro Arg
20
```

```
<210> SEQ ID NO 299
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
```

-continued

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 299

Gly	Ser	Asn	His	Leu	Arg	Ser	Glu	Lys	Leu	Thr	Phe	Asn	Tyr	Phe	Gln
1			5			10					15				
His Trp Gly Gln Gly															
			20												

<210> SEQ ID NO 300

<211> LENGTH: 23

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 300

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Tyr	Gln	Ser	Ser
1			5			10				15					

Pro Asp Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 301

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 301

Gly	Ser	Tyr	Ser	Tyr	Thr	Tyr	Thr	Tyr	Asn	Tyr	Glu	Trp	His	Val	Asp
1			5			10			15						

Val Trp Gly Gln Gly

20

<210> SEQ ID NO 302

<211> LENGTH: 23

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 302

Cys	Ala	Lys	Leu	Thr	Asp	Arg	Ser	Ala	Leu	Leu	Lys	Ser	Lys	Leu	Arg
1			5			10			15						

Ala Leu Leu Thr Ala Pro Arg

20

<210> SEQ ID NO 303

<211> LENGTH: 23

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 303

Cys	Ala	Lys	Leu	Thr	Ala	Val	Gln	Val	Lys	Leu	Glu	Leu	Gly	His	Arg
1			5			10			15						

Pro Asp Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 304

<211> LENGTH: 25

<212> TYPE: PRT

<213> ORGANISM: artificial

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 304

Cys	Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser	Tyr	Gln
1						5		10			15				
Ser	Ser	Pro	Asp	Gly	Gly	Ser	Gly	Gly							
						20					25				

<210> SEQ ID NO 305
 <211> LENGTH: 23
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 305

Gly	Ser	Tyr	Ser	Tyr	Thr	Tyr	Ser	Tyr	Thr	Tyr	Asn	Tyr	Glu	Trp	His
1						5		10			15				
Val	Asp	Val	Trp	Gly	Gln	Gly									
						20									

<210> SEQ ID NO 306
 <211> LENGTH: 25
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 306

Cys	Ala	Lys	Leu	Thr	Ala	Val	Gln	Val	Lys	Leu	Glu	Leu	Gly	His	Arg
1						5		10			15				
Ala	Gln	Pro	Asp	Gly	Gly	Ser	Gly	Gly							
						20					25				

<210> SEQ ID NO 307
 <211> LENGTH: 23
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 307

Gly	Ser	Pro	Val	Asn	His	Leu	Arg	Ser	Glu	Lys	Leu	Thr	Phe	Asn	Tyr
1						5		10			15				
Phe	Gln	His	Trp	Gly	Gln	Gly									
						20									

<210> SEQ ID NO 308
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 308

Ser	Ser	Ser	Asn	Ile	Gly	Ser	Lys	Leu	Arg	Ala	Leu	Leu	Thr	Ala	Pro
1							5		10				15		

Arg

<210> SEQ ID NO 309
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 309

Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Ser Gly Tyr Asp
 1 5 10 15

<210> SEQ ID NO 310
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 310

Gly Ser Tyr Gly Ser Gly Gly Ser Gly Ser Gly Asp
 1 5 10

<210> SEQ ID NO 311
 <211> LENGTH: 21
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 311

Ser Ser Leu Gly Gln Ile Gln Leu Thr Ile Arg His Ser Ser Pro Asp
 1 5 10 15

Gly Gly Ser Gly Gly
 20

<210> SEQ ID NO 312
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 312

Gly Ser Asn Lys Leu Ile Val Val Val His Ala Ser Arg Asn Leu Ile
 1 5 10 15

Gly Tyr Asp

<210> SEQ ID NO 313
 <211> LENGTH: 22
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 313

Ser Pro Leu Gly Gln Ile Gln Leu Thr Ile Arg His Ser Ser Gln Pro
 1 5 10 15

Asp Gly Gly Ser Gly Gly
 20

<210> SEQ ID NO 314
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 314

Gly Ser Arg Asn Lys Leu Ile Val Val Val His Ala Ser Arg Asn Leu

US 12,390,508 B2

259**260**

-continued

1	5	10	15
---	---	----	----

Ile Ala Tyr Asp
20

<210> SEQ ID NO 315
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 315

Ser Ser Leu Gly Gln Ile Gln Leu Thr Ile Arg His Ser Ser Gln Pro	5	10	15
---	---	----	----

Asp Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 316
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 316

Gly Ser Arg Asn Lys Leu Ile Val Val Val His Ala Ser Arg Asn Leu	5	10	15
---	---	----	----

Ile Gly Tyr Asp
20

<210> SEQ ID NO 317
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 317

Ser Ser Ser Asn Ile Gly Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala	5	10	15
---	---	----	----

Leu Leu Thr Ala Pro Arg
20

<210> SEQ ID NO 318
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 318

Gly Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu	5	10	15
---	---	----	----

Leu Thr Ala Asp
20

<210> SEQ ID NO 319
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 319

-continued

Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Ser Gly
 1 5 10 15

Ser Gly Tyr Asp
 20

<210> SEQ ID NO 320
 <211> LENGTH: 24
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 320

Ser Ser Ser Asn Ile Gly Ser Gly Ser Gly Ser Gly
 1 5 10 15

Ser Pro Asp Gly Gly Ser Gly Gly
 20

<210> SEQ ID NO 321
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 321

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Tyr Asp
 1 5 10 15

<210> SEQ ID NO 322
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 322

Asn Ser Asn Arg Pro Ser Gly
 1 5

<210> SEQ ID NO 323
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 323

Tyr Gly Gly Ser Gly Ser
 1 5

<210> SEQ ID NO 324
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 324

Gly Ser Gly Ser Asn Ser Asn Arg Pro Ser Gly
 1 5 10

<210> SEQ ID NO 325
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: artificial

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 325

Tyr Gly Lys Thr His Thr Ser Pro Pro Ser Pro Gly Gly
 1 5 10

<210> SEQ ID NO 326
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 326

Gly Gly Lys Thr His Thr Ser Pro Pro Ser Pro Gly Asn Arg Pro Ser
 1 5 10 15

Gly

<210> SEQ ID NO 327
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 327

Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Gly Gly
 1 5 10

<210> SEQ ID NO 328
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 328

Gly Gly Lys Thr His Thr Ser Pro Pro Ser Pro Ser Gly Asn Arg Pro
 1 5 10 15

Ser Gly

<210> SEQ ID NO 329
 <211> LENGTH: 14
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 329

Tyr Gly Ser Lys Thr His Thr Ser Pro Pro Ser Pro Gly Gly
 1 5 10

<210> SEQ ID NO 330
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 330

Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Gly Ser Gly Gly
 1 5 10 15

<210> SEQ ID NO 331

-continued

<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 331

Gly	Ser	Gly	Gly	Ser	Gly	Ser	Gly	Asn	Arg	Pro	Ser	Gly
1				5			10			15		

<210> SEQ ID NO 332
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 332

Tyr	Gly	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Ser	Pro	Gly	Gly
1				5			10			15					

<210> SEQ ID NO 333
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 333

Gly	Gly	Ser	Gly	Asn								
1				5			10			15		

Arg Pro Ser Gly
20

<210> SEQ ID NO 334
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 334

Tyr	Thr	Ser	Ala	Ser	Leu	Ala	Ile	Thr	Gly	Pro	Asp	Gly	Ser	Gly
1				5			10			15				

Gly

<210> SEQ ID NO 335
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 335

Gly	Ser	Asp	Arg	Phe	Ser	Gly	Ser	Lys	Ser	Gly	Asn	Arg	Pro	Ser	Gly
1				5				10			15				

<210> SEQ ID NO 336
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 336

Tyr Gly Phe Ile Leu Pro Ile Glu Val Tyr Pro Asp Gly Gly Ser Gly

US 12,390,508 B2

267

-continued

1	5	10	15
---	---	----	----

Gly

<210> SEQ ID NO 337
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 337

Gly Ser Lys Val Arg Phe Asp Tyr Asp Leu Phe Asn Arg Pro Ser Gly	5	10	15
---	---	----	----

<210> SEQ ID NO 338
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 338

Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Gly Ser Gly	5	10	15
---	---	----	----

Gly

<210> SEQ ID NO 339
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 339

Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Asn Arg Pro Ser	5	10	15
---	---	----	----

Gly

<210> SEQ ID NO 340
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 340

Tyr Gly Val Pro Lys Glu Lys Glu Lys Glu Lys Val Ser Thr Ala Val	1	5	10	15
---	---	---	----	----

Gly Gly

<210> SEQ ID NO 341
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 341

Gly Ser Ala Pro Leu Glu Val Pro Lys Glu Lys Glu Lys Val	1	5	10	15
---	---	---	----	----

Gly

<210> SEQ ID NO 342

268

269

270

-continued

```
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
```

<400> SEQUENCE: 342
Tyr Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Pro Asp Gly Gly Ser
1 5 10 15
Gly Gly

```
<210> SEQ ID NO 343
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)
```

<400> SEQUENCE: 343
Gly Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Gly Asn Arg Pro Ser
1 5 10 15

Gly

<210> SEQ ID NO 344
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 344

Tyr Gly Gly Ser Gly Ser Gly Ser Gly Ser Gly Pro Asp Gly Gly Ser
1 5 10 15

Gly Gly

```
<210> SEQ ID NO 345
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
```

<400> SEQUENCE: 345
Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly
1 5 10 15

Gly Gly

<210> SEQ ID NO 346
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 346
Gly Ser Tyr Glu Lys Glu Lys Glu Lys Asn Lys Thr Leu Lys Asn Val

```
<210> SEQ ID NO 347
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
```

-continued

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 347

Tyr	Gly	Thr	Tyr	Ile	Ser	Asn	Val	Asn	His	Lys	Pro	Asp	Gly	Gly	Ser
1				5				10					15		

Gly Gly

<210> SEQ ID NO 348

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 348

Gly	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Gly	Asn	Arg	Pro	Ser
1				5			10					15			

Gly

<210> SEQ ID NO 349

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 349

Tyr	Gly	Ala	Glu	Glu	Trp	Lys	Lys	Tyr	Glu	Lys	Glu	Lys	Glu	Lys	
1			5			10						15			

Gly Gly

<210> SEQ ID NO 350

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 350

Gly	Ser	1	5	10	15										
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	---	---	----	----

Gly

<210> SEQ ID NO 351

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 351

Tyr	Gly	Gly	Phe	Ile	Leu	Pro	Ile	Glu	Val	Tyr	Pro	Asp	Gly	Gly	Ser
1				5				10					15		

Gly Gly

<210> SEQ ID NO 352

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 352

-continued

Gly Ser Lys Val Arg Phe Asp Tyr Asp Leu Phe Gly Asn Arg Pro Ser
 1 5 10 15

Gly

<210> SEQ ID NO 353
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 353

Tyr Gly Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu Thr Ala
 1 5 10 15

Pro Gly

<210> SEQ ID NO 354
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 354

Gly Ser Asp Gly Ser Gly Ser Gly Ser Gly Asn Arg Pro
 1 5 10 15

Ser Gly

<210> SEQ ID NO 355
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 355

Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Pro Asp Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 356
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 356

Tyr Gly Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Pro Asp Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 357
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 357

Gly Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Gly Gly Asn Arg Pro
 1 5 10 15

Ser Gly

-continued

<210> SEQ ID NO 358
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 358

Tyr	Gly	Gly	Thr	Tyr	Ile	Ser	Asn	Val	Asn	His	Lys	Pro	Asp	Gly	Gly
1															
														15	

Ser Gly Gly

<210> SEQ ID NO 359
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 359

Gly	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Gly	Gly	Asn	Arg	Pro
1															
														15	

Ser Gly

<210> SEQ ID NO 360
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 360

Tyr	Thr	Gln	Thr	Tyr	Ile	Ser	Asn	Val	Asn	His	Lys	Pro	Asp	Gly	Gly
1															
														15	

Ser Gly Gly

<210> SEQ ID NO 361
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 361

Gly	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Asn	Arg	Pro
1															
														15	

Ser Gly

<210> SEQ ID NO 362
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 362

Tyr	Gly	Gly	Gly	Phe	Ile	Leu	Pro	Ile	Glu	Val	Tyr	Pro	Asp	Gly	Gly
1															
														15	

Ser Gly Gly

<210> SEQ ID NO 363
<211> LENGTH: 18

-continued

<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 363

Gly	Ser	Lys	Val	Arg	Phe	Asp	Tyr	Asp	Leu	Phe	Gly	Gly	Asn	Arg	Pro
1															
					5				10						15

Ser Gly

<210> SEQ ID NO 364
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 364

Tyr	Gly	Ser	Pro	Asp	Gly										
1															
					5				10						15

Gly Ser Gly Gly
20

<210> SEQ ID NO 365
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 365

Gly	Ser	Tyr	Gly	Ser	Gly	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Asn	Arg	Pro
1															
					5				10						15

Ser Gly

<210> SEQ ID NO 366
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 366

Tyr	Gly	Ser	Gln	Val	Lys	Leu	Glu	Leu	Gly	His	Arg	Ala	Pro	Asp	Gly
1															
					5				10						15

Gly Ser Gly Gly
20

<210> SEQ ID NO 367
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 367

Gly	Ser	Val	Asn	His	Leu	Arg	Ser	Glu	Lys	Leu	Thr	Ser	Gly	Asn	Arg
1															
					5				10						15

Pro Ser Gly

<210> SEQ ID NO 368
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial

US 12,390,508 B2

279

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 368

```
Tyr Pro Ala Val Val Tyr Ile Glu Ile Leu Asp Arg His Pro Asp Gly
1           5          10          15
Gly Ser Gly Gly
20
```

<210> SEQ ID NO 369
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 369

```
Gly Ser Gly Arg Glu Val Pro Ile Ser Asn Gly Ser Gly Phe Asn Arg
1           5          10          15
Pro Ser Gly
```

<210> SEQ ID NO 370
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 370

```
Tyr Gly Gly Val Val Tyr Ile Glu Ile Leu Asp Arg His Pro Asp Gly
1           5          10          15
Gly Ser Gly Gly
20
```

<210> SEQ ID NO 371
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 371

```
Gly Ser Gly Arg Glu Val Pro Ile Ser Asn Gly Ser Gly Asn Arg
1           5          10          15
```

Pro Ser Gly

<210> SEQ ID NO 372
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 372

```
Tyr Gly Ala Val Val Tyr Ile Glu Ile Leu Asp Arg His Pro Asp Gly
1           5          10          15
```

Gly Ser Gly Gly
20

<210> SEQ ID NO 373
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:

280

-continued

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 373

Tyr	Gly	Ser	Arg	Ser	Ala	Leu	Leu	Lys	Ser	Lys	Leu	Arg	Ala	Leu	Leu
1					5			10				15			
Thr Ala Pro Arg															
					20										

<210> SEQ ID NO 374

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 374

Gly	Ser	Asp	Gly	Ser	Gly	Ser	Gly	Gly	Ser	Gly	Ser	Gly	Asn		
1					5			10			15				

Arg Pro Ser Gly

20

<210> SEQ ID NO 375

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 375

Tyr	Gly	Ser	Arg	Ser	Ala	Leu	Leu	Lys	Ser	Lys	Leu	Arg	Ala	Leu	Leu
1					5			10			15				

Thr Ala Pro Gly

20

<210> SEQ ID NO 376

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 376

Tyr	Gly	Ser	Ala	Val	Gln	Val	Lys	Leu	Glu	Leu	Gly	His	Arg	Pro	Asp
1					5			10			15				

Gly Gly Ser Gly Gly

20

<210> SEQ ID NO 377

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 377

Gly	Ser	Asn	His	Leu	Arg	Ser	Glu	Lys	Leu	Thr	Phe	Asn	Ser	Gly	Asn
1					5			10			15				

Arg Pro Ser Gly

20

<210> SEQ ID NO 378

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: artificial

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 378

Cys Gly Ser Gly Ser Gly Ser Gly Pro Asp Gly Gly Ser Gly Gly
 1 5 10 15

<210> SEQ ID NO 379
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 379

Gly Ser Gly Ser Gly Ser Gly Ser Gly Phe
 1 5 10

<210> SEQ ID NO 380
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 380

Cys Gln Ser Tyr Asp Ile Leu Pro Ile Glu Pro Asp Gly Gly Ser Gly
 1 5 10 15

Gly

<210> SEQ ID NO 381
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 381

Gly Ser Arg Phe Asp Tyr Asp Gly Val Val Phe
 1 5 10

<210> SEQ ID NO 382
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 382

Cys Gly Ser Gly Ser Gly Ser Gly Ser Gly Pro Asp Gly Gly Ser Gly
 1 5 10 15

Gly

<210> SEQ ID NO 383
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 383

Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Phe
 1 5 10

<210> SEQ ID NO 384

-continued

<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 384

Cys	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Gly	Ser	Gly
1												
												15

Gly

<210> SEQ ID NO 385
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 385

Gly	Ser	Gly	Phe								
1											
											10

<210> SEQ ID NO 386
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 386

Cys	Gln	Ser	Tyr	Asp	Lys	Leu	Glu	Leu	Gly	His	Pro	Asp	Gly	Ser
1														
														15

Gly Gly

<210> SEQ ID NO 387
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 387

Gly	Ser	His	Leu	Arg	Ser	Glu	Lys	Gly	Val	Val	Phe
1											
											10

<210> SEQ ID NO 388
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 388

Cys	Gln	Ser	Tyr	Asp	Ile	Leu	Pro	Ile	Glu	Val	Tyr	Pro	Asp	Gly	Gly
1															
															15

Ser Gly Gly

<210> SEQ ID NO 389
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 389

-continued

Gly Ser Lys Val Arg Phe Asp Tyr Asp Gly Val Val Phe
 1 5 10

<210> SEQ ID NO 390
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 390

Cys Gly Ser Gly Ser Gly Ser Gly Ser Gly Pro Asp Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 391
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 391

Cys Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Asp Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 392
 <211> LENGTH: 19
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 392

Cys Gln Ser Tyr Asp Gly Phe Ile Leu Pro Ile Glu Val Tyr Gly Gly
 1 5 10 15

Ser Gly Gly

<210> SEQ ID NO 393
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 393

Gly Ser Lys Val Arg Phe Asp Tyr Asp Leu Phe Gly Val Val Phe
 1 5 10 15

<210> SEQ ID NO 394
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 394

Cys Gln Ser Tyr Asp Lys Leu Glu Leu Gly His Arg Ala Pro Asp Gly
 1 5 10 15

Gly Ser Gly Gly
 20

<210> SEQ ID NO 395

-continued

<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 395

Gly	Ser	Val	Asn	His	Leu	Arg	Ser	Glu	Lys	Gly	Val	Val	Phe
1													
					5				10				

<210> SEQ ID NO 396
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 396

Cys	Gln	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser	Pro	Asp	Gly
1															
					5			10					15		

Gly	Ser	Gly	Gly
20			

<210> SEQ ID NO 397
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 397

Gly	Ser	Tyr	Ser	Tyr	Thr	Tyr	Asn	Tyr	Glu	Trp	His	Val	Val	Phe
1														
					5			10				15		

<210> SEQ ID NO 398
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 398

Cys	Gly	Ser	Pro	Asp	Gly								
1													
					5			10			15		

Gly	Ser	Gly	Gly
20			

<210> SEQ ID NO 399
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 399

Gly	Ser	Tyr	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Phe
1												
					5			10			15	

<210> SEQ ID NO 400
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 400

291**292**

-continued

Cys Gln Ser Tyr Asp Pro Asn Pro Asn Pro Asn Pro Asp Gly
 1 5 10 15

Gly Ser Gly Gly
 20

<210> SEQ ID NO 401
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 401

Gly Ser Asn Pro Asn Pro Asn Pro Asn Ser Gly Val Val Phe
 1 5 10 15

<210> SEQ ID NO 402
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 402

Cys Ala Ala Trp Asn Pro Asn Pro Asn Pro Asn Pro Asn Gly
 1 5 10 15

Gly Ser Gly Gly
 20

<210> SEQ ID NO 403
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 403

Gly Ser Asn Pro Asn Pro Asn Pro Asn Pro Asn Pro Asn Val Phe
 1 5 10 15

<210> SEQ ID NO 404
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 404

Cys Gln Ser Tyr Asp Gln Val Lys Leu Glu Leu Gly His Arg Ala Gly
 1 5 10 15

Gly Ser Gly Gly
 20

<210> SEQ ID NO 405
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 405

Gly Ser Val Asn His Leu Arg Ser Glu Lys Leu Thr Gly Val Val Phe
 1 5 10 15

<210> SEQ ID NO 406

-continued

<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 406

Cys	Gln	Ser	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser	Pro	Asp
1															
								10							15

Gly	Gly	Ser	Gly	Gly
				20

<210> SEQ ID NO 407
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 407

Cys	Gln	Ser	Tyr	Asp	Gln	Val	Lys	Leu	Glu	Leu	Gly	His	Arg	Pro	Asp	
1																
								5							10	15

Gly	Gly	Ser	Gly	Gly
				20

<210> SEQ ID NO 408
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 408

Gly	Ser	Asn	His	Leu	Arg	Ser	Glu	Lys	Leu	Thr	Gly	Val	Val	Phe	
1															
								5						10	15

<210> SEQ ID NO 409
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 409

Cys	Gln	Ser	Tyr	Asp	Gly	Phe	Ile	Leu	Pro	Ile	Glu	Val	Tyr	Pro	Asp	
1																
								5							10	15

Gly	Gly	Ser	Gly	Gly
				20

<210> SEQ ID NO 410
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 410

Gly	Ser	Tyr	Ser	Tyr	Thr	Tyr	Asn	Tyr	Glu	Trp	His	Val	Asp	Val	Phe	
1																
								5							10	15

<210> SEQ ID NO 411
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

295

296

-continued

<400> SEQUENCE: 411

```
<210> SEQ ID NO 412
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
```

<400> SEQUENCE: 412

Cys Gly Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Pro Asp
 1 5 10 15

Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 413
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 413

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Gly Phe
 1 5 10 15

```
<210> SEQ ID NO 414
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)
```

<400> SEQUENCE: 414

Cys Gln Ser Tyr Asp Ser Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala
 1 5 10 15

Leu Leu Thr Ala Pro Arg
20

<210> SEQ ID NO 415
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 415

Cys Gln Ser Ala Val Gln Val Lys Leu Glu Leu Gly His Arg Ala Pro
1 5 10 15

Asp Gly Gly Ser Gly Gly
20

<210> SEQ ID NO 416
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:

Gly Ser Val Asn His Leu Arg Ser Glu Lys Leu Thr Phe Asn Val Phe

-continued

```
<210> SEQ_ID NO 417
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 417

Cys Gln Ser Tyr Asp Gln Val Lys Leu Glu Leu Gly His Arg Ala Pro
1           5           10          15

Asp Gly Gly Ser Gly Gly
20
```

```
<210> SEQ ID NO 418
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 418

Cys Gln Ser Tyr Asp Gly Phe Ile Leu Pro Ile Glu Val Tyr Phe Pro
1           5                   10                  15

Asp Gly Gly Ser Gly Gly
20
```

```
<210> SEQ ID NO 419
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 419

Gly Ser Arg Lys Val Arg Phe Asp Tyr Asp Leu Phe Gly Val Val Phe
1           5           10          15
```

```
<210> SEQ ID NO: 420
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 420

Cys Gln Ser Tyr Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro
1           5           10          15

Asp Gly Gly Ser Gly Gly
20
```

```
<210> SEQ_ID NO 421
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER_INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 421
```

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Gly Val Val
1 5 10 15

Phe

<210> SEQ ID NO 422

US 12,390,508 B2

299**300**

-continued

<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 422

Cys	Gln	Ser	Tyr	Asp	Val	His	Gln	Glu	Thr	Lys	Lys	Tyr	Gln	Ser	Ser
1															
					5			10						15	

Pro	Asp	Gly	Gly	Ser	Gly	Gly
					20	

<210> SEQ ID NO 423
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 423

Gly	Ser	Tyr	Ser	Tyr	Thr	Tyr	Asn	Tyr	Glu	Trp	His	Val	Ser	Gly	Val
1															
						5		10					15		

Val Phe

<210> SEQ ID NO 424
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 424

Cys	Gln	Ser	Tyr	Asp	Ala	Val	Gln	Val	Lys	Leu	Glu	Leu	Gly	His	Arg
1															
						5			10				15		

Ala	Pro	Asp	Gly	Gly	Ser	Gly	Gly
					20		

<210> SEQ ID NO 425
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 425

Gly	Ser	Val	Asn	His	Leu	Arg	Ser	Glu	Lys	Leu	Thr	Phe	Asn	Gly	Val
1															
						5			10			15			

Val Phe

<210> SEQ ID NO 426
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 426

Cys	Gln	Ser	Tyr	Asp	Ser	Ser	Asp	Arg	Ser	Ala	Leu	Leu	Lys	Ser	Lys
1															
						5			10				15		

Leu	Arg	Ala	Leu	Leu	Thr	Ala	Pro	Arg
					20		25	

<210> SEQ ID NO 427
<211> LENGTH: 19

-continued

<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 427

Gly Ser Gly Gly Ser Val Asn His Leu Arg Ser Glu Lys Leu Thr Gly
1 5 10 15

Val Val Phe

<210> SEQ ID NO 428
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 428

Gly Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu
1 5 10 15

Thr Ala Val Val Phe
20

<210> SEQ ID NO 429
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 429

Cys Gln Ser Tyr Asp Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys
1 5 10 15

Leu Arg Ala Leu Leu Thr Ala Pro Glu
20 25

<210> SEQ ID NO 430
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 430

Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly Ser Gly
20

<210> SEQ ID NO 431
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 431

Gly Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
1 5 10 15

Trp Gly Gln Gly
20

<210> SEQ ID NO 432
<211> LENGTH: 18

-continued

<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 432

Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly
1 5 10 15

Gln Gly

<210> SEQ ID NO 433
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 433

Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp
1 5 10 15

Gly Gly Ser Gly Gly Ser
20

<210> SEQ ID NO 434
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 434

Gly Ser Gly Gly Tyr Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp
1 5 10 15

His Val Asp Val Trp Gly Gln Gly
20

<210> SEQ ID NO 435
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: N-terminal sequence (with ref aa)

<400> SEQUENCE: 435

Cys Gln Ser Tyr Asp Gln Val Lys Leu Glu Leu Gly His Arg Ala Gly
1 5 10 15

Gly Ser Gly Gly Ser
20

<210> SEQ ID NO 436
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal sequence (with ref aa)

<400> SEQUENCE: 436

Gly Ser Gly Gly Ser Gly Ser Val Asn His Leu Arg Ser Glu Lys Leu
1 5 10 15

Thr Gly Val Val Phe
20

<210> SEQ ID NO 437
<211> LENGTH: 24

-continued

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 442

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Thr Ser Val His Gln Glu Thr Lys Tyr Gln Ser Ser Pro Asp Gly
 100 105 110

Gly Ser Gly Gly Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met
 115 120 125

Asp Arg Ile Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg
 130 135 140

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp
 145 150 155 160

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
 165 170 175

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 180 185 190

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
 195 200 205

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 210 215 220

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 225 230 235 240

Val Pro Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
 245 250 255

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
 260 265 270

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 275 280 285

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 290 295 300

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 305 310 315 320

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 325 330 335

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 340 345 350

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 355 360 365

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 370 375 380

US 12,390,508 B2

309**310**

-continued

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 385 390 395 400
 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 405 410 415
 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 420 425 430
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 435 440 445
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 450 455 460
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 465 470 475 480
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 485 490 495
 Ser Pro Gly

<210> SEQ ID NO 443
<211> LENGTH: 500
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC
<400> SEQUENCE: 443

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Gly Ser Val Val Val Thr Ser His Gln Ala Pro Gly
 50 55 60
 Gly Gly Ser Gly Gly Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys
 65 70 75 80
 Met Asp Arg Ile Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg
 85 90 95
 Arg Gly Glu Lys Lys Leu Lys Ser Leu Ala Tyr Gly Ser Thr Tyr
 100 105 110
 Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 115 120 125
 Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 130 135 140
 Ala Val Tyr Tyr Cys Ala Lys Leu Thr Gly Ala Glu Tyr Phe Gln His
 145 150 155 160
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
 165 170 175
 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
 180 185 190
 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
 195 200 205
 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
 210 215 220
 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
 225 230 235 240
 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val

US 12,390,508 B2

311

312

-continued

245	250	255
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys		
260	265	270
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu		
275	280	285
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr		
290	295	300
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val		
305	310	315
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val		
325	330	335
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser		
340	345	350
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu		
355	360	365
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala		
370	375	380
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro		
385	390	395
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln		
405	410	415
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala		
420	425	430
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr		
435	440	445
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu		
450	455	460
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser		
465	470	475
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser		
485	490	495
Leu Ser Pro Gly		
500		

<210> SEQ ID NO 444
<211> LENGTH: 499
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 444

Glu Val Gln Leu Leu Glu Ser Gly Gly	10	15
5		
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr		
20	25	30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly		
35	40	45
Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val		
50	55	60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr		
65	70	75
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys		
85	90	95
Ala Lys Gly Ile Thr Gly Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly		

US 12,390,508 B2

313

314

-continued

100	105	110
Gly Ser Gly Gly Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met		
115	120	125
Asp Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg		
130	135	140
Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Ala Glu Tyr Phe Gln His Trp		
145	150	155
160		
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro		
165	170	175
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr		
180	185	190
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr		
195	200	205
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro		
210	215	220
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr		
225	230	235
240		
Val Pro Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn		
245	250	255
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser		
260	265	270
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu		
275	280	285
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu		
290	295	300
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser		
305	310	315
320		
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu		
325	330	335
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr		
340	345	350
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn		
355	360	365
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro		
370	375	380
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln		
385	390	395
400		
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val		
405	410	415
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val		
420	425	430
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro		
435	440	445
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr		
450	455	460
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val		
465	470	475
480		
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu		
485	490	495
Ser Pro Gly		

<210> SEQ ID NO 445
<211> LENGTH: 499

-continued

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 445

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1															
							5					10			15

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
								20				25			30

Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
								35				40			45

Ser	Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
								50				55			60

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
								65				70			80

Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
								85				90			95

Thr	Ser	Val	His	Gln	Glu	Thr	Lys	Tyr	Gln	Ser	Ser	Pro	Tyr	Lys	
								100				105			110

Gly	Ala	Asn	Lys	Lys	Gly	Leu	Ser	Lys	Gly	Cys	Phe	Gly	Leu	Lys	Leu
								115				120			125

Asp	Arg	Ile	Gly	Ser	Met	Ser	Gly	Leu	Gly	Cys	Gly	Ser	Gly	Gly	Ser
								130				135			140

Gly	Ser	Tyr	Ser	Tyr	Thr	Tyr	Asn	Tyr	Glu	Trp	His	Val	Asp	Val	Trp
								145				150			160

Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro
								165				170			175

Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr
								180				185			190

Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr
								195				200			205

Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro
								210				215			220

Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr
								225				230			240

Val	Pro	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	
								245				250			255

His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser
								260				265			270

Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
								275				280			285

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
								290				295			300

Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
								305				310			320

His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu
								325				330			335

Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr
								340				345			350

Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn
								355				360			365

Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro
								370				375			380

-continued

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 385 390 395 400

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 405 410 415

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 420 425 430

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 435 440 445

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 450 455 460

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 465 470 475 480

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 485 490 495

Ser Pro Gly

<210> SEQ ID NO 446

<211> LENGTH: 499

<212> TYPE: PRT

<213> ORGANISM: artificial

<220> FEATURE:

<223> OTHER INFORMATION: NP engrafted HC

<400> SEQUENCE: 446

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Ser Pro Asp Gly
 100 105 110

Gly Ser Gly Gly Ser Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu
 115 120 125

Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys Gly Ser Gly Gly Tyr
 130 135 140

Gly Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp
 145 150 155 160

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
 165 170 175

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 180 185 190

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
 195 200 205

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 210 215 220

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 225 230 235 240

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn

US 12,390,508 B2

319

320

-continued

245	250	255
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser		
260	265	270
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu		
275	280	285
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu		
290	295	300
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser		
305	310	315
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu		
325	330	335
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr		
340	345	350
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn		
355	360	365
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro		
370	375	380
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln		
385	390	395
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val		
405	410	415
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val		
420	425	430
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro		
435	440	445
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr		
450	455	460
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val		
465	470	475
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu		
485	490	495

<210> SEQ ID NO 447
<211> LENGTH: 217
<212> TYPE: PRT
<213> ORGANISM: *Homo sapiens*

<400> SEQUENCE: 447
 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
 1 5 10 15
 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
 20 25 30
 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45
 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
 50 55 60
 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
 65 70 75 80
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
 85 90 95
 Leu Asp Gly Val Val Phe Gly Gly Thr Lys Leu Thr Val Leu Gly
 100 105 110
 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

US 12,390,508 B2

321**322**

-continued

115 120 125

Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
 165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
 180 185 190

His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
 195 200 205

Lys Thr Val Ala Pro Thr Glu Cys Ser
 210 215

<210> SEQ ID NO 448

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 448

Ile Ser Gly Ser Gly Ser Gly Ser Gly Ser Ser Pro Asp Gly
 1 5 10 15

Gly Ser Gly Gly
 20

<210> SEQ ID NO 449

<211> LENGTH: 24

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 449

Ser Gly Tyr Ser Phe Gly Ser Gly Ser Gly Ser Gly Ser Gly
 1 5 10 15

Ser Pro Asp Gly Gly Ser Gly Gly
 20

<210> SEQ ID NO 450

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 450

Gly Ser Tyr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ile
 1 5 10 15

<210> SEQ ID NO 451

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 451

Lys Leu Thr Gly Ala Glu Tyr Phe Gln His Trp
 1 5 10

-continued

<210> SEQ ID NO 452
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 452

Lys Leu Thr Gly Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 453
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 453

Lys Leu Thr Gly Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 454
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 454

Lys Asp Tyr Gly Asp Tyr Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 455
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 455

Lys Leu Thr Gly Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 456
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 456

Lys Leu Thr Gly Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 457
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 457

Lys Val Leu Arg Phe Leu Glu Trp Leu Leu Tyr Ala Glu Tyr Phe Gln
1 5 10 15

His Trp

-continued

<210> SEQ ID NO 458
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 458

Lys Val Gln Leu Glu Arg Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 459
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 459

Lys Tyr Asn Arg Asn His Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 460
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 460

Lys Tyr Asn Trp Asn Asp Ala Glu Tyr Phe Gln His Trp
1 5 10

<210> SEQ ID NO 461
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 461

Arg Gly Ala Thr Phe Ala Leu Asp Trp
1 5

<210> SEQ ID NO 462
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 462

Arg Gly Arg Leu Pro Asp Val Trp
1 5

327

The invention claimed is:

1. An antibody or a fragment thereof comprising a heterologous amino acid sequence incorporated within a CDR region of said antibody or fragment thereof, wherein said heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP), and a C-terminal linker sequence (Ctls), wherein the Ntls comprises at least 12 amino acid residues and the Ctls comprises at least 9 amino acid residues, wherein:
 - (i) in case of incorporation of said heterologous amino acid sequence within CDRH1, the Ntls is present between amino acid residue HC res25 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between the last amino acid residue of said BNP and amino acid residue HC res35a according to Kabat, or
 - (ii) in case of incorporation of said heterologous amino acid sequence within CDRH2, the Ntls is present between amino acid residue HC res51 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue HC res57 according to Kabat, or
 - (iii) in case of incorporation of said heterologous amino acid sequence within CDRH3, the Ntls is present between amino acid residue HC res92 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue HC res106 according to Kabat, or
 - (iv) in case of incorporation of said heterologous amino acid sequence within CDRL1, the Ntls is present between amino acid residue LC res26 according to Kabat, and the Ctls is present between amino acid residue LC res 32 according to Kabat, or
 - (v) in case of incorporation of said heterologous amino acid sequence within CDRL2, the Ntls is present between amino acid residue LC res49 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue LC res57 according to Kabat, or
 - (vi) in case of incorporation of said heterologous amino acid sequence within CDRL3, the Ntls is present between amino acid residue LC res88 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue LC res98 according to Kabat, and
- wherein:
- (i) said Ntls and said Ctls each comprise a GS linker sequence, or
 - (ii) said Ntls and said Ctls each comprise a PN linker sequence, or
 - (iii) said Ntls comprises the sequence of any one of SEQ ID NOs: 1, 2, or 4 and said Ctls comprises the sequence of any one of SEQ ID NOs: 1, 3, or 5, or
 - (iv) said Ntls and said Ctls each comprise the sequence of SEQ ID NO: 6, or
 - (v) said Ntls comprises the sequence of SEQ ID NO: 7 and said Ctls comprises the sequence of SEQ ID NO: 8, or
 - (vi) said Ntls comprises the sequence of SEQ ID NO: 9 and said Ctls comprises the sequence of SEQ ID NO: 10, or
 - (vii) said Ntls comprises the sequence of SEQ ID NO: 11 and said Ctls comprises the sequence of SEQ ID NO: 12, or

328

- (viii) said Ntls comprises the sequence of SEQ ID NO: 13 and said Ctls comprises the sequence of SEQ ID NO: 14, or
 - (ix) said Ntls and said Ctls each comprise the sequence of SEQ ID NO: 15; or
 - (x) said Ntls comprises the sequence of SEQ ID NO: 9 and said Ctls comprises the sequence of SEQ ID NO: 20, or
 - (xi) said Ntls comprises the sequence of SEQ ID NO: 21 and said Ctls comprises the sequence of SEQ ID NO: 22, and
- wherein said antibody or fragment thereof is of the class IgG.
2. The antibody or fragment thereof according to claim 1, wherein said BNP is a human BNP comprising the sequence of SEQ ID NO: 24 or a BNP comprising at least 95% sequence identity therewith.
 3. The antibody or fragment thereof according to claim 1, wherein said Ntls further comprises an anchoring element A1 at its C terminal end and/or said Ctls further comprises an anchoring element A2 at its N terminal end, and wherein at least 60% of the amino acid residues of A1 and/or A2, when present, are selected from glycine and serine residues.
 4. The antibody or fragment thereof according to claim 1, wherein: the amino acid stretch present between
 - (i) amino acid residue HC res25 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRH1; or
 - (ii) amino acid residue HC res51 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRH2; or
 - (iii) amino acid residue HC res92 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRH3; or
 - (iv) amino acid residue LC res26 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRL1; or
 - (v) amino acid residue LC res49 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRL2; or
 - (vi) amino acid residue LC res88 according to Kabat and the first amino acid residue of the BNP in case of an incorporation of said heterologous amino acid sequence within CDRL3 comprises the sequence of any one of SEQ ID NOs: 26 to 38; and
- wherein the amino acid stretch present between the last amino acid residue of said BNP and
- (i) amino acid residue HC res35a according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH1; or
 - (ii) amino acid residue HC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH2; or
 - (iii) amino acid residue HC res106 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH3; or
 - (iv) amino acid residue LC res 32 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL1; or
 - (v) amino acid residue LC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL2; or

329

(vi) amino acid residue LC res98 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL3 comprises the sequence of any one of SEQ ID NOs: 39 to 51.

5. The antibody or fragment thereof according to claim 1, wherein the amino acid stretch present between

- (i) amino acid residue HC res25 according to Kabat and amino acid residue HC res35a according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH1; or
- (ii) amino acid residue HC res51 according to Kabat and amino acid residue HC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH2; or
- (iii) amino acid residue HC res92 according to Kabat and amino acid residue HC res 106 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRH3; or
- (iv) amino acid residue LC res26 according to Kabat and amino acid residue LC res 32 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL1; or
- (v) amino acid residue LC res49 according to Kabat and amino acid residue LC res57 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL2; or
- (vi) amino acid residue LC res88 according to Kabat and amino acid residue LC res98 according to Kabat in case of an incorporation of said heterologous amino acid sequence within CDRL3

comprises the sequence of any one of SEQ ID NOs: 52 to 64.

6. The antibody or fragment thereof according to claim 1, further comprising at least one further natriuretic peptide, wherein said BNP and said at least one further natriuretic peptide are incorporated within at least two separate CDR regions, and wherein said at least one further natriuretic peptide is selected from ANP and CNP.

7. The antibody or fragment thereof according to claim 1, wherein the light chain comprises or consists of the amino acid sequence of SEQ ID NO: 66 and the heavy chain comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 442 to 444.

8. The antibody or fragment thereof according to claim 1, wherein said antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, F(ab')2, Fv fragments, diabodies, single domain antibodies (Dabs), linear antibodies, single-chain antibody molecules (scFv), and disulfide-stabilized Fv antibody fragments (dsFv).

9. A composition comprising the antibody or fragment thereof according to claim 1 and a pharmaceutically acceptable carrier.

10. The antibody or fragment thereof according to claim 7, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 66 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 442.

11. The antibody or fragment thereof according to claim 7, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 66 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 443.

12. The antibody or fragment thereof according to claim 7, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 66 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 444.

13. The antibody or fragment thereof according to claim 1, wherein at least a portion of said CDR region is replaced by said heterologous amino acid sequence incorporated therein.

330

14. The antibody or fragment thereof according to claim 1, wherein:

- (i) the Ntls comprises the amino acid sequence of SEQ ID NO: 268 and the Ctls comprises the amino acid sequence of SEQ ID NO: 252; or
- (ii) the Ntls comprises the amino acid sequence of SEQ ID NO: 430 and the Ctls comprises the amino acid sequence of SEQ ID NO: 431; or
- (iii) the Ntls comprises the amino acid sequence of SEQ ID NO: 268 and the Ctls comprises the amino acid sequence of SEQ ID NO: 252; or
- (iv) the Ntls comprises the amino acid sequence of SEQ ID NO: 259 and the Ctls comprises the amino acid sequence of SEQ ID NO: 432; or
- (v) the Ntls comprises the amino acid sequence of SEQ ID NO: 189 and the Ctls comprises the amino acid sequence of SEQ ID NO: 190; or
- (vi) the Ntls comprises the amino acid sequence of SEQ ID NO: 105 and the Ctls comprises the amino acid sequence of SEQ ID NO: 106; or
- (vii) the Ntls comprises the amino acid sequence of SEQ ID NO: 211 and the Ctls comprises the amino acid sequence of SEQ ID NO: 212; or
- (viii) the Ntls comprises the amino acid sequence of SEQ ID NO: 236 and the Ctls comprises the amino acid sequence of SEQ ID NO: 237; or
- (ix) the Ntls comprises the amino acid sequence of SEQ ID NO: 281 and the Ctls comprises the amino acid sequence of SEQ ID NO: 282; or
- (x) the Ntls comprises the amino acid sequence of SEQ ID NO: 402 and the Ctls comprises the amino acid sequence of SEQ ID NO: 403.

15. A nucleic acid or a mixture of nucleic acids encoding an antibody or fragment thereof,

wherein the antibody or the fragment thereof comprises at least one a heterologous amino acid sequence incorporated within a CDR region of said antibody or the fragment thereof,

wherein said heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP), and a C-terminal linker sequence (Ctls),

wherein the Ntls comprises at least 12 amino acid residues and the Ctls comprises at least 9 amino acid residues, wherein:

- (i) in case of an incorporation of said heterologous amino acid sequence within CDRH1, the Ntls is present between amino acid residue HC res25 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between the last amino acid residue of said BNP and amino acid residue HC res35a according to Kabat, or
- (ii) in case of an incorporation of said heterologous amino acid sequence within CDRH2, the Ntls is present between amino acid residue HC res51 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue HC res57 according to Kabat, or
- (iii) in case of an incorporation of said heterologous amino acid sequence within CDRH3, the Ntls is present between amino acid residue HC res92 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue HC res106 according to Kabat, or
- (iv) in case of an incorporation of said heterologous amino acid sequence within CDRL1, the Ntls is present between amino acid residue LC res26 according to

331

Kabat, and the Ctls is present between amino acid residue LC res 32 according to Kabat, or
 (v) in case of an incorporation of said heterologous amino acid sequence within CDRL2, the Ntls is present between amino acid residue LC res49 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue LC res57 according to Kabat, or
 (vi) in case of an incorporation of said heterologous amino acid sequence within CDRL3, the Ntls is present between amino acid residue LC res88 according to Kabat and the first amino acid residue of said BNP, and the Ctls is present between amino acid residue LC res98 according to Kabat;

wherein:

- (i) said Ntls and said Ctls each comprise a GS linker sequence, or
- (ii) said Ntls and said Ctls each comprise a PN linker sequence, or
- (iii) said Ntls comprises the sequence of any one of SEQ ID NOs: 1, 2, or 4 and said Ctls comprises the sequence of any one of SEQ ID NOs: 1, 3, or 5, or
- (iv) said Ntls and said Ctls each comprise the sequence of SEQ ID NO: 6, or
- (v) said Ntls comprises the sequence of SEQ ID NO: 7 and said Ctls comprises the sequence of SEQ ID NO: 8, or

15

20

25

332

- (vi) said Ntls comprises the sequence of SEQ ID NO: 9 and said Ctls comprises the sequence of SEQ ID NO: 10, or
- (vii) said Ntls comprises the sequence of SEQ ID NO: 11 and said Ctls comprises the sequence of SEQ ID NO: 12, or
- (viii) said Ntls comprises the sequence of SEQ ID NO: 13 and said Ctls comprises the sequence of SEQ ID NO: 14, or
- (ix) said Ntls and said Ctls each comprise the sequence of SEQ ID NO: 15; or
- (x) said Ntls comprises the sequence of SEQ ID NO: 9 and said Ctls comprises the sequence of SEQ ID NO: 20, or
- (xi) said Ntls comprises the sequence of SEQ ID NO: 21 and said Ctls comprises the sequence of SEQ ID NO: 22, and

wherein said antibody or fragment thereof is of the class IgG.

16. A host cell comprising the nucleic acid or the mixture of nucleic acids according to claim **15**.

17. A process for producing an antibody or fragment thereof, comprising culturing the host cell according to claim **16** under conditions suitable for expression of the antibody or fragment thereof.

* * * * *